
<html lang="en"     class="pb-page"  data-request-id="93d02bba-a8b0-4baf-853f-912382c70ca5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.0c01398;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-21"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties" /></meta><meta name="dc.Creator" content="Michael J.  Soth" /></meta><meta name="dc.Creator" content="Kang  Le" /></meta><meta name="dc.Creator" content="Maria Emilia  Di Francesco" /></meta><meta name="dc.Creator" content="Matthew M.  Hamilton" /></meta><meta name="dc.Creator" content="Gang  Liu" /></meta><meta name="dc.Creator" content="Jason P.  Burke" /></meta><meta name="dc.Creator" content="Chris L.  Carroll" /></meta><meta name="dc.Creator" content="Jeffrey J.  Kovacs" /></meta><meta name="dc.Creator" content="Jennifer P.  Bardenhagen" /></meta><meta name="dc.Creator" content="Christopher A.  Bristow" /></meta><meta name="dc.Creator" content="Mario  Cardozo" /></meta><meta name="dc.Creator" content="Barbara  Czako" /></meta><meta name="dc.Creator" content="Elisa  de Stanchina" /></meta><meta name="dc.Creator" content="Ningping  Feng" /></meta><meta name="dc.Creator" content="Jill R.  Garvey" /></meta><meta name="dc.Creator" content="Jason P.  Gay" /></meta><meta name="dc.Creator" content="Mary K. Geck  Do" /></meta><meta name="dc.Creator" content="Jennifer  Greer" /></meta><meta name="dc.Creator" content="Michelle  Han" /></meta><meta name="dc.Creator" content="Angela  Harris" /></meta><meta name="dc.Creator" content="Zachary  Herrera" /></meta><meta name="dc.Creator" content="Sha  Huang" /></meta><meta name="dc.Creator" content="Virginia  Giuliani" /></meta><meta name="dc.Creator" content="Yongying  Jiang" /></meta><meta name="dc.Creator" content="Sarah B.  Johnson" /></meta><meta name="dc.Creator" content="Troy A.  Johnson" /></meta><meta name="dc.Creator" content="Zhijun  Kang" /></meta><meta name="dc.Creator" content="Paul G.  Leonard" /></meta><meta name="dc.Creator" content="Zhen  Liu" /></meta><meta name="dc.Creator" content="Timothy  McAfoos" /></meta><meta name="dc.Creator" content="Meredith  Miller" /></meta><meta name="dc.Creator" content="Pietro  Morlacchi" /></meta><meta name="dc.Creator" content="Robert A.  Mullinax" /></meta><meta name="dc.Creator" content="Wylie S.  Palmer" /></meta><meta name="dc.Creator" content="Jihai  Pang" /></meta><meta name="dc.Creator" content="Norma  Rogers" /></meta><meta name="dc.Creator" content="Charles M.  Rudin" /></meta><meta name="dc.Creator" content="Hannah E.  Shepard" /></meta><meta name="dc.Creator" content="Nakia D.  Spencer" /></meta><meta name="dc.Creator" content="Jay  Theroff" /></meta><meta name="dc.Creator" content="Qi  Wu" /></meta><meta name="dc.Creator" content="Alan  Xu" /></meta><meta name="dc.Creator" content="Ju Anne  Yau" /></meta><meta name="dc.Creator" content="Giulio  Draetta" /></meta><meta name="dc.Creator" content="Carlo  Toniatti" /></meta><meta name="dc.Creator" content="Timothy P.  Heffernan" /></meta><meta name="dc.Creator" content="Philip  Jones" /></meta><meta name="dc.Description" content="Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are potentially lim..." /></meta><meta name="Description" content="Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are potentially lim..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 29, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01398" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01398" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01398" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01398" /></link>
        
    
    

<title>Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01398" /></meta><meta property="og:title" content="Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0024.jpeg" /></meta><meta property="og:description" content="Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are potentially limited due to poor physicochemical properties. We initiated a GLS-1 inhibitor discovery program focused on optimizing physicochemical and pharmacokinetic properties, and have developed a new selective inhibitor, compound 27 (IPN60090), which is currently in phase 1 clinical trials. Compound 27 attains high oral exposures in preclinical species, with strong in vivo target engagement, and should robustly inhibit glutaminase in humans." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01398"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01398">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01398&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01398&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01398&amp;href=/doi/10.1021/acs.jmedchem.0c01398" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 12957-12977</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01391" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01271" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Michael J. Soth</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael J. Soth</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3c51564f5348547c51585d5258594e4f535212534e5b"><span class="__cf_email__" data-cfemail="7e13140d110a163e131a1f101a1b0c0d111050110c19">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Soth">Michael J. Soth</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2649-5537" title="Orcid link">http://orcid.org/0000-0002-2649-5537</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kang Le</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kang Le</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kang++Le">Kang Le</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Emilia Di Francesco</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Emilia Di Francesco</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria+Emilia++Di+Francesco">Maria Emilia Di Francesco</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew M. Hamilton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew M. Hamilton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+M.++Hamilton">Matthew M. Hamilton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Liu">Gang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason P. Burke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason P. Burke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+P.++Burke">Jason P. Burke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chris L. Carroll</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chris L. Carroll</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chris+L.++Carroll">Chris L. Carroll</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey J. Kovacs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey J. Kovacs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+J.++Kovacs">Jeffrey J. Kovacs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer P. Bardenhagen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer P. Bardenhagen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+P.++Bardenhagen">Jennifer P. Bardenhagen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher A. Bristow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher A. Bristow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+A.++Bristow">Christopher A. Bristow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mario Cardozo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mario Cardozo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mario++Cardozo">Mario Cardozo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Barbara Czako</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barbara Czako</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Czako">Barbara Czako</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3357-7514" title="Orcid link">http://orcid.org/0000-0002-3357-7514</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elisa de Stanchina</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elisa de Stanchina</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Antitumor Assessment Core Facility—Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elisa++de+Stanchina">Elisa de Stanchina</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ningping Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ningping Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ningping++Feng">Ningping Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jill R. Garvey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jill R. Garvey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jill+R.++Garvey">Jill R. Garvey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason P. Gay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason P. Gay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+P.++Gay">Jason P. Gay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mary K. Geck Do</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mary K. Geck Do</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mary+K.+Geck++Do">Mary K. Geck Do</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer Greer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer Greer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Greer">Jennifer Greer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle Han</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle Han</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Han">Michelle Han</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Angela Harris</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Angela Harris</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Angela++Harris">Angela Harris</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zachary Herrera</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zachary Herrera</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zachary++Herrera">Zachary Herrera</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sha Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sha Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sha++Huang">Sha Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Virginia Giuliani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Virginia Giuliani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Virginia++Giuliani">Virginia Giuliani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongying Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongying Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongying++Jiang">Yongying Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah B. Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah B. Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+B.++Johnson">Sarah B. Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Troy A. Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Troy A. Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Troy+A.++Johnson">Troy A. Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhijun Kang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhijun Kang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhijun++Kang">Zhijun Kang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul G. Leonard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul G. Leonard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+G.++Leonard">Paul G. Leonard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhen Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhen Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhen++Liu">Zhen Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy McAfoos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy McAfoos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy++McAfoos">Timothy McAfoos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Meredith Miller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meredith Miller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meredith++Miller">Meredith Miller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pietro Morlacchi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pietro Morlacchi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pietro++Morlacchi">Pietro Morlacchi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert A. Mullinax</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert A. Mullinax</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Mullinax">Robert A. Mullinax</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wylie S. Palmer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wylie S. Palmer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wylie+S.++Palmer">Wylie S. Palmer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jihai Pang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jihai Pang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jihai++Pang">Jihai Pang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Norma Rogers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Norma Rogers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Norma++Rogers">Norma Rogers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charles M. Rudin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charles M. Rudin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drunkenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charles+M.++Rudin">Charles M. Rudin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hannah E. Shepard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hannah E. Shepard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hannah+E.++Shepard">Hannah E. Shepard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nakia D. Spencer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nakia D. Spencer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nakia+D.++Spencer">Nakia D. Spencer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jay Theroff</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jay Theroff</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jay++Theroff">Jay Theroff</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qi Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qi Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qi++Wu">Qi Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alan Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alan Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alan++Xu">Alan Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ju Anne Yau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ju Anne Yau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ju+Anne++Yau">Ju Anne Yau</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Giulio Draetta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giulio Draetta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giulio++Draetta">Giulio Draetta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlo Toniatti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlo Toniatti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlo++Toniatti">Carlo Toniatti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy P. Heffernan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy P. Heffernan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+P.++Heffernan">Timothy P. Heffernan</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Philip Jones</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip Jones</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Jones">Philip Jones</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01398&amp;href=/doi/10.1021%2Facs.jmedchem.0c01398" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 12957–12977</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 29, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 August 2020</li><li><span class="item_label"><b>Published</b> online</span>29 October 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01398" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01398</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D12957%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMichael%2BJ.%2BSoth%252C%2BKang%2BLe%252C%2BMaria%2BEmilia%2BDi%2BFrancesco%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D21%26contentID%3Dacs.jmedchem.0c01398%26title%3DDiscovery%2Bof%2BIPN60090%252C%2Ba%2BClinical%2BStage%2BSelective%2BGlutaminase-1%2B%2528GLS-1%2529%2BInhibitor%2Bwith%2BExcellent%2BPharmacokinetic%2Band%2BPhysicochemical%2BProperties%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D12977%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01398"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1804</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01398" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Soth&quot;},{&quot;first_name&quot;:&quot;Kang&quot;,&quot;last_name&quot;:&quot;Le&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Emilia Di Francesco&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;M. Hamilton&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;P. Burke&quot;},{&quot;first_name&quot;:&quot;Chris&quot;,&quot;last_name&quot;:&quot;L. Carroll&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;J. Kovacs&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;P. Bardenhagen&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;A. Bristow&quot;},{&quot;first_name&quot;:&quot;Mario&quot;,&quot;last_name&quot;:&quot;Cardozo&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Czako&quot;},{&quot;first_name&quot;:&quot;Elisa&quot;,&quot;last_name&quot;:&quot;de Stanchina&quot;},{&quot;first_name&quot;:&quot;Ningping&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Jill&quot;,&quot;last_name&quot;:&quot;R. Garvey&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;P. Gay&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;K. Geck Do&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Greer&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;Harris&quot;},{&quot;first_name&quot;:&quot;Zachary&quot;,&quot;last_name&quot;:&quot;Herrera&quot;},{&quot;first_name&quot;:&quot;Sha&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Virginia&quot;,&quot;last_name&quot;:&quot;Giuliani&quot;},{&quot;first_name&quot;:&quot;Yongying&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;B. Johnson&quot;},{&quot;first_name&quot;:&quot;Troy&quot;,&quot;last_name&quot;:&quot;A. Johnson&quot;},{&quot;first_name&quot;:&quot;Zhijun&quot;,&quot;last_name&quot;:&quot;Kang&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;G. Leonard&quot;},{&quot;first_name&quot;:&quot;Zhen&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;McAfoos&quot;},{&quot;first_name&quot;:&quot;Meredith&quot;,&quot;last_name&quot;:&quot;Miller&quot;},{&quot;first_name&quot;:&quot;Pietro&quot;,&quot;last_name&quot;:&quot;Morlacchi&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Mullinax&quot;},{&quot;first_name&quot;:&quot;Wylie&quot;,&quot;last_name&quot;:&quot;S. Palmer&quot;},{&quot;first_name&quot;:&quot;Jihai&quot;,&quot;last_name&quot;:&quot;Pang&quot;},{&quot;first_name&quot;:&quot;Norma&quot;,&quot;last_name&quot;:&quot;Rogers&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;M. Rudin&quot;},{&quot;first_name&quot;:&quot;Hannah&quot;,&quot;last_name&quot;:&quot;E. Shepard&quot;},{&quot;first_name&quot;:&quot;Nakia&quot;,&quot;last_name&quot;:&quot;D. Spencer&quot;},{&quot;first_name&quot;:&quot;Jay&quot;,&quot;last_name&quot;:&quot;Theroff&quot;},{&quot;first_name&quot;:&quot;Qi&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Ju&quot;,&quot;last_name&quot;:&quot;Anne Yau&quot;},{&quot;first_name&quot;:&quot;Giulio&quot;,&quot;last_name&quot;:&quot;Draetta&quot;},{&quot;first_name&quot;:&quot;Carlo&quot;,&quot;last_name&quot;:&quot;Toniatti&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;P. Heffernan&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Jones&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;12957-12977&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01398&quot;},&quot;abstract&quot;:&quot;Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are potentially limited due to poor physicochemical properties. We initiated a GLS-1 inhibitor discovery program focused on optimizing physicochemical and pharmacokinetic properties, and have developed a new selective inhibitor, compound 27 (IPN60090), which is currently in phase 1 clinical trials. Compound 27 attains high oral exposures in preclinical species, with strong in vivo target engagement, and should robustly inhibit glutaminase in humans.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01398&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01398" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01398&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01398" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01398&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01398" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01398&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01398&amp;href=/doi/10.1021/acs.jmedchem.0c01398" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01398" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01398" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01398%26sid%3Dliteratum%253Aachs%26pmid%3D33118821%26genre%3Darticle%26aulast%3DSoth%26date%3D2020%26atitle%3DDiscovery%2Bof%2BIPN60090%252C%2Ba%2BClinical%2BStage%2BSelective%2BGlutaminase-1%2B%2528GLS-1%2529%2BInhibitor%2Bwith%2BExcellent%2BPharmacokinetic%2Band%2BPhysicochemical%2BProperties%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D21%26spage%3D12957%26epage%3D12977%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/jmcmar.2020.63.issue-21/20201112/jmcmar.2020.63.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are potentially limited due to poor physicochemical properties. We initiated a GLS-1 inhibitor discovery program focused on optimizing physicochemical and pharmacokinetic properties, and have developed a new selective inhibitor, compound <b>27</b> (IPN60090), which is currently in phase 1 clinical trials. Compound <b>27</b> attains high oral exposures in preclinical species, with strong in vivo target engagement, and should robustly inhibit glutaminase in humans.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46067" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46067" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Glutaminase (GLS-1), an enzyme that converts glutamine to glutamate, is a promising therapeutic target in tumors dependent on glutamine.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> Inhibition of GLS-1 should affect the production of multiple biochemical intermediates required for cellular proliferation and maintenance, including glutathione (involved in cellular redox balance), α-ketoglutarate (tricarboxylic acid cycle intermediate), and ammonia (building block for protein synthesis) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In addition, by increasing the amount of glutamine in the tumor microenvironment, glutaminase inhibition may help support activation and proliferation of T-cells to combat tumor growth.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Glutamine metabolism through GLS-1. GLS-1 converts glutamine to glutamate and ammonia. The produced glutamate can be further converted by the cellular machinery to glutathione (which regulates reactive oxygen species (ROS)) or α-ketoglutarate (α-KG) (key building block in the tricarboxylic acid (TCA) cycle). The produced ammonia is a building block for cellular protein syntheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A growing pool of evidence suggests that tumors rewire metabolic pathways to sustain their needs for energy and cellular building blocks, and that these changes can increase reliance on GLS-1. For example, we and others have disclosed that certain tumors characterized by loss or mutations in Kelch-like ECH-associated protein (KEAP) and/or NRF2 genes, which encode for proteins that regulate glutathione production, are sensitive to GLS-1 inhibition.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Additionally, there are multiple reports demonstrating additive or synergistic effects of GLS-1 inhibition in tumor cells when combined with a variety of agents in both in vitro and in vivo models.<a onclick="showRef(event, 'ref5 ref9 ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref5 ref9 ref10 ref11 ref12 ref13 ref14">(5,9−14)</a> GLS-1 inhibition has also been reported to sensitize tumor cells to radiation.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a></div><div class="NLM_p">There are two known isoforms of glutaminase: GLS-1 (also called kidney-type or KGA), and GLS-2 (also called liver-type or LGA). GLS-2 expression appears limited primarily to the liver, while GLS-1 is ubiquitous. As mentioned above, GLS-1 has been validated as a cancer target, and our program focused on selective GLS-1 inhibitors.</div><div class="NLM_p">GLS-1 can exist as two variants (KGA and GAC), both of which appear susceptible to the same classes of inhibitors. There are three main classes of GLS-1 inhibitors reported, represented by the irreversible and unselective active-site inhibitor 6-diazo-5-oxy-<span class="smallcaps smallerCapital">l</span>-norleucine (DON, <b>1</b>)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and the GLS-1-selective allosteric inhibitors <i>bis</i>-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES, <b>2</b>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and compound 968 (<b>3</b>)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of known GLS inhibitors DON (<b>1</b>), BPTES (<b>2</b>), “compound 968” (<b>3</b>), and CB-839 (<b>4</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>1</b>, first reported to inhibit glutamine catabolism by Willis and Seegmiller,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> inhibits multiple glutamine-utilizing enzymes including glutaminase, and its polypharmacology presumably underlies unacceptable toxicities observed in the clinic, although efforts are ongoing to potentially overcome these issues through the use of targeted prodrugs with low dosing regimens.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Compound <b>3</b>, reported by Cerione and co-workers, appears to operate through a unique allosteric mechanism; information on exact binding modes is currently limited, but the compound has been reported to inhibit both GLS-1 and GLS-2.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a></div><div class="NLM_p">Compound <b>2</b>, first disclosed in a patent from Elan<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and inhibition mechanism elucidated by Robinson and co-workers,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> also has a unique allosteric binding mode, which has been elucidated with protein crystallography.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Compound <b>2</b> is reported to have high selectivity over GLS-2, and has served as a chemical starting point for multiple discovery efforts,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> including those of Johns Hopkins University,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Calithera Biosciences,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> University of Pittsburgh,<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Zhejiang University of Technology,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> AstraZeneca,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Pfizer,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Agios,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and Rhizen.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Calithera’s efforts have progressed the furthest, with CB-839 (telaglenastat, <b>4</b>) currently in pivotal clinical trials for multiple oncology indications.<a onclick="showRef(event, 'ref26 ref35'); return false;" href="javascript:void(0);" class="ref ref26 ref35">(26,35)</a> Compound <b>4</b> is a potent inhibitor of GLS-1, although its physicochemical and PK properties appear to require fairly high doses (recommended phase 2 doses of 600–800 mg, twice a day).<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> Both preclinical and clinical results for compound <b>4</b> are encouraging for the use of GLS-1 inhibitors in combination therapies against multiple cancer types.</div><div class="NLM_p last">We also selected compound <b>2</b> as an initial lead and focused on improving upon its metabolic stability and solubility profile. Our program prioritized properties in the hope that an eventual candidate would be able to achieve high sustained exposures relative to potencies in the clinic, and thus be positioned to test the clinical potential of maximally inhibiting glutaminase. We describe herein the efforts that culminated in the discovery of IPN60090, a compound with excellent physicochemical and pharmacokinetic properties, currently in phase 1 clinical trials for solid tumors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Lead Identification</h3><div class="NLM_p">Our strategy started with consideration of a published crystal structure of compound <b>2</b> bound to full-length human GLS-1 (GAC isoform).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Compound <b>2</b> binds at the interface of GLS-1 molecules in a 4:2 protein/inhibitor ratio, with the two aminothiadiazole moeities making key hydrogen-bonding interactions with the protein. We therefore embarked on a broad empirical exercise testing aminothiadiazole alternatives expected to present similar patterns of hydrogen-bond donors and acceptors. We discovered a variety of unique GLS-1 inhibitors;<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> this manuscript focuses on the series that produced our clinical candidate, containing an amidotriazole linked to an acylaminopyridazine. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows our proposed chemical series and its hypothesized binding mode to the targeted site of GLS-1. For the sake of discussion, we label the various portions of the scaffold as “cores”, “linker”, and “wings”.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Proposed binding of series example <b>5</b> in the GLS-1 tetramer, modeled using PDB 3UO9.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The acylaminopyridazine core is a known motif in GLS-1 inhibitors and is present in <b>4</b>; pyridazine can be considered an isostere of thiadiazole, in the same way that benzene and thiophene are considered to be isosteres of each other.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Amidotriazole cores are, to our knowledge, unprecedented in GLS-1 inhibitors. A comparison of amidotriazole and acylaminopyridazine fragments suggests a close overlay of most hydrogen-bond donors and acceptors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Hydrogen-bonding motifs of amidotriazoles overlay well onto those of aminopyridazines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The four-carbon linker was first popularized by Thangavelu and co-workers as a substitute for the thioether linker present in <b>2</b>,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and was suggested by modeling and early empirical studies to be an optimal length for our series. We were able to further improve upon this linker, as will be described later in the manuscript. The wings are tolerant of a wide variety of modifications and were a major focus of our optimization efforts.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Scaffold Proof of Concept</h3><div class="NLM_p">For proof of potency for this novel scaffold, we synthesized compounds <b>5</b>, <b>6</b>, and <b>7</b>, which contain benzyl, or pyridylmethyl and trifluoromethoxybenzyl wings, similar to those present in compounds <b>2</b> and <b>4</b>. Enzyme potencies were evaluated in a GLS-1 (GAC isoform) enzyme assay indirectly measuring the conversion of glutamine to glutamate, and cellular potencies were evaluated in a cellular viability assay (A549 cell line). For comparison purposes, we include data from the same assays for compounds <b>2</b> and <b>4</b>. All three of our new compounds demonstrate good potencies in enzyme and cell-based assays (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), thus giving us confidence in exploring the scaffold further.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Scaffold Proof of Concept</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0015.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Inhibition of purified recombinant human GAC assessed via a dual-coupled enzyme assay. IC<sub>50</sub> values are reported as the mean of at least three determinations, except for compound <b>5</b> (<i>n</i> = 1). Standard deviations and counts are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Inhibition of proliferation of A549 cells. IC<sub>50</sub> values are reported as the mean of at least three determinations, except for compound <b>5</b> (<i>n</i> = 2). Standard deviations and counts are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Liver microsomal intrinsic clearance (mL/min/kg protein).</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Kinetic aqueous solubility (μM) in phosphate buffer (100 mM) at pH 7.4; shaken for 1 h at RT.</p></div></div><div></div></div><div class="NLM_p last">Further profiling of compounds <b>5</b>–<b>7</b> revealed two major liabilities, also issues for literature comparators <b>2</b> and <b>4</b>, which were the primary foci of our lead optimization efforts (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). First, microsomal stabilities were low (most Cl<sub>int</sub>’s ranked as high clearance by internal criteria, >83 mL/min/kg in rat and >58 mL/min/kg in human); second, solubilities were very low (<1 μM). The low solubilities, and possibly the low microsomal stabilities, are likely attributable to the large number of aromatic rings in the compounds; therefore, our first optimization efforts focused on replacing one of the aromatic wings with smaller and/or less lipophilic groups. Based on the liabilities just described, the key data that we monitored at this early stage were potencies, microsomal stabilities, and solubilities.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Triazole Wing Exploration</h3><div class="NLM_p">Our scan of triazole wingpieces focused on replacing the heteroaryl motif of parent compound <b>7</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). All replacements investigated showed a loss in potency. However, the simple methylamide <b>8</b> still retained a reasonable amount of potency, with a higher ligand binding efficiency (0.30 compared to 0.27 for <b>7</b>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> More importantly, compound <b>8</b> showed much improved microsomal stabilities relative to the original compounds and literature comparators <b>2</b> and <b>4</b>, especially human. We therefore favored the methylamide to keep constant as we probed other substituents on the scaffold. While the microsomal properties of compound <b>8</b> were promising, solubility remained low.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationship (SAR) on the Triazole Wing: Benzyl Replacements</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0016.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0017.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Inhibition of purified recombinant human GLS-1 (GAC isoform) assessed via a dual-coupled enzyme assay. IC<sub>50</sub> values are reported as the mean of at least three determinations. Standard deviations and counts are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Inhibition of proliferation of A549 cells. IC<sub>50</sub> values are reported as the mean of at least three determinations. Standard deviations and counts are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Liver microsomal intrinsic clearance (mL/min/kg protein).</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Kinetic aqueous solubility (μM) in phosphate buffer (100 mM) at pH 7.4; shaken for 1 h at RT.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Pyridazine Wing Exploration</h3><div class="NLM_p">Keeping the triazole wing constant as a methylamide, we explored pyridazine wings (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). In the hope of improving solubility, we first replaced the trifluoromethylbenzyl group of compound <b>8</b> with simple pyridylmethyl side chains (compounds <b>14</b> and <b>15</b>), which did improve solubilities while retaining most of the potency of <b>8</b>. The <i>ortho</i>-pyridine <b>14</b> was chosen for further optimization because of its superior cell potency.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of Pyridazine Wing: Pyridylmethyls</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0018.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0019.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Inhibition of purified recombinant human GLS-1 (GAC isoform) assessed via a dual-coupled enzyme assay. IC<sub>50</sub> values are reported as the mean of at least three determinations. Standard deviations and counts are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Inhibition of proliferation of A549 cells. IC<sub>50</sub> values are reported as the mean of at least three determinations. Standard deviations and counts are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Liver microsomal intrinsic clearance (mL/min/kg protein).</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Kinetic aqueous solubility (μM) in phosphate buffer (100 mM) at pH 7.4; shaken for 1 h at RT.</p></div></div><div></div></div><div class="NLM_p last">The 4-trifluoromethyl variant (compound <b>16</b>) was well tolerated, with only a slight loss of cellular potency compared to the trifluoromethoxybenzyl analogue <b>8</b>, and more importantly retained the improved solubility. We therefore embarked on a more extensive scan of 4-substituted-2-pyridylmethyl wingpieces, resulting in many analogues with good to excellent potencies, low microsomal clearances, and reasonable solubilities. Particularly noteworthy were analogues <b>16</b> and <b>19</b>, which showed promising overall profiles, and analogue <b>20</b>, which while less soluble was especially potent in our cellular assays.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Linker: Benefits of Fluorine</h3><div class="NLM_p">We were interested in probing the effects of fluorine substitution on potencies and microsomal stabilities.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Molecular modeling suggested that a fluorine substituent would be well tolerated on the linker, specifically on either of the two internal carbons.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> For synthetic reasons, we focused on fluorination of the internal carbon closer to the triazole core. Fluorination is not only tolerated, but consistently improved both cell potencies (albeit moderately) and microsomal stabilities (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Fluorination introduces a chiral center; we focused on the <i>R</i>-enantiomer because it often showed small potency advantages (e.g., compound <b>21</b> vs compound <b>22</b>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Linker Fluorination and Pyridine Methylation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0020.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0021.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Inhibition of purified recombinant human GLS-1 (GAC isoform) assessed via a dual-coupled enzyme assay. IC<sub>50</sub> values are reported as the mean of at least three determinations. Standard deviations and counts are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Inhibition of proliferation of A549 cells. IC<sub>50</sub> values are reported as the mean of at least three determinations. Standard deviations and counts are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Liver microsomal intrinsic clearance (mL/min/kg protein).</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Kinetic aqueous solubility (μM) in phosphate buffer (100 mM) at pH 7.4; shaken for 1 h at RT.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Thermodynamic aqueous solubility (μM) in phosphate buffer (100 mM) at pH 7.0; shaken for 1 h then equilibrated overnight at RT.</p></div></div><div></div></div><div class="NLM_p last">We also found that introduction of an <i>ortho</i>-methyl group to the pyridine could, in select cases, slightly improve potencies (compound <b>26</b> vs compound <b>23</b>). While the <i>ortho</i>-methyl group of compound <b>27</b> did not improve potencies relative to the <i>des</i>-methyl analogue <b>24</b>, ultimately <b>27</b> showed superior in vivo properties.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Final Triaging</h3><div class="NLM_p">Based primarily on physicochemical and metabolic properties coupled with cellular potencies, we selected compounds <b>24</b>, <b>26</b>, and <b>27</b> for further characterization. In addition, we profiled analogue <b>25</b>, on the rationale that this example, despite overall poorer properties, may have a lower bar on required exposures due to its excellent potencies. We triaged the set based on solubilities, permeabilities, microsomal stabilities, and in vivo PK (rat and dog). <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> show summaries of in vitro and in vivo PK (rat and dog) data for these compounds.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Properties of Select Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0022.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Thermodynamic aqueous solubility (μM) in phosphate buffer (100 mM) at pH 7.0, fed-state simulated intestinal fluid (FeSSIF) at pH 5.0, or fasted-state simulated gastrointestinal fluid (SGF) at pH 1.6; shaken for 1 h then equilibrated overnight at RT.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Thermodynamic aqueous solubilities for the crystalline most stable polymorph of <b>27</b>, identified during later development, in phosphate buffer (50 mM) at pH 6.8, FeSSIF or SGF, shaken for 24 h at 25 °C (phosphate buffer) or 37 °C (FeSSIF and SGF).</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Permeability in Caco-2 cells AB (apical to basolateral) and BA (basolateral to apical) movement of 10 μM test compound in 21-day cultured Caco-2 cells ((cm/s) × 10<sup>–6</sup>).</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Liver microsomal intrinsic clearance (mL/min/kg protein).</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Liver hepatocyte intrinsic clearance (mL/min/kg protein).</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Plasma protein binding (PPB) determined by equilibrium dialysis.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo Properties of Select Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0023.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last"><i>C</i><sub>max</sub>, area under the curve (AUC)<sub>last</sub>, and <i>F</i>% were determined from the oral dose, and CL, Vd<sub>ss</sub>, and <i>t</i><sub>1/2</sub> were determined from the IV dose.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Dosed as a hydrochloride salt.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Dosed as a bis-hydrochloride salt.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Male Sprague Dawley (SD) rats. Doses were 0.3 mg/kg IV (intravenous) and 3 mpk PO (per os), except for compound <b>25</b> (0.3 mpk IV, 2 mpk PO).</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">Male beagle dogs. Doses were 0.3 mg/kg IV (intravenous) and 3 mpk PO (per os).</p></div></div><div></div></div><div class="NLM_p last">Compound <b>27</b> was chosen for further evaluation based on its overall profile, including significantly longer half-lives in rat and dog relative to the other leading compounds. Importantly, while compound <b>25</b> is significantly more potent than compound <b>27</b>, we believe its higher in vivo clearances and low oral exposures could present challenges at later stages of development, and therefore favored the less potent compound <b>27</b>. Compound <b>27</b> has moderate solubility in pH 7 buffer and simulated intestinal fluid, but high solubility in simulated gastrointestinal fluid. These solubility results were attained for the crystalline freebase form that was carried into development. The compound shows mild efflux in a Caco-2 assay, used to assess intestinal permeability; this mild efflux potential has a minimal effect on oral absorption, based on the high bioavailabilities observed with oral dosing.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Deeper Profiling of Compound 27 (IPN60090)</h3><div class="NLM_p">A summary of potency, selectivity, and pharmacokinetic properties of compound <b>27</b> is shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Compound <b>27</b> is a highly selective inhibitor of GLS-1, with no activity observed against GLS-2. Testing in a cellular target engagement assay, which measured the conversion of glutamine to glutamate, showed a similar IC<sub>50</sub> to that seen in the cellular viability assay. As summarized in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, compound <b>27</b> showed no significant inhibition of the hERG channel or common cytochrome P450 (CYP) enzymes. Compound <b>27</b> also showed no significant activities against an 80-member Eurofins CEREP panel of various ion channels and receptors, or against a 97-member Eurofins DiscoverX kinase panel. Specific results from the CEREP and DiscoverX panels are contained in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Summary of potencies, selectivities, and pharmacokinetic properties of compound <b>27</b>. <sup>a</sup>All IC<sub>50</sub> values are reported as the mean of at least two determinations. <sup>b</sup>Inhibition of purified recombinant human GLS-1 (GAC isoform) assessed via a dual-coupled enzyme assay. IC<sub>50</sub> value is the mean ± standard deviation for 36 determinations. <sup>c</sup>Inhibition of purified recombinant human GLS-2 assessed via a dual-coupled enzyme assay. <sup>d</sup>Inhibition of proliferation of A549 cells. IC<sub>50</sub> value is the mean ± standard deviation for 36 determinations. <sup>e</sup>Inhibition of cellular glutaminase assessed via direct measurement of glutamine and glutamate levels in the cellular media. IC<sub>50</sub> value is the mean ± standard deviation for four determinations. <sup>f</sup>hERG QPatch assay, CHO cell line. <sup>g</sup>Inhibition of metabolism of known substrates for the indicated cytochrome P450 enzymes. <sup>h</sup>Eurofins CEREP profiling service; details are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>. <sup>i</sup>Eurofins DiscoverX KINOMEscan profiling service, scanEDGE product; details are in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>. <sup>j</sup>Liver microsomal intrinsic clearance (mL/min/kg protein). <sup>k</sup>Liver hepatocyte intrinsic clearance (mL/min/kg protein). <sup>l</sup>Plasma protein binding determined by equilibrium dialysis. <sup>m</sup>Dosed as a bis-hydrochloride salt to female CD-1 mice, male Sprague Dawley rats, male cynomolgus monkeys, and male beagle dogs. Doses were 0.3 mg/kg IV (intravenous) and 3 mpk PO (per os), except for mouse (3 mpk IV, 10 mpk PO). <i>C</i><sub>max</sub>, AUC<sub>last</sub>, and <i>F</i>% were determined from the oral dose, and CL, Vd<sub>ss</sub>, and <i>t</i><sub>1/2</sub> were determined from the IV dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The pharmacokinetic properties of compound <b>27</b> in rat and dog are superior to its properties in mouse and monkey, with rat and dog showing lower in vivo clearances and 5–6 times longer half-lives. Because of the low volumes of distribution across species, half-lives are short unless clearances are extremely low, as is the case for rat and dog. Clearances across species are qualitatively in agreement with in vitro metabolic stabilities. Given that the in vitro clearances in human microsomes and hepatocytes are very low (similar to or lower than values for rat and dog), we expect low in vivo clearances and favorable half-lives in humans, more similar to rat and dog than to mouse and monkey.</div><div class="NLM_p">Compound <b>27</b> was further tested in ascending single-dose oral PK experiments in mouse, rat, and dog (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Across the dose ranges tested (up to 200 mg/kg in mouse, 100 mg/kg in rat, and 10 mg/kg in dog), maximal concentrations and total exposures continually increased with dose, with high exposures achieved across species.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Ascending dose oral PK of compound <b>27</b> (bis-hydrochloride salt) in mouse, rat, and dog dosed in 0.5% aqueous methylcellulose vehicle. Values are the means with standard deviation for three animals except for mouse AUC values, which are composite determinations, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vivo Target Engagement of Compound <b>27</b></h3><div class="NLM_p">To demonstrate that <b>27</b> could robustly inhibit glutaminolysis in vivo, and to determine plasma concentrations required for in vivo target engagement, the compound was orally administered in an H460 non-small cell lung cancer xenograft model at doses of 10, 50, or 250 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). To determine target engagement, we analyzed tumor samples at the 8 and 24 h time points for changes in glutamine and glutamate concentrations relative to vehicle control, on the expectation that inhibition of glutaminase should increase levels of glutamine relative to glutamate. <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>a shows the ratio of glutamate to glutamine in tumors when the animals were treated with ascending doses of compound <b>27</b>. The expected changes were indeed observed, with the effect at 50 mg/kg similar to that at 250 mg/kg despite an increase in plasma concentrations, suggesting that we are maximally inhibiting target at doses of 50–250 mg/kg. The average free plasma concentrations observed at these doses and time points were 0.058–0.316 μM (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>b).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo target engagement and concentrations of compound <b>27</b> in an H460 NSG mouse xenograft model. Compound <b>27</b> (<i>bis</i>-hydrochloride) was administered orally at the indicated doses in a 0.5% aqueous methylcellulose vehicle. There were six animals per group. (a) Glutamate/glutamine ratios at 8 and 24 h after each dose, with standard deviation bars; (b) free plasma concentrations, with standard deviations, of compound <b>27</b> at 8 and 24 h for each dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vivo Efficacy of Compound <b>27</b></h3><div class="NLM_p">In a benchmarking study detailed in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Figures S1 and S2</a>), we compared compound <b>27</b> to clinical stage compound <b>4</b> (Calithera’s CB-839) in an H2122 non-small cell lung cancer cell line-derived xenograft mouse model. The results from that study indicated that compound <b>27</b> dosed orally at 100 mg/kg twice daily shows similar efficacy and target engagement to compound <b>4</b> dosed orally at 250 mg/kg twice daily.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">To demonstrate antitumor efficacy in an additional model, which was also used to confirm a combination therapy hypothesis, <b>27</b> was tested in an Ru337 non-small cell lung cancer patient-derived xenograft (PDX) mouse model (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Compound <b>27</b> demonstrates robust in vivo target engagement when orally dosed to this model at doses of 25–100 mg/kg twice daily, at both 4 and 28 days (see Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Figure S3</a>). We tested the compound at oral doses of 100 mg/kg twice daily, as both a monotherapy and in combination with the dual TORC1/2 inhibitor TAK-228 (also known as MLN0128, INK128).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> This combination was chosen based on results from translational biology studies to define rational combination strategies (manuscript under revision).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacies in an Ru337 PDX subcutaneous mouse tumor model of compound <b>27</b> as monotherapy and in combination with dual TORC inhibitor TAK-228. Compound <b>27</b> (neutral compound) was administered orally twice daily at 100 mg/kg in an 0.5% aqueous methylcellulose vehicle; TAK-228 was dosed orally once daily at 1 mg/kg in an 0.5% aqueous methylcellulose, 5% sucrose vehicle. Both compounds were dosed on a schedule of 5 days on/2 days off,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and there were eight animals per group. (a) Tumor volumes plotted as mean ± standard deviation; (b) average % bodyweights relative to day 0 plotted as mean ± standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As a single agent, <b>27</b> caused a 28% tumor growth inhibition. This result is consistent with other reported preclinical studies on GLS inhibitors as monotherapies.<a onclick="showRef(event, 'ref9 ref10 ref13 ref31'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref13 ref31">(9,10,13,31)</a> The effects of TAK-228 administration were likewise modest at the dose tested (41% tumor growth inhibition). However, the combination regimen caused an 85% tumor growth inhibition, an improvement over either single agent. The results strongly support testing this combination clinically.</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry</h3><div class="NLM_p">The general synthetic routes for the preparation of compounds are shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> shows an early synthesis, which was particularly helpful for exploring variations in the triazole wing. 4-Azido-1-propyne was reacted with <i>tert</i>-butyl propiolate in a selective azide-alkyne Huisgen cyclization to afford triazole <b>28</b>, and the remaining alkyne was then coupled with 1-iodo-4-aminopyridazine to afford alkynyl aminopyridazine <b>29</b>. Alkyne <b>29</b> was reduced to alkyl aminopyridazine <b>30</b>, which was converted to varied amide intermediates <b>31</b>. Finally, the <i>tert</i>-butyl esters of intermediates <b>31</b> were deprotected to the corresponding acids, which were coupled with amines to afford final products <b>5</b>–<b>13</b>.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Compounds <b>5</b>–<b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) copper sulfate, ascorbic acid, <i>tert</i>-butanol/water (54%); (ii) <i>bis</i>(triphenylphosphine) palladium(II) dichloride, copper iodide, triethylamine, tetrahydrofuran (THF), 60 °C (84%); (iii) Raney nickel, hydrogen, methanol (89%); (iv) R-CO<sub>2</sub>H, propanephosphonic acid anhydride, pyridine (25–78%); (v) (a) trifluoroacetic acid (TFA), dichloromethane (DCM), (b) R-NH<sub>2</sub>, amide coupling reagent, solvent (15–98%).</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> shows the synthesis used to explore variations in the pyridazine wing, in which the triazole wing was kept constant as a methylamide. The <i>tert</i>-butyl ester of alkyl aminopyridazine <b>30</b> was deprotected to the corresponding acid, which was coupled with methylamine to afford methylamide <b>31</b>, which was subsequently converted to varied final products <b>14</b>–<b>20</b>.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Compounds <b>14</b>–<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) (a) trifluoroacetic acid, dichloromethane, (b) methylamine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA), 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate, tetrahydrofuran/<i>N</i>,<i>N</i>-dimethylformamide (29%); (ii) R-CO<sub>2</sub>H, amide coupling reagent, solvent (5–82%).</p></p></figure><div class="NLM_p">Synthesis of fluorinated analogues relied on intermediate iodide <b>32</b>, the synthesis of which is shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. 2-((Benzyloxy)methyl)oxirane was reacted with sodium azide to afford azido alcohol <b>33</b>, which was reacted with <i>tert</i>-butyl propiolate in an azide-alkyne Huisgen cyclization to afford triazole alcohol <b>34</b>. Alcohol <b>34</b> was converted to fluoride <b>35</b>, and the benzyl ether of <b>35</b> was removed to afford new alcohol <b>36</b>. The alcohol of intermediate <b>36</b> was converted via intermediate tosylate <b>37</b> to the corresponding iodide <b>32</b>. Most of the compounds in this manuscript were synthesized as <i>R</i>-enantiomers, starting from (<i>R</i>)-2-((benzyloxy)methyl)oxirane as shown in the scheme, with the exception of <b>22</b>, which followed the same synthesis except starting from (<i>S</i>)-2-((benzyloxy)methyl)oxirane.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Intermediate Iodide <b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) sodium azide, ammonium chloride, methanol/water (91%); (ii) <i>tert</i>-butyl propiolate, <i>N</i>,<i>N</i>-diisopropylethylamine, acetic acid, dichloromethane (82% crude); (iii) (diethylamino)sulfur trifluoride (DAST), pyridine, dichloromethane (45%); (iv) 10% palladium hydroxide on carbon, hydrogen, ethyl acetate (101% crude); (v) 4-toluenesulfonyl chloride, 4-dimethylaminopyridine (DMAP), dichloromethane (84% crude); sodium iodide, acetone (91%).</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> shows one synthetic route to our fluorinated analogues. 3,6-Dichloropyridazine was first treated with hydroiodic acid, and the resulting 3,6-diiodopyridazine was reacted with the anion of <i>tert</i>-butyl malonate to selectively afford mono-substituted malonate <b>38</b>. Malonate <b>38</b> was then coupled with intermediate iodide <b>32</b> to afford di-substituted malonate <b>39</b>. Di-substituted malonate <b>39</b> was then treated with trifluoroacetic acid to remove all three <i>tert</i>-butyl esters, with in situ bis-decarboxylation of the alkyl linker, and the remaining carboxylic acid was coupled with methylamine to afford pyridazine iodide <b>40</b>. The pyridazine iodide was then coupled with varied primary amides, under palladium catalysis conditions, to afford final products <b>21</b>–<b>23</b>, <b>25</b> or <b>26</b>.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. General Synthesis of Compounds <b>21</b>–<b>23</b>, <b>25</b>, and <b>26</b><sup>a</sup><sup>,</sup><sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) (a) 55% aqueous hydrogen iodide, 90 °C (90%), (b) di-<i>tert</i>-butyl propanedioate, sodium hydride, tetrahydrofuran, 65 °C (78%); (ii) intermediate <b>32</b>, potassium carbonate, <i>N</i>,<i>N</i>-dimethylformamide (75%); (iii) (a) trifluoroacetic acid, dichloromethane, 40 °C, (b) methylamine, <i>N</i>,<i>N</i>-diisopropylethylamine, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate, tetrahydrofuran/<i>N</i>,<i>N</i>-dimethylformamide (56%); (iv) R-CONH<sub>2</sub>, palladium-catalyzed coupling, solvent (15–57%).</p><p class="last"><span class="fn-label"><sup>b</sup></span>Compound <b>22</b>, the enantiomer of compound <b>21</b>, was made using the same synthetic route including preparation of starting material shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, but starting from (<i>S</i>)-2-((benzyloxy)methyl)oxirane in place of (<i>R</i>)-2-((benzyloxy)methyl)oxirane.</p></p></figure><div class="NLM_p">The final coupling step shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> was sometimes problematic due to the generally poor solubility of intermediate <b>40</b>. The alternative route shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> circumvented this issue by instead performing the iodopyridazine-amide coupling on tri-ester <b>39</b> (to afford intermediate <b>41</b>), which was treated with hydrogen chloride to remove all three <i>tert</i>-butyl esters with in situ bis-decarboxylation of the alkyl linker, and the product acid <b>42</b> was then coupled with methylamine to afford final compounds <b>24</b> and <b>27</b>.</div><figure id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0014.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. General Synthesis of Compounds <b>24</b>, <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) R-CONH<sub>2,</sub> palladium-catalyzed coupling, solvent (34–86%); (ii) hydrogen chloride, dioxane; (iii) methylamine, <i>N</i>,<i>N</i>-diisopropylethylamine, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate, tetrahydrofuran/<i>N</i>,<i>N</i>-dimethylformamide (two-step 56–68%).</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25641" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25641" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Based on its overall profile, compound <b>27</b> (IPN60090) was selected for development and taken into IND-enabling studies. Additional translational research was conducted to inform the future clinical program and is being reported elsewhere.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Importantly, while this candidate was not the most potent analogue created in the series, its excellent physicochemical and pharmacokinetic properties outweighed potency considerations. Compound <b>27</b> is currently in the clinic, and robust target engagement is being achieved in human subjects.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30068" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30068" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemistry</h3><div class="NLM_p last">Reagents and solvents were obtained from commercial sources and were used without further purification. Chromatographic purification of compounds was performed by column chromatography utilizing a Biotage system applying Biotage SNAP columns with Biotage KP-Sil silica or Biotage Zip Si columns with Biotage KP-Sil silica, or a Teledyne ISCO system with RediSep Rf normal phase silica cartridges. Other compounds were purified by preparative HPLC in reverse-phase mode using a Waters Autopurify system with a Waters Xbridge Prep C18 5 μm OBD, 19 mm × 150 mm or 50 mm × 100 mm column and an SQ detector mass spectrometer with electrospray ionization (ESI) ionization. The identity and purity of inhibitors were confirmed by NMR spectroscopy and ultraperformance liquid chromatography (UPLC) coupled to low-resolution mass spectrometry (LRMS) and were ≥95%. High-resolution mass spectrometry (HRMS) data were collected for leading compounds <b>24</b>–<b>27</b>. NMR spectra were recorded on Bruker Instruments operating at 500 or 600 MHz. NMR spectra were obtained as CDCl<sub>3</sub>, CD<sub>3</sub>OD, D<sub>2</sub>O, (CD<sub>3</sub>)<sub>2</sub>SO, (CD<sub>3</sub>)<sub>2</sub>CO, C<sub>6</sub>D<sub>6</sub>, or CD<sub>3</sub>CN solutions (reported in ppm), using tetramethylsilane (0.00 ppm) or residual solvent (CDCl<sub>3</sub>, 7.26 ppm; CD<sub>3</sub>OD, 3.31 ppm; D<sub>2</sub>O, 4.79 ppm; (CD<sub>3</sub>)<sub>2</sub>SO, 2.50 ppm; (CD<sub>3</sub>)<sub>2</sub>CO, 2.05 ppm; C<sub>6</sub>D<sub>6</sub>, 7.16 ppm; CD<sub>3</sub>CN, 1.94 ppm) as the reference standard. Low-resolution mass spectra were obtained on either a Waters H-class UPLC with a Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm × 50 mm column, UV detection between 200 and 400 nm, evaporating light scattering detection, and an SQ detector mass spectrometer with ESI ionization; or a Water I class UPLC with a Waters Acquity UPLC CSH C18 1.7 μm, 2.1 mm × 50 mm column, UV detection at 254 and 290 nm, evaporating light scattering detection, and an SQ detector 2 mass spectrometer with ESI ionization. High-resolution mass spectra on leading compounds <b>24</b>–<b>27</b> were obtained on a Waters Acquity I-Class UPLC–Thermo LTQ Orbitrap Elite MS instrument, with a Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm × 100 mm column, ESI ionization.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Di-<i>tert</i>-butyl 2-(6-iodopyridazin-3-yl)malonate (<b>38</b>)</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Step 1: 3,6-Diiodopyridazine</h4><div class="NLM_p last">A mixture of 3,6-dichloropyridazine (60.00 g, 402.7 mmol) and 55% aqueous hydrogen iodide solution (30.30 mL, 402.7 mmol) was stirred at 90 °C for 12 h. A solid was isolated by filtration and then suspended in a sat. aq NaHCO<sub>3</sub> solution (300 mL). The solid was isolated by filtration and washed with petroleum ether (2 × 200 mL) to give crude 3,6-diiodopyridazine (120.0 g, 90%) as a yellow solid, which was used without further purification. MS (ES<sup>+</sup>) C<sub>4</sub>H<sub>2</sub>I<sub>2</sub>N<sub>2</sub> requires: 332, found: 333 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Step 2: Di-<i>tert</i>-butyl 2-(6-iodopyridazin-3-yl)malonate (<b>38</b>)</h4><div class="NLM_p last">To a suspension of NaH (60% in mineral oil, 27.12 g, 678.0 mmol) in THF (750 mL) was added di-<i>tert</i>-butyl propanedioate (100.8 mL, 452.0 mmol), and the mixture was stirred at 28 °C for 15 min. To the mixture was added the above-prepared 3,6-diiodopyridazine (75.00 g, 226.0 mmol), and the reaction mixture was stirred at reflux for 8 h. The reaction mixture was quenched with a sat. aq NH<sub>4</sub>Cl solution (500 mL) and extracted with 1:1 EtOAc/petroleum ether (3 × 500 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by SiO<sub>2</sub> gel chromatography (10:1 petroleum ether/EtOAc) to give di-<i>tert</i>-butyl 2-(6-iodopyridazin-3-yl)malonate (83.00 g, 87%) as a white solid. MS (ES<sup>+</sup>) C<sub>15</sub>H<sub>21</sub>IN<sub>2</sub>O<sub>4</sub> requires: 420, found: 421 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.47 (d, <i>J</i> = 8.8 H, 1H), 5.03 (s, 1H), 1.43 (s, 18H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 165.86, 156.63, 137.92, 129.60, 127.16, 83.03, 59.95, 27.90.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>S</i>)-<i>tert</i>-Butyl 1-(2-fluoro-3-iodopropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (<b>32</b>)</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Step 1: (<i>R</i>)-1-Azido-3-benzyloxy(propan-2-ol) (<b>33</b>)</h4><div class="NLM_p last">To a solution of (<i>R</i>)-2-((benzyloxy)methyl)oxirane (2.423 mL, 15.89 mmol) and NH<sub>4</sub>Cl (1.70 g, 31.8 mmol) in MeOH (39.5 mL) and water (5.92 mL) was added sodium azide (5.17 g, 79.0 mmol), and the resulting mixture was stirred at RT overnight. The mixture was concentrated under reduced pressure, and the residue was partitioned between EtOAc (50 mL) and water (60 mL). The two layers were separated, and the aqueous layer was extracted with EtOAc (3 × 50 mL). The organic layers were combined, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to give (<i>R</i>)-1-azido-3-(benzyloxy)propan-2-ol (3.01 g, 91%) as a colorless oil. MS (ES<sup>+</sup>) C<sub>10</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub> requires: 207, found: 208 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Step 2: (<i>R</i>)-<i>tert</i>-Butyl 1-(3-Benzyloxy)-2-hydroxypropyl-1<i>H</i>-1,2,3-triazole-4-carboxylate (<b>34</b>)</h4><div class="NLM_p last">To a solution of the above-prepared (<i>R</i>)-1-azido-3-(benzyloxy)propan-2-ol (3.01 g, 14.5 mmol), <i>tert</i>-butyl propiolate (2.393 mL, 17.43 mmol), DIEA (0.253 mL, 1.45 mmol), and AcOH (0.083 mL, 1.45 mmol) in DCM (58.1 mL) was added CuI (0.138 g, 0.726 mmol), and the resulting mixture was stirred at RT overnight. SiO<sub>2</sub> gel (10 g) was added to the stirring mixture, and the resulting suspension was filtered and washed with DCM (20 mL) and EtOAc (20 mL). The filtrate was concentrated under reduced pressure to give crude (<i>R</i>)-<i>tert</i>-butyl 1-(3-(benzyloxy)-2-hydroxypropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (3.95 g, 82%) as an orange oil, which was used without further purification. MS (ES<sup>+</sup>) C<sub>17</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub> requires: 333, found: 334 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Step 3: (<i>S</i>)-<i>tert</i>-Butyl 1-(3-Benzyloxy)-2-fluoropropyl-1<i>H</i>-1,2,3-triazole-4-carboxylate (<b>35</b>)</h4><div class="NLM_p last">To a 0 °C solution of the above-prepared (<i>R</i>)-<i>tert</i>-butyl 1-(3-(benzyloxy)-2-hydroxypropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (3.95 g, 11.8 mmol) and pyridine (1.909 mL, 23.70 mmol) in DCM (23.70 mL) was added DAST (3.13 mL, 23.7 mmol). The resulting mixture was stirred at RT for 2.5 h, then filtered through a plug of SiO<sub>2</sub> gel, and rinsed with DCM (50 mL). The filtrate was concentrated under reduced pressure, and the residue was adsorbed onto Celite and purified by SiO<sub>2</sub> chromatography (0–50% EtOAc in hexanes) to give (<i>S</i>)-<i>tert</i>-butyl 1-(3-(benzyloxy)-2-fluoropropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (1.781 g, 45%) as a tan crystalline solid. MS (ES<sup>+</sup>) C<sub>17</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>3</sub> requires: 335, found: 336 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 4: (<i>S</i>)-<i>tert</i>-Butyl 1-(2-Fluoro-3-hydroxypropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (<b>36</b>)</h4><div class="NLM_p last">A reaction vessel was charged with the above-prepared (<i>S</i>)-<i>tert</i>-butyl 1-(3-(benzyloxy)-2-fluoropropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (1.78 g, 5.31 mmol) and EtOAc (53.1 mL) under an atmosphere of N<sub>2</sub>. The solution was purged with N<sub>2</sub> for 10 min and then with N<sub>2</sub> still flowing, Pd(OH)<sub>2</sub> on carbon (0.746 g, 1.06 mmol) was added. The resulting suspension was stirred as it was purged with H<sub>2</sub> for 2 min. The reaction mixture was then stirred under an atmosphere of H<sub>2</sub> at 1 atm for 12 h, then purged with N<sub>2</sub>, filtered through Celite, and concentrated under reduced pressure to give crude (<i>S</i>)-<i>tert</i>-butyl 1-(2-fluoro-3-hydroxypropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (1.32 g, 101%) as a pale yellow solid, which was used without further purification. (1.32 g, 101%). MS (ES<sup>+</sup>) C<sub>10</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>3</sub> requires: 245, found: 246 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 5: (<i>S</i>)-<i>tert</i>-Butyl 1-(2-Fluoro-3-(tosyloxy)propyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (<b>37</b>)</h4><div class="NLM_p last">To a solution of the above-prepared (<i>S</i>)-<i>tert</i>-butyl 1-(2-fluoro-3-hydroxypropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (1.32 g, 5.38 mmol) and DMAP (0.986 g, 8.07 mmol) in DCM (26.9 mL) was added 4-methylbenzene-1-sulfonyl chloride (1.23 g, 6.46 mmol), while the solution was maintained at RT by a water bath. The resulting mixture was stirred at RT for 1.5 h, then diluted with EtOAc (100 mL), and washed with sat. aq NH<sub>4</sub>Cl (2 × 40 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to give crude (<i>S</i>)-<i>tert</i>-butyl 1-(2-fluoro-3-(tosyloxy)propyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (1.803 g, 84%), which was used without further purification. MS (ES<sup>+</sup>) C<sub>17</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>5</sub>S requires: 399, found: 400 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step 6: (<i>S</i>)-<i>tert</i>-Butyl 1-(2-Fluoro-3-iodopropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (<b>32</b>)</h4><div class="NLM_p last">To a solution of the above-prepared (<i>S</i>)-<i>tert</i>-butyl 1-(2-fluoro-3-(tosyloxy)propyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (2.12 g, 5.31 mmol) in acetone (26.5 mL) was added sodium iodide (0.796 g, 5.31 mmol), and the resulting mixture was stirred at 80 °C for 3 h. Additional sodium iodide (1.6 g) was added, and the mixture was stirred at 90 °C for 2 h. The mixture was allowed to cool to RT, then diluted with 1:1 EtOAc/hexanes (150 mL), and sequentially washed with water (2 × 50 mL) and a sat. aq. NaCl solution (50 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was adsorbed onto Celite and purified by SiO<sub>2</sub> gel chromatography (0–50% EtOAc/hexanes) to give (<i>S</i>)-<i>tert</i>-butyl 1-(2-fluoro-3-iodopropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (1.71 g, 91%) as a white crystalline solid. MS (ES<sup>+</sup>) C<sub>10</sub>H<sub>15</sub>FIN<sub>3</sub>O<sub>2</sub> requires: 355, found: 356 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.69 (s, 1H), 5.09–4.95 (m, 1H), 4.87–4.72 (m, 2H), 3.62–3.54 (m, 1H), 3.48–3.40 (m, 1H), 1.54 (s, 9H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 159.87. 140.57, 130.12, 90.42 (d, <i>J</i> = 178.3 Hz), 81.80, 53.52 (d, <i>J</i> = 21.4 Hz), 28.32, 4.26 (d, <i>J</i> = 21.5 Hz).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 2-(4-(3,3-Difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamide</h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Step 1: 2-Chloro-4-(3,3-difluorocyclobutoxy)-6-methylpyridine</h4><div class="NLM_p last">To a suspension of 3,3-difluorocyclobutanol (590 mg, 5.46 mmol) and 2-chloro-6-methyl-4-nitropyridine (0.660 mL, 5.38 mmol) in THF (5.5 mL) was added cesium carbonate (3562.4 mg, 10.93 mmol), and the resulting orange-yellow mixture was stirred at 65 °C for 24 h. The resulting brown mixture was allowed to cool, then diluted with 11 mL of EtOAc, and filtered through Celite 545, rinsing well with ethyl acetate. The dark yellow filtrate was concentrated to give crude 2-chloro-4-(3,3-difluorocyclobutoxy)-6-methylpyridine (1231.5 mg, 98%) as a dark yellow oil, which was used without further purification. MS (ES<sup>+</sup>) C<sub>10</sub>H<sub>10</sub>ClF<sub>2</sub>NO requires: 233, found: 234 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Step 2: <i>tert</i>-Butyl 2-Cyano-2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetate</h4><div class="NLM_p last">A mixture of the above-prepared 2-chloro-4-(3,3-difluorocyclobutoxy)-6-methylpyridine (487 mg, 2.08 mmol), <i>tert</i>-butyl 2-cyanoacetate (0.456 mL, 3.13 mmol), cesium carbonate (2048.6 mg, 6.29 mmol), and chloro(2-di-<i>tert</i>-butylphosphino-2′.4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) (74.1 mg, 0.108 mmol) in toluene (20 mL) was degassed by blowing N<sub>2</sub> through a needle for 5 min, then put under N<sub>2</sub> in an air condenser, heated to 110 °C over 5 min, and stirred for 1 h. The orange mixture was allowed to cool, then concentrated to a yellow-orange solid. The residue was purified via SiO<sub>2</sub> gel chromatography (0–100% EtOAc in hexanes) to give <i>tert</i>-butyl 2-cyano-2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetate (555.6 mg, 79%) as a yellow solid.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step 3: 2-(4-(3,3-Difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamide</h4><div class="NLM_p last">A flask with stirbar was sequentially charged with water (0.296 mL), conc. aq HCl (5.616 mL), and <i>tert</i>-butyl 2-cyano-2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetate (203.0 mg, 0.600 mmol). The yellow mixture was stirred at RT for 4 h, in which time it became a yellow solution. The solution was chilled in an ice/water bath, then treated with 30 mL of a 2.0 M aqueous NaOH solution and further adjusted to pH 7 using 2.0 M aqueous NaOH (3–4 mL) then 1 M aqueous HCl (0.5–1 mL). The solution was extracted with EtOAc (3 × 15 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give 2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamide (133.0 mg, 87%) as an off-white solid, which was used without further purification. MS (ES<sup>+</sup>) C<sub>12</sub>H<sub>14</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> requires: 256, found: 257 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.46 (br. s, 1H), 6.94 (br. s, 1H), 6.69–6.68 (m, 2H), 4.84–4.78 (m, 1H), 3.46 (s, 2H), 3.27–3.19 (m, 2H), 2.74–2.65 (m, 2H), 2.38 (s, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 171.57, 163.79, 159.43, 157.74, 119.43 (dd, <i>J</i> = 281.5, 270.9 Hz), 108.55, 107.88, 61.69 (dd, <i>J</i> = 17.0, 10.3 Hz), 45.13, 42.89 (appar. t, <i>J</i> = 22.8 Hz), 24.52.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>R</i>)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) Pyridazin-3-yl)-2-fluorobutyl)-<i>N</i>-methyl-1<i>H</i>-1,2,3-triazole-4-carboxamide (<b>27</b>)</h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Step 1: (<i>R</i>)-di-<i>tert</i>-Butyl 2-(3-(4-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-1,2,3-triazol-1-yl)-2-fluoropropyl)-2-(6-iodopyridazin-3-yl)malonate (<b>39</b>)</h4><div class="NLM_p last">A mixture of potassium carbonate (0.412 g, 2.98 mmol), di-<i>tert</i>-butyl 2-(6-iodopyridazin-3-yl)malonate (38) (1.25 g, 2.98 mmol), and (<i>S</i>)-<i>tert</i>-butyl 1-(2-fluoro-3-iodopropyl)-1<i>H</i>-1,2,3-triazole-4-carboxylate (32) (1.00 g, 2.82 mmol) in a vial was degassed and then treated with DMF (9.39 mL). The mixture was degassed and backfilled with N<sub>2</sub> for three cycles and then stirred at 25 °C for 80 h. The mixture was diluted with EtOAc/hexanes (1:1, 200 mL) and washed with water (2 × 100 mL). The combined aqueous layers were extracted with EtOAc/hexanes (1:1, 100 mL). The combined organic layers were concentrated, washed with a sat. aq NaCl solution, and concentrated under reduced pressure. The residue was purified by SiO<sub>2</sub> gel chromatography (5–60% EtOAc in hexanes) to give (<i>R</i>)-di-<i>tert</i>-butyl 2-(3-(4-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-1,2,3-triazol-1-yl)-2-fluoropropyl)-2-(6-iodopyridazin-3-yl)malonate (1.36 g, 75%) as a yellow liquid. MS (ES<sup>+</sup>) C<sub>25</sub>H<sub>35</sub>FIN<sub>5</sub>O<sub>6</sub> requires: 647, found: 648 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Step 2: Di-<i>tert</i>-butyl (<i>R</i>)-2-(3-(4-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-1,2,3-triazol-1-yl)-2-fluoropropyl)-2-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)malonate (<b>41</b>)</h4><div class="NLM_p last">A degassed solution of (<i>R</i>)-di-<i>tert</i>-butyl 2-(3-(4-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-1,2,3-triazol-1-yl)-2-fluoropropyl)-2-(6-iodopyridazin-3-yl)malonate (<b>39</b>) (42.4 g, 65.6 mmol), 2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamide (14.0 g, 54.6 mmol), cesium carbonate (35.6 g, 109 mmol), Xantphos (6.32 g, 10.9 mmol), and allylpalladium chloride dimer (1.00 g, 2.73 mmol) in 1,4-dioxane (300 mL) was stirred at 70 °C for 16 h. The reaction mixture was allowed to cool to RT, then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by SiO<sub>2</sub> gel chromatography (0–3% MeOH in DCM) to give di-<i>tert</i>-butyl (<i>R</i>)-2-(3-(4-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-1,2,3-triazol-1-yl)-2-fluoropropyl)-2-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)malonate (36.5 g, 86%) as a foamy yellow solid. MS (ES<sup>+</sup>) C<sub>37</sub>H<sub>48</sub>F<sub>3</sub>N<sub>7</sub>O<sub>8</sub> requires: 775, found: 776 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Step 3: (<i>R</i>)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) Pyridazin-3-yl)-2-fluorobutyl)-1<i>H</i>-1,2,3-triazole-4-carboxylic Acid (<b>42</b>)</h4><div class="NLM_p last">A solution of (<i>R</i>)-di-<i>tert</i>-butyl 2-(3-(4-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-1,2,3-triazol-1-yl)-2-fluoropropyl)-2-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)malonate (36.0 g, 46.4 mmol) in 4.0 M HCl in 1,4-dioxane (696.0 mL, 2784 mmol) was stirred at 70 °C for 16 h. A white precipitate formed. The reaction mixture was allowed to cool to RT, and the precipitate was isolated by filtration, washed with EtOAc, and dried in vacuo to give crude (<i>R</i>)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-1<i>H</i>-1,2,3-triazole-4-carboxylic acid as an off-white solid, which was used without further purification in the next step. MS (ES<sup>+</sup>) C<sub>23</sub>H<sub>24</sub>F<sub>3</sub>N<sub>7</sub>O<sub>4</sub> requires: 519, found: 520 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Step 4: (<i>R</i>)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) Pyridazin-3-yl)-2-fluorobutyl)-<i>N</i>-methyl-1<i>H</i>-1,2,3-triazole-4-carboxamide (<b>27</b>)</h4><div class="NLM_p last">To a solution of crude (<i>R</i>)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-1<i>H</i>-1,2,3-triazole-4-carboxylic acid hydrochloride prepared in the previous step (assumed 46.4 mmol) in DMF (200 mL) at 0 °C were added 1-[<i>bis</i>(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]- pyridinium 3-oxide hexafluorophosphate (HATU; 17.64 g, 46.4 mmol), DIEA (40.5 mL, 232 mmol), and 2.0 M methylamine in THF (27.8 mL, 55.7 mmol). The resulting mixture was stirred at 20 °C for 1 h and then concentrated under reduced pressure. Water (1000 mL) and DCM (500 mL) were added, and the layers were separated. The aqueous layer was extracted with DCM (3 × 300 mL), and the combined organic layers were washed with sat. aq NaCl, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by SiO<sub>2</sub> gel chromatography (0–8% MeOH in DCM) to give (<i>R</i>)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-<i>N</i>-methyl-1<i>H</i>-1,2,3-triazole-4-carboxamide (16.8 g, 68%) as a white solid. HRMS (ES<sup>+</sup>) C<sub>24</sub>H<sub>28</sub>F<sub>3</sub>N<sub>8</sub>O<sub>3</sub> requires: 533.2231 [M + H]<sup>+</sup>, found: 533.2229 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 11.30 (s, 1 H), 8.51 (s, 1 H), 8.47 (q, <i>J</i> = 4.4, 1 H), 8.22 (d, <i>J</i> = 9.1 Hz, 1 H), 7.60 (d, <i>J</i> = 9.3 Hz, 1 H), 6.79 (d, <i>J</i> = 2.5 Hz, 1 H), 6.72 (d, <i>J</i> = 2.5 Hz, 1 H), 5.09–4.96 (m, 1 H), 4.90–4.70 (m, 3 H), 3.87 (s, 2 H), 3.28–3.18 (m, 2 H), 3.08–2.98 (m, 2 H), 2.76 (d, <i>J</i> = 4.9 Hz, 3 H), 2.75–2.63 (m, 2 H), 2.39 (s, 3H), 2.20–1.95 (m, 2 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 169.58, 163.45, 160.01, 159.21, 158.70, 156.32, 154.13, 142.99, 128.42, 126.88, 118.94 (dd, <i>J</i> = 281.7, 270.4 Hz), 108.52, 107.73, 91.25 (d, <i>J</i> = 172.3 Hz), 62.31 (dd, <i>J</i> = 16.98, 10.69 Hz), 52.99 (d, <i>J</i> = 21.4 Hz), 45.14, 42.41 (appar. t, <i>J</i> = 22.6 Hz), 31.04 (d, <i>J</i> = 20.1 Hz), 30.07 (d, <i>J</i> = 3.8 Hz), 25.53, 24.07. An assumed <i>bis</i>-hydrochloride salt was used in in vivo experiments described in the text, as well as to confirm enantiopurity using a chiral HPLC method validated with mixtures of the title compound and its (<i>S</i>) enantiomer (synthesized in the same way but starting with (<i>S</i>)-2-((benzyloxy)methyl)oxirane in place of (<i>R</i>)-2-((benzyloxy)methyl)oxirane). The <i>bis</i>-hydrochloride salt was made as follows: To a solution of (<i>R</i>)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-<i>N</i>-methyl-1<i>H</i>-1,2,3-triazole-4-carboxamide (12.71 g, 23.87 mmol) in MeOH (20 mL) and DCM (60 mL) at 0 °C was added HCl in dioxane (4.0 M, 11.93 mL, 47.70 mmol), and the resulting mixture was stirred for 5 min and then concentrated under reduced pressure. The residue was redissolved in acetonitrile (ACN) and water, lyophilized, and the resulting solid was triturated with EtOAc and dried in vacuo to give (<i>R</i>)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-<i>N</i>-methyl-1<i>H</i>-1,2,3-triazole-4-carboxamide <i>bis</i>-hydrochloride (14.03 g, 97%) as a white solid. MS (ES<sup>+</sup>) C<sub>24</sub>H<sub>27</sub>F<sub>3</sub>N<sub>8</sub>O<sub>3</sub> requires: 532, found: 533 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 11.66 (s, 1 H), 8.53 (s, 1 H), 8.47 (q, <i>J</i> = 5.3, 1 H), 8.23 (d, <i>J</i> = 9.1 Hz, 1 H), 7.73 (d, <i>J</i> = 9.5 Hz, 1 H), 7.44 (d, <i>J</i> = 2.0 Hz, 1 H), 7.39 (d, <i>J</i> = 2.0 Hz, 1 H), 4.96–5.11 (m, 2 H), 4.67–4.86 (m, 2 H), 4.36 (s, 2 H), 3.34 (m, 2 H), 3.07 (m, 2 H), 2.87 (m, 2 H), 2.76 (d, <i>J</i> = 4.9 Hz, 3 H), 2.68 (s, 3 H), 2.24–1.95 (m, 2 H). The compound (2 mg/mL, 10 μL per injection) was analyzed on a Shimadzu Prominence HPLC system with a Lux Cellulose 4 column (4.6 mm × 150 mm, 5 μM, 1 mL/min) using a mobile phase of water/acetonitrile (50:50) and showed an enantiomeric excess of >98%. Retention time: 11.3 min.</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> In Vitro Pharmacology</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> GLS-1 Enzyme Assay</h4><div class="NLM_p last">The glutaminase dual-coupled fluorescence assay was performed in a 384-well, black, Greiner, nonbinding plate (Greiner, Catalog #784900) with assay buffer consisting of 50 mM Hepes (pH 7.4) (Gibco, Catalog #15630-080), 250 μM ethylenediaminetetraacetic acid (EDTA; pH 8) (Calbiochem, Catalog #4055), and 0.12 mM Triton-X 100 (Sigma, Catalog #T9284). All final concentrations refer to a 20 μL volume. Stock solutions of the test compounds were prepared in 100% dimethyl sulfoxide (DMSO; Sigma, Catalog #D2650) and serially diluted 1:3 using 100% DMSO. Compounds were additionally diluted 1:50 in assay buffer, and 5 μL/well were transferred to the assay plate. A 4× stock of glutaminase and potassium phosphate dibasic trihydrate (Sigma, Catalog #P5504) diluted in assay buffer was preincubated at RT for 10 min. Glutaminase with potassium phosphate dibasic trihydrate (5 μL/well) was added to the microplate (final concentrations 2 nM and 50 mM, respectively) followed by a 10 min incubation at RT. The coupled reaction consisted of glutamate oxidase (Sigma, Catalog #G5921), Amplex UltraRED (Molecular Probes, Catalog #A36006), glutamine (Sigma, Catalog #G3126), and horseradish peroxidase (Sigma, Catalog #P8375). Glutamate oxidase (5 μL/well) and Amplex UltraRED diluted in assay buffer (final concentrations 100 mU/mL and 75 μM, respectively) and 5 μL/well of glutamine and horseradish peroxidase diluted in assay buffer (final concentrations 1 mM and 100 mU/mL, respectively) were added to the microplate under subdued light followed by a 20 min incubation at RT. The resorufin signal was measured using a PerkinElmer Envision plate reader: excitation, 535 nm; emission, 590 nm. IC<sub>50</sub> values were calculated using a four-parameter logistic curve fit using Genedata Screener software.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> GLS-2 Enzyme Assay</h4><div class="NLM_p last">The GLS2 dual-coupled fluorescence assay was performed in a 384-well, black, Greiner, nonbinding plate (Greiner, Catalog #784900) with assay buffer consisting of 50 mM Hepes (pH 7.4) (Gibco, Catalog #15630-080), 250 μM EDTA (pH 8) (Calbiochem, Catalog #4055), and 0.12 mM Triton-X 100 (Sigma, Catalog #T9284). All final concentrations refer to a 20 μL volume. Stock solutions of the test compounds were prepared in 100% DMSO (Sigma, Catalog #D2650) and serially diluted 1:3 using 100% DMSO. Compounds were additionally diluted 1:50 in assay buffer, and 5 μL/well were transferred to the assay plate. A 4× stock of GLS-2 and potassium phosphate dibasic trihydrate (Sigma, Catalog #P5504) diluted in assay buffer was preincubated at RT for 10 min. GLS-2 with potassium phosphate dibasic trihydrate (5 μL/well) was added to the microplate (final concentrations 33 nM and 50 mM, respectively) followed by a 10 min incubation at RT. The coupled reaction consisted of glutamate oxidase (Sigma, Catalog #G5921), Amplex UltraRED (Molecular Probes, Catalog #A36006), glutamine (Sigma, Catalog #G3126), and horseradish peroxidase (Sigma, Catalog #P8375). Glutamate oxidase (5 μL/well) and Amplex UltraRED diluted in assay buffer (final concentrations 100 mU/mL and 75 μM, respectively) and 5 μL/well of glutamine and horseradish peroxidase diluted in assay buffer (final concentrations 3 mM and 100 mU/mL, respectively) were added to the microplate under subdued light. The resorufin signal was measured continuously for 20 min using a PerkinElmer Envision plate reader: excitation, 535 nm; emission, 590 nm. IC<sub>50</sub> values were calculated using a four-parameter logistic curve fit using Genedata Screener software.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> A549 Cell Viability Assay</h4><div class="NLM_p last">A549 cells were routinely maintained in filtered Roswell Park Memorial Institute (RPMI) media (Gibco, Catalog #11875) supplemented with 10% dialyzed fetal bovine serum (FBS; Corning, Catalog #35-071-CV) using a humidified incubator (37 °C, 5% CO<sub>2</sub>, and ambient O<sub>2</sub>). In preparation for the viability assay, the cells were harvested and resuspended in filtered RPMI media supplemented with 10% dialyzed FBS (Corning, Catalog #35-071-CV). The cells were seeded onto a 384-well, black PerkinElmer tissue culture plate (PerkinElmer, Catalog #6007660) at a density of 1000 cells/well in a volume of 40 μL. The tissue culture plate was incubated for 24 h at 37 °C with 5% CO<sub>2</sub> and ambient O<sub>2</sub>. Stock solutions of the test compounds were prepared in 100% DMSO (Sigma, Catalog #D2650) and serially diluted 1:3 using 100% DMSO. Compounds were additionally diluted 1:40 in culture medium, and 10 μL/well were transferred to the tissue culture plate. Following compound addition, the microplate was incubated at 37 °C for 72 h. Promega’s CellTiter-Fluor reagent (10 μL, Promega, Catalog #G6082), GF-AFC substrate diluted in assay buffer, was added to the plate for a 1× final concentration. 0.5% DMSO and 20 μM etoposide were used as controls to define 100 and 0% viability, respectively. The plate was then shaken on an orbital shaker at 300 revolutions per minute (RPM) for 15 min at RT followed by a 30 min incubation at 37 °C. The CellTiter-Fluor signal was measured using a PerkinElmer Envision plate reader: excitation, 400 nm; emission, 505 nm. IC<sub>50</sub> values were calculated using a four-parameter logistic curve fit using Genedata Screener software.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> A549 Target Engagement Assay</h4><div class="NLM_p last">A549 cells were routinely maintained in filtered RPMI media (Gibco, Catalog 11875) supplemented with 10% dialyzed FBS (Corning, Catalog #35-071-CV) using a humidified incubator (37 °C, 5% CO<sub>2</sub>, and ambient O<sub>2</sub>). In preparation for the target engagement assay, the cells were harvested and resuspended in filtered RPMI media supplemented with 10% dialyzed FBS (Corning, Catalog #35-071-CV). The cells were seeded onto a 96-well tissue culture plate (Falcon, Catalog #353072) at a density of 15 000 cells/well in a volume of 100 μL. The tissue culture plate was incubated for 24 h at 37 °C with 5% CO<sub>2</sub> and ambient O<sub>2</sub>. Stock solutions of the test compounds were prepared in 100% DMSO (Sigma, Catalog #D2650) and serially diluted 1:3 using 100% DMSO. Compounds were additionally diluted 1:200 in culture medium, and 200 μL/well were transferred to the tissue culture plate. Following compound addition, the microplate was incubated at 37 °C for 24 h. The <span class="smallcaps smallerCapital">l</span>-glutamine and <span class="smallcaps smallerCapital">l</span>-glutamate levels in the media were then measured using the YSI 2900 Biochemistry Analyzer (Xylem). IC<sub>50</sub> values were calculated using a four-parameter logistic curve fit using Genedata Screener software.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> In Vitro Metabolic Stability, Solubility, Caco-2 Permeability, Plasma Protein Binding, hERG and CYP Inhibition Experiments</h3><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Microsomal Stability</h4><div class="NLM_p last">Microsomal stability assays were conducted on a Beckmann Biomek FXp laboratory automation system. The liver microsomal incubation mixture consisted of liver microsomes (0.5 mg microsomal protein/mL), the test compound (1 μM), MgCl<sub>2</sub> (3 mM), and EDTA (1 mM) in potassium phosphate buffer (100 mM, pH 7.4). Midazolam and Ketanserin were used as the assay control substrates. The reaction was initiated with the addition of a nicotinamide adenine dinucleotide phosphate (NADPH) regeneration solution (1.3 mM NADPH) and maintained at 37 °C with shaking. At five time points ranging from 0 to 45 min, aliquots (50 μL) were removed and quenched with acetonitrile (100 μL) containing an internal standard (imipramine). After vortex and centrifugation, the samples were analyzed by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Calculation of the in vitro half-lives and clearance followed literature guidelines.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Hepatocytes Stability</h4><div class="NLM_p last">Hepatocytes were purchased from Bioreclamation IVT, Xenotech, or RILD. Stock solutions were prepared at 10 mM in DMSO for the test compound. Aliquots of the stock solutions were diluted to 200 μM with DMSO and then further diluted to 2 μM with Krebs–Henseleit buffer (KHB) buffer. The procedure was as follows: Count hepatocytes and then dilute the cell suspensions to the appropriate density (viable cell density = 2 × 10<sup>6</sup> cells/mL). Add 50 μL of prewarmed (37 °C) 2 μM test compound to the wells designated for different time points. For 0 min, add 100 μL of ACN containing internal standard (IS) to the wells followed by 50 μL of hepatocytes solution and then seal the wells. Add 50 μL of prewarmed hepatocytes solution to the wells designated for 15, 30, 60, and 120 min, and start timing. Place the assay plate in an incubator at 37 °C. At 15, 30, 60, and 120 min, add 100 μL of ACN to the wells, respectively, then seal the corresponding wells. After quenching, sonicate the plate for 5 min and then centrifuge at 5594<i>g</i> for 15 min (Thermo Multifuge × 3R). Transfer 50 μL of the supernatant from each well into a 96-well sample plate containing 120 μL of ultrapure water for LC/MS analysis. The peak area response ratio (PARR) to IS of the compounds at 15, 30, 60, and 120 min was compared to the PARR at 0 min to determine the percent of the test compound remaining at each time point. Half-lives were calculated using Excel software, fitting to a single-phase exponential decay equation.</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Kinetic Solubility</h4><div class="NLM_p last">Studies were conducted in 100 mM phosphate buffer (pH 7.4). A stock solution was prepared at 10 mM in DMSO for each test compound. Stock solutions (10 μL) were added into 990 μL of 100 mM phosphate buffer (pH 7.4) for final concentrations of test compounds of 100 μM. The assay plate was shaken on a vibrator (IKA, MTS 2/4) for 1 h at 1000 rpm at RT and then centrifuged at 12 000 rpm (Thermo Fisher) for 10 min to precipitate undissolved particles. An aliquot of the supernatant was taken from each well and diluted 10× with buffer, then analyzed by LC-MS/MS compared to a standard curve.</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Thermodynamic Solubility</h4><div class="NLM_p last">Studies were conducted in buffers as listed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Tables <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Approximately 2 mg of each test compound was weighed into a 2 mL vial, and to the vial was then added 1 mL of buffer. Each sample was vortexed for 30 s to achieve a homogenous dispersion, and then shaken on a Labquaker for 24 h at RT. If all solid dissolved, then an additional test compound was added. After 24 h, the visual appearance of each sample was noted, and the sample was manually filtered through a 0.45 μm nylon filter. The subsequent filtrate, diluted as necessary with a suitable solvent, was analyzed by LC-MS/MS compared to a standard curve.</div></div><div id="sec4_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Caco-2 Permeability</h4><div class="NLM_p last">Caco-2 cells were obtained from American Tissue Culture Collection (Rockville, MD). The cells were maintained in modified Eagle’s medium (MEM) containing 10% heat-inactivated FBS and 1% non-essential amino acids, in CO<sub>2</sub> at 37 °C. Cells were seeded on polycarbonate filter inserts (Millipore, CAT#PSHT 010 R5). The cells were cultured for 21–28 days prior to the transport experiments. The transepithelial electric resistance (TEER) and Lucifer Yellow permeability were checked before and after the assay. Compounds were dissolved at 10 mM in DMSO and diluted for studies in Hank’s Balanced Salt Solution (HBSS, Invitrogen, Cat #14025-092) with 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4. Compounds were tested at 10 μM, in both the apical-to-basolateral (A–B) and basolateral-to-apical (B–A) directions, and were tested at 37 °C for 90 min. At the end of incubation, donor samples were diluted 10-fold by assay buffer, then 60 μL of receiver and diluted-donor samples were mixed with 60 μL of acetonitrile and concentrations were analyzed by LC-MS/MS compared to a standard curve.</div></div><div id="sec4_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Plasma Protein Binding</h4><div class="NLM_p last">Plasma protein binding (PPB) assays were conducted using the Rapid Equilibrium Dialysis (RED) device (Thermo Fisher Scientific). Warfarin and metoprolol were used as the control substrates. To the receiver side was added 350 μL of phosphate buffered saline (pH 7.4, 1×, Gibco). To the donor side was added 200 μL of plasma (Bioreclamation IVT) spiked with the test compound (5 μM). The same plasma/test compound solution (50 μL) was also used for the recovery sample. The plate was covered with Immunoware sealing tape and was incubated at 37 °C with shaking at 100 rpm for 5 h. After the incubation, both the receiver and donor sides were sampled (50 μL) and matched with the same volume of matrix from the other side. The recovery, donor, and receiver samples were extracted with 300 μL of cold ACN containing imipramine as the internal standard. After vortex and centrifugation, the supernatant (150 μL) was subjected to LC-MS quantitation. PPB (% bound) was calculated as % bound = 100 × ([donor] – [receiver])/[donor].</div></div><div id="sec4_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> hERG Qpatch (Automated Electrophysiology) Assay</h4><div class="NLM_p last">A CHO cell line stably transfected with hERG cDNA and expressing hERG channels was used for studies. The cells were cultured in medium (from Invitrogen) containing Ham’s F12, 10% (v/v) heat-inactivated FBS, 100 μg/mL hygromycin B, and 100 μg/mL Geneticin. The cells used in the QPatch study met the following criteria: under microscopy examination, the majority of cells in suspension were single and isolated; their viability was greater than 95%, with only a few debris and cell clumps (which may clog the holes in QPlate during whole-cell clamp recording); cell density ranged within 3–8 × 10<sup>6</sup> cells/mL in the final suspension before applying to the QPatch stir chamber. After leaving the CO<sub>2</sub> incubator, the cells were maintained in serum-free medium buffered with HEPES. The cells were used for recording within 4 h after harvesting. Whole-cell recordings were performed using automated QPatch (Sophion, Denmark). The cells were voltage clamped at a holding potential of −80 mV. The hERG current was activated by depolarizing at +20 mV for 5 s, after which the current was taken back to −50 mV for 5 s to remove the inactivation and observe the outward tail current. The maximum amount of tail current size was used to determine hERG current amplitude. After achieving break-in (whole-cell) configuration, the cells were recorded for 120 s to assess current stability. The voltage protocol described above was then applied to the cells every 15 s throughout the whole procedure. Only stable cells with recording parameters above threshold were allowed to enter the drug application procedure. All experiments were conducted at RT (about 25 °C). External solution containing 0.1% DMSO (vehicle) was applied to the cells to establish the baseline. After allowing the current to stabilize for 3 min, the compound was applied. Compound solution was added, and the cells were kept in the test solution until the compound’s effect reached a steady state or for a maximum of 4 min. For the dose–response assay, the compound was applied to the cells accumulatively from low to high concentrations. Washout with external solution was performed after compound testing. Positive control cisapride was used to test the same batch of hERG cells for compound testing to ensure the normal response and quality of cells. Data were analyzed using Assay Software provided by Sophion, XLFit, and GraphPad Prism.</div></div><div id="sec4_7_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> CYP Inhibition Assays</h4><div class="NLM_p last">Studies were carried out in human liver microsomes (0.1 mg/mL for CYP 1A2/2C9/2D6/3A4; 0.5 mg/mL for CYP 2C19). Liver microsomes were purchased from BD Gentest. Aliquots of the compound stock solutions were diluted to 4 mM with acetonitrile, and then further diluted upon the addition of liver microsomes (0.2 mg/mL). An aliquot of 30 μL of diluted test compound solution was mixed with 15 μL of substrate solution. The plate was prewarmed to 37 °C, then 15 μL of 8 mM NADPH (also prewarmed to 37 °C) was added. The plate was incubated at 37 °C for the following incubation times: 5 min for 3A4, 10 min for 1A2/2C9/2D6, and 45 min for 2C19. The reaction was stopped by adding acetonitrile at the designated time point. The assay plates were shaken on a vibrator (IKA, MTS 2/4) for 10 min (600 rpm) and centrifuged at 5594<i>g</i> for 15 min (Thermo Multifuge × 3R). Aliquots of the supernatant were taken, diluted 1:3 into distilled water, and metabolite concentrations were analyzed by LC-MS/MS compared to internal standards. Substrates used were Phenacetin (30 μM) for 1A2, diclofenac (10 μM) for 2C9, <i>S</i>-Mephenytoin (35 μM) for 2C19, Midazolam (10 μM) or Testosterone (80 μM) for 3A4, and Bufuralol (10 μM) for 2D6. Metabolites measured were Acetaminophen for 1A2, 4′-Hydroxy-Diclofenac for 2C9, Hydroxy-Mephenytoin for 2C19, 1-Hydroxy-Midazolam or Osalmid for 3A4, and 1-Hydroxy-Bufuralol for 2D6. Positive control inhibitors used were α-Naphthoflavone for CYP1A2, Sulfaphenazole for CYP2C9, Omeprazole for CYP2C19, Quinidine for CYP2D6, and Ketoconazole for CYP3A4. The peak area response ratio (PARR) of metabolite to internal standard of the metabolites in test compound samples at desired time points was compared to the PARR in control samples to determine the percent of control sample (% control) at each time point. Percent inhibition was calculated as 100% control.</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> In Vivo Pharmacokinetics</h3><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Mouse</h4><div class="NLM_p last">Female mice (CD1 strain, purchased from Shanghai JH Laboratory Animal Co., Ltd.), weighing 20–30 g were used for studies. Food and water were available to all of the animals ad libitum. Test article was dosed via tail vein (IV doses) or oral gavage (PO doses), respectively. Blood samples were collected from all of the animals at predose and at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose into tubes containing the anticoagulant K2EDTA (three animals per time point with three time points collected per animal). Plasma was separated from the blood by centrifugation at 4 °C and stored at −70 °C until analysis. Test article concentrations in plasma were quantified using a liquid chromatography with tandem mass spectrometry (LC-MS/MS) method.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Rat</h4><div class="NLM_p last">Male rats (SD strain, purchased from Shanghai JH Laboratory Animal Co., Ltd.) weighing 200–300 g were used for studies. The animals were fasted overnight and fed 4 h postdose. Water was available ad libitum for all of the animals. Test article was dosed via dorsal foot vein (IV doses) or oral gavage (PO doses). Blood samples were collected via tail vein from all of the animals at predose and at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose into tubes containing the anticoagulant K2EDTA. Plasma was separated from the blood by centrifugation at 4 °C and stored at −70 °C until analysis. Test article concentrations in plasma were quantified using a liquid chromatography with tandem mass spectrometry (LC-MS/MS) method.</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Dog</h4><div class="NLM_p last">Male Beagle dogs (purchased from Beijing Marshall Biotechnology Co., Ltd.) weighing 7–10 kg were used for studies. The animals were fasted overnight and fed 4 h postdose. Test article was administered to dogs via the cephalic vein (IV doses) or oral gavage (PO doses). Blood samples were collected via the saphenous vein or cephalic vein from all of the animals at predose and 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose into tubes containing the anticoagulant K2EDTA. Plasma was separated from the blood by centrifugation at 4 °C and stored at −70 °C until analysis. Test article concentrations in plasma were quantified using a liquid chromatography with tandem mass spectrometry (LC-MS/MS) method.</div></div><div id="sec4_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Monkey</h4><div class="NLM_p last">Male Cynomolgus monkeys (purchased from Hainan Jingang Biotech. Co., Ltd.) weighing 3–5 kg were used for studies. The animals were fasted overnight and fed 4 h postdose. Test article was administered to monkeys via the cephalic vein (IV doses) or nasal gavage (PO doses). Blood samples were collected via the saphenous vein or cephalic vein from all of the animals at predose and 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose into tubes containing the anticoagulant K2EDTA. Plasma was separated from the blood by centrifugation at 4 °C and stored at −70 °C until analysis. Test article concentrations in plasma were quantified using a liquid chromatography with tandem mass spectrometry (LC-MS/MS) method.</div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> In Vivo Models</h3><div class="NLM_p">All experiments were conducted in compliance with institutional guidelines.</div><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Glutamine and Glutamate Levels in H460 Xenograft Model</h4><div class="NLM_p last">NSG female mice (Jackson Labs) were implanted with H460 cells (5 × 10<sup>5</sup> cells/mouse diluted with matrigel 1:1). The mice were between 6 and 10 weeks old. All of the animals received LabDiet 5053 chow ad libitum. Tumors were allowed to grow to 300–400 mm<sup>3</sup>, and the animals were treated with compound <b>27</b> (<i>bis</i>-hydrochloride) formulated in 0.5% methylcellulose in sterile water. The animals were euthanized via CO<sub>2</sub> at 8 or 24 h after a single dose of compound <b>27</b> by oral gavage, and tumors were harvested. Each group contained six animals. The tumors were weighed and snap-frozen. Tumor sections were homogenized using an OmniBEAD Ruptor 24 at 100 mg tissue/mL in MeOH/Water (80:20) containing <sup>13</sup>C5-<span class="smallcaps smallerCapital">l</span>-glutamine and <sup>13</sup>C5-<span class="smallcaps smallerCapital">l</span>-glutamate as internal standards. Homogenates were centrifuged at 15 000 rpm at 4 °C for 10 min. An aliquot of 10 μL of the supernatant was diluted with 190 μL of 0.1% formic acid in ACN/water (50:50), vortexed for 15 s, and centrifuged at 15 000 rpm at 4 °C for 5 min. The samples were analyzed on an Agilent 1290 infinity LC system coupled with an Agilent 6460 triple quadrupole mass spectrometer operated at positive mode (ESI<sup>+</sup>). A Waters XBridge Amide column (3.5 μm; 4.6 × 100 mm) was used for analyte separation. The HPLC buffer A was 95% (v/v) water/ACN containing 20 mM ammonium hydroxide and 20 mM ammonium acetate. The HPLC buffer B was 100% ACN. The gradient was 80% B (0–1 min), 80–10% B (1–3 min), 10% B (3–5 min), 10–80% B (5–5.3 min), and 80% B (5.3–10 min). The column temperature was 40 °C, and the flow rate 0.5 mL/min. The sample injection volume was 2 μL. The detection conditions of the mass spectrometer were as follows: capillary voltage, 4000 V; nebulizer pressure, 35 psi; cell accelerate voltage, 4 V; sheath gas temperature, 400 °C; sheath gas flow, 11 L/min; source gas temperature, 300 °C; source gas flow, 11 L/min; fragmenter voltage, 80 V; collision energy, 26 V (glutamate) and 14 V (glutamine). Metabolites were detected by compound-specific multiple reaction monitoring transition (MRM) and retention time (RT): Glutamine (<i>m</i>/<i>z</i> 147 > 84, RT 4.93 min), <sup>13</sup>C5-Glutamine (<i>m</i>/<i>z</i> 152 > 88, RT 4.93 min), Glutamate (<i>m</i>/<i>z</i> 148 > 84, RT 4.78 min), <sup>13</sup>C5-Glutamate (<i>m</i>/<i>z</i> 153 > 88, RT 4.78 min). The method was validated with an analytical range of 10–5000 ng/mL for both glutamine and glutamate in ACN/water (1:1). GraphPad Prism was used for generation of graphs, and data are expressed as mean ± standard deviation.</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Efficacy in Ru337 PDX Model</h4><div class="NLM_p last">NSG female mice (8 weeks old, Jackson Labs) were implanted with Ru337 (Memorial Sloan Kettering Cancer Center) patient-derived xenografts (PDX) subcutaneously on the right flank. Tumors were allowed to grow to an average volume of 100 mm<sup>3</sup>, as monitored by caliper measurements. The animals were then randomized into groups of eight. All of the animals received chow ad libitum. The mice were treated with compounds on a 5 day-on/2 day-off schedule. Compound <b>27</b> was formulated in 0.5% methylcellulose in sterile water and dosed at 100 mg/kg, PO, BID (doses administered approximately 8 h apart (8:00 and 16:00) each dosing day followed by a 16 h gap before the next day’s dose). TAK-228 was formulated in 5% sucrose and 0.5% methylcellulose in sterile water and dosed at 1 mg/kg, PO, QD. Bodyweights were monitored twice per week. Tumor volume was calculated using the formula: <i>V</i> = <i>l</i><sup>2</sup> × <i>L</i>/2 (<i>l</i> = length; <i>L</i> = width). GraphPad Prism was used for generation of graphs, and data are expressed as mean ± standard deviation. For the combination arms, standard deviations were very low (bars smaller than the size of plotted datapoints).</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Molecular Modeling</h3><div class="NLM_p last">The molecular model in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> of compound <b>5</b> bound to GLS1 was generated using Molecular Operating Environment (MOE, 2019.01; Chemical Computing Group ULC, 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2019). The X-ray crystal structure of GLS1 with <b>2</b> (BPTES) bound (PDB 3UO9) was prepared for modeling using the QuickPrep routine in MOE. Compound <b>2</b> was then removed from the structure, and <b>5</b> was docked using the general docking module within MOE. The top-scoring ligand pose for <b>5</b> that replicated the binding mode and interactions between BPTES and GLS1 was subjected to additional energy minimization in MOE, while holding the protein coordinates fixed to arrive at the final model.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01398" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01398?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01398</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Experimental details for the preparation of compounds <b>5</b>–<b>26</b>; UPLC and high-resolution mass spectrometry data for componds <b>24</b>–<b>27</b>; log<i>D</i>, log<i>P</i>, and p<i>K</i><sub>a</sub> determinations for compound <b>27</b>; experimental procedures for oral dosing formulations and additional in vivo studies; standard deviations for GLS-1 and A549 assay results for compounds <b>2</b>, <b>4</b>, and <b>5</b>–<b>27</b>; representative IC<sub>50</sub> curve for compound <b>27</b> in the A549 assay; and Kinomescan and CEREP off-target screening data for <b>27;</b> Figures S1–S3 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_001.csv">jm0c01398_si_001.csv (2.0 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf">jm0c01398_si_002.pdf (1.59 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01398" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43338" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43338" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Soth</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2649-5537" title="Orcid link">http://orcid.org/0000-0002-2649-5537</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1d70776e7269755d70797c7379786f6e727333726f7a"><span class="__cf_email__" data-cfemail="9ef3f4edf1eaf6def3fafff0fafbecedf1f0b0f1ecf9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kang Le</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Emilia Di Francesco</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew M. Hamilton</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Liu</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason P. Burke</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chris L. Carroll</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey J. Kovacs</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer P. Bardenhagen</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher A. Bristow</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mario Cardozo</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Czako</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3357-7514" title="Orcid link">http://orcid.org/0000-0002-3357-7514</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elisa de Stanchina</span> - <span class="hlFld-Affiliation affiliation">Antitumor
Assessment Core Facility—Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ningping Feng</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jill R. Garvey</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason P. Gay</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary K. Geck Do</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Greer</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Han</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela Harris</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zachary Herrera</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sha Huang</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Virginia Giuliani</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongying Jiang</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah B. Johnson</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Troy A. Johnson</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhijun Kang</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul G. Leonard</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhen Liu</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy McAfoos</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meredith Miller</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pietro Morlacchi</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Mullinax</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wylie S. Palmer</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jihai Pang</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Norma Rogers</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles M. Rudin</span> - <span class="hlFld-Affiliation affiliation">Drunkenmiller
Center for Lung Cancer Research, Memorial
Sloan Kettering Cancer Center, New York New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hannah E. Shepard</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nakia D. Spencer</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jay Theroff</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi Wu</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Xu</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ju Anne Yau</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giulio Draetta</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlo Toniatti</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy P. Heffernan</span> - <span class="hlFld-Affiliation affiliation">Translational
Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Jones</span> - <span class="hlFld-Affiliation affiliation">Institute
for Applied Cancer Science (IACS), The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): This program is licensed to Ipsen, with potential milestone payments to MD Anderson and possible financial benefit to the MD Anderson co-authors.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3535-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank the following chemists at Shanghai Chempartner Co., Ltd. for help in synthesizing compounds: Yanbing Ding, Li Wang, Fagui Liu, Baoquan Tian, Xuejie Xuan, Hui Yang, and Chun Zhou. They acknowledge Richard Lewis, Alessia Petrocchi, and Naphtali Reyna in their chemistry department for helpful discussions throughout the project. They also thank Jason Cross in their structural chemistry department for preparing the modeling snapshot.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice daily</p></td></tr><tr><td class="NLM_term">BPTES</td><td class="NLM_def"><p class="first last"><i>bis</i>-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide</p></td></tr><tr><td class="NLM_term">Cl/CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DAST</td><td class="NLM_def"><p class="first last">(diethylamino)sulfur trifluoride</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DON</td><td class="NLM_def"><p class="first last">6-diazo-5-oxy-<span class="smallcaps smallerCapital">l</span>-norleucine</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term"><i>F</i>%</td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">FESSIF</td><td class="NLM_def"><p class="first last">fed-state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">α-KG</td><td class="NLM_def"><p class="first last">α-ketoglutarate</p></td></tr><tr><td class="NLM_term">LC</td><td class="NLM_def"><p class="first last">liquid chromatography</p></td></tr><tr><td class="NLM_term">GLS-1</td><td class="NLM_def"><p class="first last">glutaminase-1</p></td></tr><tr><td class="NLM_term">GLS-2</td><td class="NLM_def"><p class="first last">glutaminase-2</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-<i>b</i>]- pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hank’s balanced salt solution</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go related gene</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-ol</p></td></tr><tr><td class="NLM_term">IND</td><td class="NLM_def"><p class="first last">investigational new drug</p></td></tr><tr><td class="NLM_term">IS</td><td class="NLM_def"><p class="first last">internal standard</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">KEAP</td><td class="NLM_def"><p class="first last">Kelch-like ECH-associated protein</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">ND</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NRF2</td><td class="NLM_def"><p class="first last">nuclear factor (erythroid-derived 2)-like 2</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">PARR</td><td class="NLM_def"><p class="first last">peak area response ratio</p></td></tr><tr><td class="NLM_term">PDX</td><td class="NLM_def"><p class="first last">patient-derived xenograft</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic(s)</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once daily</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">RPM</td><td class="NLM_def"><p class="first last">revolutions per minute</p></td></tr><tr><td class="NLM_term">RPMI</td><td class="NLM_def"><p class="first last">Roswell Park Memorial Institute</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">Sprague Dawley</p></td></tr><tr><td class="NLM_term">SGF</td><td class="NLM_def"><p class="first last">fast-state simulated gastrointestinal fluid</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">TCA</td><td class="NLM_def"><p class="first last">tricarboxylic acid cycle</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">propylphosphonic anhydride</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">Vd<sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr><tr><td class="NLM_term">Xantphos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene</p></td></tr><tr><td class="NLM_term">X-Phos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i73">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Overview of the development of glutaminase inhibitors: Achievements and future directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1096</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00961</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00961" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyqtbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1096-1115&author=X.+Xuauthor=Y.+Mengauthor=L.+Liauthor=P.+Xuauthor=J.+Wangauthor=Z.+Liauthor=J.+Bian&title=Overview+of+the+development+of+glutaminase+inhibitors%3A+Achievements+and+future+directions&doi=10.1021%2Facs.jmedchem.8b00961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions</span></div><div class="casAuthors">Xu, Xi; Meng, Ying; Li, Lei; Xu, Pengfei; Wang, Jubo; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1096-1115</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">It has been demonstrated that glutamine metab. has become the main energy and building blocks supply for the growth and viability of a potentially large subset of malignant tumors.  The glutamine metab. often depends upon mitochondrial glutaminase (GLS) activity, which converts glutamine to glutamate and serves as a significant role for bioenergetic processes.  Thus, recently, the GLS has become a key target for small mol. therapeutic intervention.  Numerous medicinal chem. studies are currently aimed at the design of novel and potent inhibitors for GLS, however, to date, only one compd. (named CB-839) have entered clin. trials for the treatment of advanced solid tumors and hematol. malignancies.  The perspective summarizes the progress in the discovery and development of GLS inhibitors, including the potential binding site, biochem. techniques for inhibitor identification, and approaches for identifying small-mol. inhibitors, as well as future therapeutic perspectives in glutamine metab. are also put forward in order to provide ref. and rational for the drug discovery of novel and potent glutamine metab. modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrwroUUbG7grVg90H21EOLACvtfcHk0lisK16nAUydZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyqtbjE&md5=799044e083ce769a67c0adfdd248e3f8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00961%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DOverview%2520of%2520the%2520development%2520of%2520glutaminase%2520inhibitors%253A%2520Achievements%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1096%26epage%3D1115%26doi%3D10.1021%2Facs.jmedchem.8b00961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span> <span> </span><span class="NLM_article-title">Glutaminase regulation in cancer cells: a druggable chain of events</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.drudis.2013.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=24140288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSls7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=450-457&author=W.+P.+Kattauthor=R.+A.+Cerione&title=Glutaminase+regulation+in+cancer+cells%3A+a+druggable+chain+of+events&doi=10.1016%2Fj.drudis.2013.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Glutaminase regulation in cancer cells: a druggable chain of events</span></div><div class="casAuthors">Katt, William P.; Cerione, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">450-457</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Metab. is the process by which cells convert relatively simple extracellular nutrients into energy and building blocks necessary for their growth and survival.  In cancer cells, metab. is dramatically altered compared with normal cells.  These alterations are known as the Warburg effect.  One consequence of these changes is cellular addiction to glutamine.  Because of this, in recent years the enzyme glutaminase has become a key target for small mol. therapeutic intervention.  Like many oncotargets, however, glutaminase has a no. of upstream partners that might offer addnl. druggable targets.  This review summarizes the work from the current decade surrounding glutaminase and its regulation, and suggests strategies for therapeutic intervention in relevant cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY9cKMRSje5LVg90H21EOLACvtfcHk0lisK16nAUydZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSls7vF&md5=01b37117a2665312031d0cf5af24b7e9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DKatt%26aufirst%3DW.%2BP.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26atitle%3DGlutaminase%2520regulation%2520in%2520cancer%2520cells%253A%2520a%2520druggable%2520chain%2520of%2520events%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D450%26epage%3D457%26doi%3D10.1016%2Fj.drudis.2013.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasti, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span> <span> </span><span class="NLM_article-title">Glutamine and cancer: cell biology, physiology, and clinical opportunities</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">3678</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1172/JCI69600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1172%2FJCI69600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=23999442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=3678-3684&author=C.+T.+Hensleyauthor=A.+T.+Wastiauthor=R.+J.+DeBerardinis&title=Glutamine+and+cancer%3A+cell+biology%2C+physiology%2C+and+clinical+opportunities&doi=10.1172%2FJCI69600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine and cancer: cell biology, physiology, and clinical opportunities</span></div><div class="casAuthors">Hensley, Christopher T.; Wasti, Ajla T.; DeBerardinis, Ralph J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3678-3684</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Glutamine is an abundant and versatile nutrient that participates in energy formation, redox homeostasis, macromol. synthesis, and signaling in cancer cells.  These characteristics make glutamine metab. an appealing target for new clin. strategies to detect, monitor, and treat cancer.  Here the authors review the metabolic functions of glutamine as a super nutrient and the surprising roles of glutamine in supporting the biol. hallmarks of malignancy.  The authors also review recent efforts in imaging and therapeutics to exploit tumor cell glutamine dependence, discuss some of the challenges in this arena, and suggest a disease-focused paradigm to deploy these emerging approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocNnK_GlTtRrVg90H21EOLACvtfcHk0lisK16nAUydZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bL&md5=fb704a7773710a20add6edbf0da08616</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1172%2FJCI69600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69600%26sid%3Dliteratum%253Aachs%26aulast%3DHensley%26aufirst%3DC.%2BT.%26aulast%3DWasti%26aufirst%3DA.%2BT.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26atitle%3DGlutamine%2520and%2520cancer%253A%2520cell%2520biology%252C%2520physiology%252C%2520and%2520clinical%2520opportunities%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D3678%26epage%3D3684%26doi%3D10.1172%2FJCI69600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wise, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">Glutamine addiction: a new therapeutic target in cancer</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2010.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.tibs.2010.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=20570523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=427-433&author=D.+R.+Wiseauthor=C.+B.+Thompson&title=Glutamine+addiction%3A+a+new+therapeutic+target+in+cancer&doi=10.1016%2Fj.tibs.2010.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine addiction: A new therapeutic target in cancer</span></div><div class="casAuthors">Wise, David R.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">427-433</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Most cancers depend on a high rate of aerobic glycolysis for their continued growth and survival.  Paradoxically, some cancer cell lines also display addiction to glutamine despite the fact that glutamine is a nonessential amino acid that can be synthesized from glucose.  The high rate of glutamine uptake exhibited by glutamine-dependent cells does not appear to result solely from its role as a nitrogen donor in nucleotide and amino acid biosynthesis.  Instead, glutamine plays a required role in the uptake of essential amino acids and in maintaining activation of TOR (target of rapamycin) kinase.  Moreover, in many cancer cells, glutamine is the primary mitochondrial substrate and is required for maintenance of mitochondrial membrane potential and integrity and for support of the NADPH prodn. needed for redox control and macromol. synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Gv_LsNdulLVg90H21EOLACvtfcHk0ljHtbsZJNbbjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKqs7s%253D&md5=915fa51996bc1c9b3ec3970b2dae7163</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2010.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2010.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DGlutamine%2520addiction%253A%2520a%2520new%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2010%26volume%3D35%26spage%3D427%26epage%3D433%26doi%3D10.1016%2Fj.tibs.2010.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodiriquez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackinnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span> <span> </span><span class="NLM_article-title">Abstract 2329: glutaminase inhibition with CB-839 enhances anti-tumor activity of PD-1 and PD-L1 antibodies by overcoming a metabolic checkpoint blocking T cell activation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>, <span class="NLM_elocation-id">2329</span> <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1538-7445.AM2016-2329" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&author=M.+Grossauthor=J.+Chenauthor=J.+Englertauthor=J.+Janesauthor=R.+Leoneauthor=M.+Rodiriquezauthor=A.+Mackinnonauthor=F.+Parlatiauthor=P.+Shwonekauthor=J.+Powell&title=Abstract+2329%3A+glutaminase+inhibition+with+CB-839+enhances+anti-tumor+activity+of+PD-1+and+PD-L1+antibodies+by+overcoming+a+metabolic+checkpoint+blocking+T+cell+activation&doi=10.1158%2F1538-7445.AM2016-2329"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-2329%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DEnglert%26aufirst%3DJ.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DLeone%26aufirst%3DR.%26aulast%3DRodiriquez%26aufirst%3DM.%26aulast%3DMackinnon%26aufirst%3DA.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DShwonek%26aufirst%3DP.%26aulast%3DPowell%26aufirst%3DJ.%26atitle%3DAbstract%25202329%253A%2520glutaminase%2520inhibition%2520with%2520CB-839%2520enhances%2520anti-tumor%2520activity%2520of%2520PD-1%2520and%2520PD-L1%2520antibodies%2520by%2520overcoming%2520a%2520metabolic%2520checkpoint%2520blocking%2520T%2520cell%2520activation%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26doi%3D10.1158%2F1538-7445.AM2016-2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, I.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arwood, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettencourt, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blosser, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prchalova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1126/science.aav2588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1126%2Fscience.aav2588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=31699883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1anu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2019&pages=1013-1021&author=R.+D.+Leoneauthor=L.+Zhaoauthor=J.+M.+Englertauthor=I.-M.+Sunauthor=M.-H.+Ohauthor=I.-H.+Sunauthor=M.+L.+Arwoodauthor=I.+A.+Bettencourtauthor=C.+H.+Patelauthor=J.+Wenauthor=A.+Tamauthor=R.+L.+Blosserauthor=P.+Prchalovaauthor=J.+Altauthor=R.+Raisauthor=B.+S.+Slusherauthor=J.+D.+Powell&title=Glutamine+blockade+induces+divergent+metabolic+programs+to+overcome+tumor+immune+evasion&doi=10.1126%2Fscience.aav2588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion</span></div><div class="casAuthors">Leone, Robert D.; Zhao, Liang; Englert, Judson M.; Sun, Im-Meng; Oh, Min-Hee; Sun, Im-Hong; Arwood, Matthew L.; Bettencourt, Ian A.; Patel, Chirag H.; Wen, Jiayu; Tam, Ada; Blosser, Richard L.; Prchalova, Eva; Alt, Jesse; Rais, Rana; Slusher, Barbara S.; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">6468</span>),
    <span class="NLM_cas:pages">1013-1021</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Glutamine is essential for tumor growth and has long been an attractive therapeutic target for cancer researchers.  Some attempts at blocking glutamine metab. in cancer patients resulted in toxicity, prompting Leone et al. to develop an innovative approach to reduce general side effects.  They designed a prodrug form (JHU083) of the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON), which is administered in an inert state but then preferentially activated by enzymes enriched in the tumor microenvironment.  JHU083 simultaneously shut down glycolysis and oxidative phosphorylation in mouse cancer cells while enhancing T cell oxidative phosphorylation and anticancer immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohlhLbE1xLvLVg90H21EOLACvtfcHk0ljHtbsZJNbbjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1anu7rE&md5=cdc7642118e455d547bb8d2723797e6d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.aav2588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aav2588%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DR.%2BD.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DEnglert%26aufirst%3DJ.%2BM.%26aulast%3DSun%26aufirst%3DI.-M.%26aulast%3DOh%26aufirst%3DM.-H.%26aulast%3DSun%26aufirst%3DI.-H.%26aulast%3DArwood%26aufirst%3DM.%2BL.%26aulast%3DBettencourt%26aufirst%3DI.%2BA.%26aulast%3DPatel%26aufirst%3DC.%2BH.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DBlosser%26aufirst%3DR.%2BL.%26aulast%3DPrchalova%26aufirst%3DP.%26aulast%3DAlt%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DGlutamine%2520blockade%2520induces%2520divergent%2520metabolic%2520programs%2520to%2520overcome%2520tumor%2520immune%2520evasion%26jtitle%3DScience%26date%3D2019%26volume%3D366%26spage%3D1013%26epage%3D1021%26doi%3D10.1126%2Fscience.aav2588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T.</span>; <span class="NLM_string-name">Toniatti, C.</span>; <span class="NLM_string-name">Kovacs, J.</span>; <span class="NLM_string-name">Giuliani, V.</span>; <span class="NLM_string-name">Spencer, N.</span>; <span class="NLM_string-name">Di Francesco, M. E.</span>; <span class="NLM_string-name">Bristow, C. A.</span></span> <span> </span><span class="NLM_article-title">GlutaminaseInhibitor Therapy for Cancer</span>. International Patent Application Number <span class="NLM_patent">WO2016/004418A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Heffernan&author=C.+Toniatti&author=J.+Kovacs&author=V.+Giuliani&author=N.+Spencer&author=M.+E.+Di+Francesco&author=C.+A.+Bristow&title=GlutaminaseInhibitor+Therapy+for+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeffernan%26aufirst%3DT.%26atitle%3DGlutaminaseInhibitor%2520Therapy%2520for%2520Cancer%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayin, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBoeuf, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakousi, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Rivera, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbaraj, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prigge, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goparaju, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgalev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heguy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaj, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papgiannakopoulos, T.</span></span> <span> </span><span class="NLM_article-title">Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1362</span>– <span class="NLM_lpage">1368</span>, <span class="refDoi"> DOI: 10.1038/nm.4407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1038%2Fnm.4407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=28967920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFylurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=1362-1368&author=R.+Romeroauthor=V.+I.+Sayinauthor=S.+M.+Davidsonauthor=M.+R.+Bauerauthor=S.+X.+Singhauthor=S.+E.+LeBoeufauthor=T.+R.+Karakousiauthor=D.+C.+Ellisauthor=A.+Bhutkarauthor=F.+J.+S%C3%A1nchez-Riveraauthor=L.+Subbarajauthor=B.+Martinezauthor=R.+T.+Bronsonauthor=J.+R.+Priggeauthor=E.+E.+Schmidtauthor=C.+J.+Thomasauthor=C.+Goparajuauthor=A.+Daviesauthor=I.+Dolgalevauthor=A.+Heguyauthor=V.+Allajauthor=J.+T.+Poirierauthor=A.+L.+Moreiraauthor=C.+M.+Rudinauthor=H.+I.+Passauthor=M.+G.+Vander+Heidenauthor=T.+Jacksauthor=T.+Papgiannakopoulos&title=Keap1+loss+promotes+Kras-driven+lung+cancer+and+results+in+dependence+on+glutaminolysis&doi=10.1038%2Fnm.4407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis</span></div><div class="casAuthors">Romero, Rodrigo; Sayin, Volkan I.; Davidson, Shawn M.; Bauer, Matthew R.; Singh, Simranjit X.; Le Boeuf, Sarah E.; Karakousi, Triantafyllia R.; Ellis, Donald C.; Bhutkar, Arjun; Sanchez-Rivera, Francisco J.; Subbaraj, Lakshmipriya; Martinez, Britney; Bronson, Roderick T.; Prigge, Justin R.; Schmidt, Edward E.; Thomas, Craig J.; Goparaju, Chandra; Davies, Angela; Dolgalev, Igor; Heguy, Adriana; Allaj, Viola; Poirier, John T.; Moreira, Andre L.; Rudin, Charles M.; Pass, Harvey I.; Vander Heiden, Matthew G.; Jacks, Tyler; Papagiannakopoulos, Thales</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1362-1368</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties assocd. with directly inhibiting the KRAS oncoprotein.  One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselves may lead to therapeutic vulnerabilities in tumors.  Approx. 20% of KRAS-mutant LUAD tumors carry loss-of-function mutations in the KEAP1 gene encoding Kelch-like ECH-assocd. protein 1 (refs. 2, 3, 4), a neg. regulator of nuclear factor erythroid 2-like 2 (NFE2L2; hereafter NRF2), which is the master transcriptional regulator of the endogenous antioxidant response.  The high frequency of mutations in KEAP1 suggests an important role for the oxidative stress response in lung tumorigenesis.  Using a CRISPR-Cas9-based approach in a mouse model of KRAS-driven LUAD, we examd. the effects of Keap1 loss in lung cancer progression.  We show that loss of Keap1 hyperactivates NRF2 and promotes KRAS-driven LUAD in mice.  Through a combination of CRISPR-Cas9-based genetic screening and metabolomic analyses, we show that Keap1- or Nrf2-mutant cancers are dependent on increased glutaminolysis, and this property can be therapeutically exploited through the pharmacol. inhibition of glutaminase.  Finally, we provide a rationale for stratification of human patients with lung cancer harboring KRAS/KEAP1- or KRAS/NRF2-mutant lung tumors as likely to respond to glutaminase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofWgHF0gdsW7Vg90H21EOLACvtfcHk0liSD3dDbwkETw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFylurrK&md5=2bc4122a4c757cc3a5fdab3eb62b26e3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnm.4407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4407%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DR.%26aulast%3DSayin%26aufirst%3DV.%2BI.%26aulast%3DDavidson%26aufirst%3DS.%2BM.%26aulast%3DBauer%26aufirst%3DM.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BX.%26aulast%3DLeBoeuf%26aufirst%3DS.%2BE.%26aulast%3DKarakousi%26aufirst%3DT.%2BR.%26aulast%3DEllis%26aufirst%3DD.%2BC.%26aulast%3DBhutkar%26aufirst%3DA.%26aulast%3DS%25C3%25A1nchez-Rivera%26aufirst%3DF.%2BJ.%26aulast%3DSubbaraj%26aufirst%3DL.%26aulast%3DMartinez%26aufirst%3DB.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DPrigge%26aufirst%3DJ.%2BR.%26aulast%3DSchmidt%26aufirst%3DE.%2BE.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DGoparaju%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DDolgalev%26aufirst%3DI.%26aulast%3DHeguy%26aufirst%3DA.%26aulast%3DAllaj%26aufirst%3DV.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DMoreira%26aufirst%3DA.%2BL.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DPass%26aufirst%3DH.%2BI.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DPapgiannakopoulos%26aufirst%3DT.%26atitle%3DKeap1%2520loss%2520promotes%2520Kras-driven%2520lung%2520cancer%2520and%2520results%2520in%2520dependence%2520on%2520glutaminolysis%26jtitle%3DNat.%2520Med.%26date%3D2017%26volume%3D23%26spage%3D1362%26epage%3D1368%26doi%3D10.1038%2Fnm.4407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennison, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernov-Rogan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidig, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKinnon, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjogren, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. K.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1535-7163.MCT-13-0870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=24523301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=890-901&author=M.+I.+Grossauthor=S.+D.+Demoauthor=J.+B.+Dennisonauthor=L.+Chenauthor=T.+Chernov-Roganauthor=B.+Goyalauthor=J.+R.+Janesauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=J.+Liauthor=A.+L.+MacKinnonauthor=F.+Parlatiauthor=M.+L.+M.+Rodriguezauthor=P.+J.+Shwonekauthor=E.+B.+Sjogrenauthor=T.+F.+Stantonauthor=T.+Wangauthor=J.+Yangauthor=F.+Zhaoauthor=M.+K.+Bennett&title=Antitumor+activity+of+the+glutaminase+inhibitor+CB-839+in+triple-negative+breast+cancer&doi=10.1158%2F1535-7163.MCT-13-0870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Gross, Matt I.; Demo, Susan D.; Dennison, Jennifer B.; Chen, Lijing; Chernov-Rogan, Tania; Goyal, Bindu; Janes, Julie R.; Laidig, Guy J.; Lewis, Evan R.; Li, Jim; MacKinnon, Andrew L.; Parlati, Francesco; Rodriguez, Mirna L. M.; Shwonek, Peter J.; Sjogren, Eric B.; Stanton, Timothy F.; Wang, Taotao; Yang, Jinfu; Zhao, Frances; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">890-901</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glutamine serves as an important source of energy and building blocks for many tumor cells.  The first step in glutamine utilization is its conversion to glutamate by the mitochondrial enzyme glutaminase.  CB-839 is a potent, selective, and orally bioavailable inhibitor of both splice variants of glutaminase (KGA and GAC).  CB-839 had antiproliferative activity in a triple-neg. breast cancer (TNBC) cell line, HCC-1806, that was assocd. with a marked decrease in glutamine consumption, glutamate prodn., oxygen consumption, and the steady-state levels of glutathione and several tricarboxylic acid cycle intermediates.  In contrast, no antiproliferative activity was obsd. in an estrogen receptor-pos. cell line, T47D, and only modest effects on glutamine consumption and downstream metabolites were obsd.  Across a panel of breast cancer cell lines, GAC protein expression and glutaminase activity were elevated in the majority of TNBC cell lines relative to receptor pos. cells.  Furthermore, the TNBC subtype displayed the greatest sensitivity to CB-839 treatment and this sensitivity was correlated with (i) dependence on extracellular glutamine for growth, (ii) intracellular glutamate and glutamine levels, and (iii) GAC (but not KGA) expression, a potential biomarker for sensitivity.  CB-839 displayed significant antitumor activity in two xenograft models: as a single agent in a patient-derived TNBC model and in a basal like HER2+ cell line model, JIMT-1, both as a single agent and in combination with paclitaxel.  Together, these data provide a strong rationale for the clin. investigation of CB-839 as a targeted therapeutic in patients with TNBC and other glutamine-dependent tumors.  Mol Cancer Ther; 13(4); 890-901.2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDfUGWU-VZObVg90H21EOLACvtfcHk0liSD3dDbwkETw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurg%253D&md5=5b9ddb35c56409b58ce2b889bbbbc33f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0870%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DM.%2BI.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DDennison%26aufirst%3DJ.%2BB.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChernov-Rogan%26aufirst%3DT.%26aulast%3DGoyal%26aufirst%3DB.%26aulast%3DJanes%26aufirst%3DJ.%2BR.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMacKinnon%26aufirst%3DA.%2BL.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRodriguez%26aufirst%3DM.%2BL.%2BM.%26aulast%3DShwonek%26aufirst%3DP.%2BJ.%26aulast%3DSjogren%26aufirst%3DE.%2BB.%26aulast%3DStanton%26aufirst%3DT.%2BF.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520glutaminase%2520inhibitor%2520CB-839%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D890%26epage%3D901%26doi%3D10.1158%2F1535-7163.MCT-13-0870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csibi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">E21</span>– <span class="NLM_lpage">E29</span>, <span class="refDoi"> DOI: 10.1073/pnas.1417015112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1073%2Fpnas.1417015112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=25524627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E21-E29&author=J.+Liauthor=A.+Csibiauthor=S.+Yangauthor=G.+R.+Hoffmanauthor=C.+Liauthor=E.+Zhangauthor=J.+J.+Yuauthor=J.+Blenis&title=Synthetic+lethality+of+combined+glutaminase+and+Hsp90+inhibition+in+mTORC1-driven+tumor+cells&doi=10.1073%2Fpnas.1417015112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells</span></div><div class="casAuthors">Li, Jing; Csibi, Alfredo; Yang, Sun; Hoffman, Gregory R.; Li, Chenggang; Zhang, Erik; Yu, Jane J.; Blenis, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">E21-E29</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin complex 1 (mTORC1) integrates multiple signals from growth factors, nutrients, and cellular energy status to control a wide range of metabolic processes, including mRNA biogenesis; protein, nucleotide, and lipid synthesis; and autophagy.  Deregulation of the mTORC1 pathway is found in cancer as well as genetic disorders such as tuberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis.  Recent studies have shown that the mTORC1 inhibitor rapamycin and its analogs generally suppress proliferation rather than induce apoptosis.  Therefore, it is crit. to use alternative strategies to induce death of cells with activated mTORC1.  In this study, a small-mol. screen has revealed that the combination of glutaminase (GLS) and heat shock protein 90 (Hsp90) inhibitors selectively triggers death of TSC2-deficient cells.  At a mechanistic level, high mTORC1-driven translation rates in TSC1/2-deficient cells, unlike wild-type cells, sensitizes these cells to endoplasmic reticulum (ER) stress.  Thus, Hsp90 inhibition drives accumulation of unfolded protein and ER stress.  When combining proteotoxic stress with oxidative stress by depletion of the intracellular antioxidant glutathione by GLS inhibition, acute cell death is obsd. in cells with activated mTORC1 signaling.  This study suggests that this combination strategy may have the potential to be developed into a therapeutic use for the treatment of mTORC1-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_GzMngCRwAbVg90H21EOLACvtfcHk0lj_3rETQRZVDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrt73K&md5=a543aa696f8d1601549fda8dc4b51c24</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1417015112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1417015112%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCsibi%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DG.%2BR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DYu%26aufirst%3DJ.%2BJ.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DSynthetic%2520lethality%2520of%2520combined%2520glutaminase%2520and%2520Hsp90%2520inhibition%2520in%2520mTORC1-driven%2520tumor%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3DE21%26epage%3DE29%26doi%3D10.1073%2Fpnas.1417015112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elgogary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poore, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neisser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semenza, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A.</span></span> <span> </span><span class="NLM_article-title">Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E5328</span>– <span class="NLM_lpage">E5336</span>, <span class="refDoi"> DOI: 10.1073/pnas.1611406113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1073%2Fpnas.1611406113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=27559084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2ktbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E5328-E5336&author=A.+Elgogaryauthor=Q.+Xuauthor=B.+Pooreauthor=J.+Altauthor=S.+C.+Zimmermannauthor=L.+Zhaoauthor=J.+Fuauthor=B.+Chenauthor=S.+Xiaauthor=Y.+Liuauthor=M.+Neisserauthor=C.+Nguyenauthor=R.+Leeauthor=J.+K.+Parkauthor=J.+Reyesauthor=T.+Hartungauthor=C.+Rojasauthor=R.+Raisauthor=T.+Tsukamotoauthor=G.+L.+Semenzaauthor=J.+Hanesauthor=B.+Slusherauthor=A.+Le&title=Combination+therapy+with+BPTES+nanoparticles+and+metformin+targets+the+metabolic+heterogeneity+of+pancreatic+cancer&doi=10.1073%2Fpnas.1611406113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer</span></div><div class="casAuthors">Elgogary, Amira; Xu, Qingguo; Poore, Brad; Alt, Jesse; Zimmermann, Sarah C.; Zhao, Liang; Fu, Jie; Chen, Baiwei; Xia, Shiyu; Liu, Yanfei; Neisser, Marc; Nguyen, Christopher; Lee, Ramon; Park, Joshua K.; Reyes, Juvenal; Hartung, Thomas; Rojas, Camilo; Rais, Rana; Tsukamoto, Takashi; Semenza, Gregg L.; Hanes, Justin; Slusher, Barbara S.; Le, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">E5328-E5336</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Targeting glutamine metab. via pharmacol. inhibition of glutaminase has been translated into clin. trials as a novel cancer therapy, but available drugs lack optimal safety and efficacy.  In this study, we used a proprietary emulsification process to encapsulate bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), a selective but relatively insol. glutaminase inhibitor, in nanoparticles.  BPTES nanoparticles demonstrated improved pharmacokinetics and efficacy compared with unencapsulated BPTES.  In addn., BPTES nanoparticles had no effect on the plasma levels of liver enzymes in contrast to CB-839, a glutaminase inhibitor that is currently in clin. trials.  In a mouse model using orthotopic transplantation of patient-derived pancreatic tumor tissue, BPTES nanoparticle monotherapy led to modest antitumor effects.  Using the HypoxCR reporter in vivo, we found that glutaminase inhibition reduced tumor growth by specifically targeting proliferating cancer cells but did not affect hypoxic, noncycling cells.  Metabolomics analyses revealed that surviving tumor cells following glutaminase inhibition were reliant on glycolysis and glycogen synthesis.  Based on these findings, metformin was selected for combination therapy with BPTES nanoparticles, which resulted in significantly greater pancreatic tumor redn. than either treatment alone.  Thus, targeting of multiple metabolic pathways, including effective inhibition of glutaminase by nanoparticle drug delivery, holds promise as a novel therapy for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEO264JigFOLVg90H21EOLACvtfcHk0lj_3rETQRZVDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2ktbbM&md5=2765c0794c6ed0e5068079d5912a0468</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1611406113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1611406113%26sid%3Dliteratum%253Aachs%26aulast%3DElgogary%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DPoore%26aufirst%3DB.%26aulast%3DAlt%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DS.%2BC.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DXia%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DNeisser%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DReyes%26aufirst%3DJ.%26aulast%3DHartung%26aufirst%3DT.%26aulast%3DRojas%26aufirst%3DC.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DTsukamoto%26aufirst%3DT.%26aulast%3DSemenza%26aufirst%3DG.%2BL.%26aulast%3DHanes%26aufirst%3DJ.%26aulast%3DSlusher%26aufirst%3DB.%26aulast%3DLe%26aufirst%3DA.%26atitle%3DCombination%2520therapy%2520with%2520BPTES%2520nanoparticles%2520and%2520metformin%2520targets%2520the%2520metabolic%2520heterogeneity%2520of%2520pancreatic%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3DE5328%26epage%3DE5336%26doi%3D10.1073%2Fpnas.1611406113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronchetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decroocq, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciel, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospital, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujobert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moura, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouscary, D.</span></span> <span> </span><span class="NLM_article-title">Targeting glutaminase has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1346</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-01-621870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1182%2Fblood-2015-01-621870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=26186940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1WisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=1346-1356&author=N.+Jacqueauthor=A.+M.+Ronchettiauthor=C.+Larrueauthor=G.+Meunierauthor=R.+Birsenauthor=L.+Willemsauthor=E.+Salandauthor=J.+Decroocqauthor=T.+T.+Macielauthor=M.+Lambertauthor=L.+Poulainauthor=M.+A.+Hospitalauthor=P.+Sujobertauthor=L.+Josephauthor=N.+Chapuisauthor=C.+Lacombeauthor=I.+C.+Mouraauthor=S.+Demoauthor=J.+E.+Sarryauthor=C.+Recherauthor=P.+Mayeuxauthor=J.+Tamburiniauthor=D.+Bouscary&title=Targeting+glutaminase+has+antileukemic+activity+in+acute+myeloid+leukemia+and+synergizes+with+BCL-2+inhibition&doi=10.1182%2Fblood-2015-01-621870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition</span></div><div class="casAuthors">Jacque, Nathalie; Ronchetti, Anne Marie; Larrue, Clement; Meunier, Godelieve; Birsen, Rudy; Willems, Lise; Saland, Estelle; Decroocq, Justine; Macie, Thiago Trovati; Lambert, Mireille; Poulain, Laury; Hospital, Marie Anne; Sujobert, Pierre; Joseph, Laure; Chapuis, Nicolas; Lacombe, Catherine; Moura, Ivan Cruz; Demo, Susan; Sarry, Jean Emmanuel; Recher, Christian; Mayeux, Patrick; Tamburini, Jerome; Bouscary, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1346-1356</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Cancer cells require glutamine to adapt to increased biosynthetic activity.  The limiting step in intracellular glutamine catabolism involves its conversion to glutamate by glutaminase (GA).  Different GA isoforms are encoded by the genes GLS1 and GLS2 in humans.  Herein, we show that glutamine levels control mitochondrial oxidative phosphorylation (OXPHOS) in acute myeloid leukemia (AML) cells.  Glutaminase C (GAC) is the GA isoform that is most abundantly expressed in AML.  Both knockdown of GLS1 expression and pharmacol. GLS1 inhibition by the drug CB-839 can reduce OXPHOS, leading to leukemic cell proliferation arrest and apoptosis without causing cytotoxic activity against normal human CD34+ progenitors.  Strikingly, GLS1 knockdown dramatically inhibited AML development in NSG mice.  The antileukemic activity of CB-839 was abrogated by both the expression of a hyperactive GACK320A allele and the addn. of the tricarboxyclic acid cycle product α-ketoglutarate, indicating the crit. function of GLS1 in AML cell survival.  Finally, glutaminolysis inhibition activated mitochondrial apoptosis and synergistically sensitized leukemic cells to priming with the BCL-2 inhibitor ABT-199.  These findings show that targeting glutamine addiction via GLS1 inhibition offers a potential novel therapeutic strategy for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_p-hOsAD2CbVg90H21EOLACvtfcHk0lhKpERSPwOIHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1WisLs%253D&md5=b4530d3ae6fd6d6c3e74fdcbf8967f76</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-01-621870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-01-621870%26sid%3Dliteratum%253Aachs%26aulast%3DJacque%26aufirst%3DN.%26aulast%3DRonchetti%26aufirst%3DA.%2BM.%26aulast%3DLarrue%26aufirst%3DC.%26aulast%3DMeunier%26aufirst%3DG.%26aulast%3DBirsen%26aufirst%3DR.%26aulast%3DWillems%26aufirst%3DL.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3DDecroocq%26aufirst%3DJ.%26aulast%3DMaciel%26aufirst%3DT.%2BT.%26aulast%3DLambert%26aufirst%3DM.%26aulast%3DPoulain%26aufirst%3DL.%26aulast%3DHospital%26aufirst%3DM.%2BA.%26aulast%3DSujobert%26aufirst%3DP.%26aulast%3DJoseph%26aufirst%3DL.%26aulast%3DChapuis%26aufirst%3DN.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DMoura%26aufirst%3DI.%2BC.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DBouscary%26aufirst%3DD.%26atitle%3DTargeting%2520glutaminase%2520has%2520antileukemic%2520activity%2520in%2520acute%2520myeloid%2520leukemia%2520and%2520synergizes%2520with%2520BCL-2%2520inhibition%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D1346%26epage%3D1356%26doi%3D10.1182%2Fblood-2015-01-621870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Momcilovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbein, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magyar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graebor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czernin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emberley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackinnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Works, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walser, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinett, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, D. B.</span></span> <span> </span><span class="NLM_article-title">Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.celrep.2016.12.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=28099841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ChsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=601-610&author=M.+Momcilovicauthor=S.+T.+Baileyauthor=J.+T.+Leeauthor=M.+C.+Fishbeinauthor=C.+Magyarauthor=D.+Braasauthor=T.+Graeborauthor=N.+J.+Jacksonauthor=J.+Czerninauthor=E.+Emberleyauthor=M.+Grossauthor=J.+Janesauthor=A.+Mackinnonauthor=A.+Panauthor=M.+Rodriguezauthor=M.+Worksauthor=W.+Zhangauthor=F.+Parlatiauthor=S.+Demoauthor=E.+Garonauthor=K.+Krysanauthor=T.+C.+Walserauthor=S.+M.+Dubinettauthor=S.+Sadeghiauthor=H.+R.+Christofkauthor=D.+B.+Shackelford&title=Targeted+inhibition+of+EGFR+and+glutaminase+induces+metabolic+crisis+in+EGFR+mutant+lung+cancer&doi=10.1016%2Fj.celrep.2016.12.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer</span></div><div class="casAuthors">Momcilovic, Milica; Bailey, Sean T.; Lee, Jason T.; Fishbein, Michael C.; Magyar, Clara; Braas, Daniel; Graeber, Thomas; Jackson, Nicholas J.; Czernin, Johannes; Emberley, Ethan; Gross, Matthew; Janes, Julie; MacKinnon, Andy; Pan, Alison; Rodriguez, Mirna; Works, Melissa; Zhang, Winter; Parlati, Francesco; Demo, Susan; Garon, Edward; Krysan, Kostyantyn; Walser, Tonya C.; Dubinett, Steven M.; Sadeghi, Saman; Christofk, Heather R.; Shackelford, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">601-610</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cancer cells exhibit increased use of nutrients, including glucose and glutamine, to support the bioenergetic and biosynthetic demands of proliferation.  We tested the small-mol. inhibitor of glutaminase CB-839 in combination with erlotinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) as a therapeutic strategy to simultaneously impair cancer glucose and glutamine utilization and thereby suppress tumor growth.  Here, we show that CB-839 cooperates with erlotinib to drive energetic stress and activate the AMP-activated protein kinase (AMPK) pathway in EGFR (del19) lung tumors.  Tumor cells undergo metabolic crisis and cell death, resulting in rapid tumor regression in vivo in mouse NSCLC xenografts.  Consistently, positron emission tomog. (PET) imaging with 18F-fluoro-2-deoxyglucose (18F-FDG) and 11C-glutamine (11C-Gln) of xenografts indicated reduced glucose and glutamine uptake in tumors following treatment with CB-839 + erlotinib.  Therefore, PET imaging with 18F-FDG and 11C-Gln tracers can be used to non-invasively measure metabolic response to CB-839 and erlotinib combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDi9ghbRHBG7Vg90H21EOLACvtfcHk0lhKpERSPwOIHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ChsL4%253D&md5=b335b9e4ba83b1d462f8baceae85074f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.061%26sid%3Dliteratum%253Aachs%26aulast%3DMomcilovic%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DS.%2BT.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DFishbein%26aufirst%3DM.%2BC.%26aulast%3DMagyar%26aufirst%3DC.%26aulast%3DBraas%26aufirst%3DD.%26aulast%3DGraebor%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DN.%2BJ.%26aulast%3DCzernin%26aufirst%3DJ.%26aulast%3DEmberley%26aufirst%3DE.%26aulast%3DGross%26aufirst%3DM.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DMackinnon%26aufirst%3DA.%26aulast%3DPan%26aufirst%3DA.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DWorks%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DGaron%26aufirst%3DE.%26aulast%3DKrysan%26aufirst%3DK.%26aulast%3DWalser%26aufirst%3DT.%2BC.%26aulast%3DDubinett%26aufirst%3DS.%2BM.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DShackelford%26aufirst%3DD.%2BB.%26atitle%3DTargeted%2520inhibition%2520of%2520EGFR%2520and%2520glutaminase%2520induces%2520metabolic%2520crisis%2520in%2520EGFR%2520mutant%2520lung%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D601%26epage%3D610%26doi%3D10.1016%2Fj.celrep.2016.12.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ospina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Escheverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederschain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, L.</span></span> <span> </span><span class="NLM_article-title">Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0185092</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0185092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1371%2Fjournal.pone.0185092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=28950000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotV2nsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=M.+Lampaauthor=H.+Arltauthor=T.+Heauthor=B.+Ospinaauthor=J.+Reevesauthor=B.+Zhangauthor=J.+Murtieauthor=G.+Dengauthor=C.+Barberisauthor=D.+Hoffmannauthor=H.+Chengauthor=J.+Pollardauthor=C.+Winterauthor=V.+Richonauthor=C.+Garcia-Escheverriaauthor=F.+Adrianauthor=D.+Wiederschainauthor=L.+Srinivasan&title=Glutaminase+is+essential+for+the+growth+of+triple-negative+breast+cancer+cells+with+a+deregulated+glutamine+metabolism+pathway+and+its+suppression+synergizes+with+mTOR+inhibition&doi=10.1371%2Fjournal.pone.0185092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition</span></div><div class="casAuthors">Lampa, Michael; Arlt, Heike; He, Timothy; Ospina, Beatriz; Reeves, Jason; Zhang, Bailin; Murtie, Joshua; Deng, Gejing; Barberis, Claude; Hoffmann, Dietmar; Cheng, Hong; Pollard, Jack; Winter, Christopher; Richon, Victoria; Garcia-Escheverria, Carlos; Adrian, Francisco; Wiederschain, Dmitri; Srinivasan, Lakshmi</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0185092/1-e0185092/24</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tumor cells display fundamental changes in metab. and nutrient uptake in order to utilize addnl. nutrient sources to meet their enhanced bioenergetic requirements.  Glutamine (Gln) is one such nutrient that is rapidly taken up by tumor cells to fulfill this increased metabolic demand.  A vital step in the catabolism of glutamine is its conversion to glutamate by the mitochondrial enzyme glutaminase (GLS).  This study has identified GLS a potential therapeutic target in breast cancer, specifically in the basal subtype that exhibits a deregulated glutaminolysis pathway.  Using inducible shRNA mediated gene knockdown, we discovered that loss of GLS function in triple-neg. breast cancer (TNBC) cell lines with a deregulated glutaminolysis pathway led to profound tumor growth inhibition in vitro and in vivo.  GLS knockdown had no effect on growth and metabolite levels in non-TNBC cell lines.  We rescued the anti-tumor effect of GLS knockdown using shRNA resistant cDNAs encoding both GLS isoforms and by addn. of an a-ketoglutarate (αKG) analog thus confirming the crit. role of GLS in TNBC.  Pharmacol. inhibition of GLS with the small mol. inhibitor CB-839 reduced cell growth and led to a decrease in mammalian target of rapamycin (mTOR) activity and an increase in the stress response pathway driven by activating transcription factor 4 (ATF4).  Finally, we found that GLS inhibition synergizes with mTOR inhibition, which introduces the possibility of a novel therapeutic strategy for TNBC.  Our study revealed that GLS is essential for the survival of TNBC with a deregulated glutaminolysis pathway.  The synergistic activity of GLS and mTOR inhibitors in TNBC cell lines suggests therapeutic potential of this combination for the treatment of vulnerable subpopulations of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxPfQ2FostHrVg90H21EOLACvtfcHk0ljKqJw09tpyLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotV2nsLg%253D&md5=6b68e9038486853cd3612ffd8ef7f918</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0185092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0185092%26sid%3Dliteratum%253Aachs%26aulast%3DLampa%26aufirst%3DM.%26aulast%3DArlt%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DOspina%26aufirst%3DB.%26aulast%3DReeves%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMurtie%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DBarberis%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DGarcia-Escheverria%26aufirst%3DC.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DWiederschain%26aufirst%3DD.%26aulast%3DSrinivasan%26aufirst%3DL.%26atitle%3DGlutaminase%2520is%2520essential%2520for%2520the%2520growth%2520of%2520triple-negative%2520breast%2520cancer%2520cells%2520with%2520a%2520deregulated%2520glutamine%2520metabolism%2520pathway%2520and%2520its%2520suppression%2520synergizes%2520with%2520mTOR%2520inhibition%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0185092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sappington, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi-Parsian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boysen, G.</span></span> <span> </span><span class="NLM_article-title">Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1860</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">843</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2016.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.bbagen.2016.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=26825773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs12gsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1860&publication_year=2016&pages=836-843&author=D.+R.+Sappingtonauthor=E.+R.+Siegelauthor=G.+Hiattauthor=A.+Desaiauthor=R.+B.+Penneyauthor=A.+Jamshidi-Parsianauthor=R.+J.+Griffinauthor=G.+Boysen&title=Glutamine+drives+glutathione+synthesis+and+contributes+to+radiation+sensitivity+of+A549+and+H460+lung+cancer+cell+lines&doi=10.1016%2Fj.bbagen.2016.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines</span></div><div class="casAuthors">Sappington, Daniel R.; Siegel, Eric R.; Hiatt, Gloria; Desai, Abhishek; Penney, Rosalind B.; Jamshidi-Parsian, Azemat; Griffin, Robert J.; Boysen, Gunnar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1860</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">836-843</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Increased glutamine uptake is known to drive cancer cell proliferation, making tumor cells glutamine-dependent.  Glutamine provides addnl. carbon and nitrogen sources for cell growth.  The first step in glutamine utilization is its conversion to glutamate by glutaminase (GLS).  Glutamate is a precursor for glutathione synthesis, and we investigated the hypothesis that glutamine drives glutathione synthesis and thereby contributes to cellular defense systems.The importance of glutamine for glutathione synthesis was studied in H460 and A549 lung cancer cell lines using glutamine-free medium and bis-2-(5-phenyl-acetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) a GLS inhibitor.  Metabolic activities were detd. by targeted mass spectrometry.A significant correlation between glutamine consumption and glutathione excretion was demonstrated in H460 and A549 tumor cells.  Culturing in the presence of [13C5]glutamine demonstrated that by 12 h > 50% of excreted glutathione was derived from glutamine.  Culturing in glutamine-free medium or treatment with BPTES, a GLS-specific inhibitor, reduced cell proliferation and viability and abolished glutathione excretion.  Treatment with glutathione-ester prevented BPTES-induced cytotoxicity.  Inhibition of GLS markedly radiosensitized the lung tumor cell lines, suggesting an important role of glutamine-derived glutathione in detg. radiation sensitivity.We demonstrate here for the first time that a significant amt. of extracellular glutathione is directly derived from glutamine.  This finding adds yet another important function to the already known glutamine dependence of tumor cells and probably tumors as well.Glutamine is essential for synthesis and excretion of glutathione to promote cell growth and viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFRlEk2tVJrVg90H21EOLACvtfcHk0lg5uUIHavf7zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs12gsrY%253D&md5=50b758d3f4c5203f63cf91b08a77ab4a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2016.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2016.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DSappington%26aufirst%3DD.%2BR.%26aulast%3DSiegel%26aufirst%3DE.%2BR.%26aulast%3DHiatt%26aufirst%3DG.%26aulast%3DDesai%26aufirst%3DA.%26aulast%3DPenney%26aufirst%3DR.%2BB.%26aulast%3DJamshidi-Parsian%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DBoysen%26aufirst%3DG.%26atitle%3DGlutamine%2520drives%2520glutathione%2520synthesis%2520and%2520contributes%2520to%2520radiation%2520sensitivity%2520of%2520A549%2520and%2520H460%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2016%26volume%3D1860%26spage%3D836%26epage%3D843%26doi%3D10.1016%2Fj.bbagen.2016.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boysen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi-Parsian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simecka, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kore, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dings, R. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span> <span> </span><span class="NLM_article-title">Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human tumor xenografts in mice</span>. <i>Int. J. Rad. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1080/09553002.2018.1558299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1080%2F09553002.2018.1558299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=30557074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2019&pages=436-442&author=G.+Boysenauthor=A.+Jamshidi-Parsianauthor=M.+A.+Davisauthor=E.+R.+Siegelauthor=C.+M.+Simeckaauthor=R.+A.+Koreauthor=R.+P.+M.+Dingsauthor=R.+J.+Griffin&title=Glutaminase+inhibitor+CB-839+increases+radiation+sensitivity+of+lung+tumor+cells+and+human+tumor+xenografts+in+mice&doi=10.1080%2F09553002.2018.1558299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice</span></div><div class="casAuthors">Boysen, Gunnar; Jamshidi-Parsian, Azemat; Davis, Mary A.; Siegel, Eric R.; Simecka, Christine M.; Kore, Rajshekhar A.; Dings, Ruud P. M.; Griffin, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">436-442</span>CODEN:
                <span class="NLM_cas:coden">IJRBE7</span>;
        ISSN:<span class="NLM_cas:issn">0955-3002</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The purpose of this study was to translate our in vitro therapy approach to an in vivo model.  Increased glutamine uptake is known to drive cancer cell proliferation, making tumor cells glutamine-dependent.  Studying lymph-node aspirates contg. malignant lung tumor cells showed a strong correlation between glutamine consumption and glutathione (GSH) excretion.  Subsequent expts. with A549 and H460 lung tumor cell lines provided addnl. evidence for glutamine's role in driving synthesis and excretion of GSH.  Using stable-isotope-labeled glutamine as a tracer metabolite, we demonstrated that the glutamate group in GSH is directly derived from glutamine, linking glutamine utilization intimately to GSH syntheses.  To understand the possible mechanistic link between glutamine consumption and GSH excretion, we studied GSH metab. in more detail.  Inhibition of glutaminase (GLS) with BPTES, a GLS-specific inhibitor, effectively abolished GSH synthesis and excretion.  Since our previous work, several novel GLS inhibitors became available and we report herein effects of CB-839 in A427, H460 and A549 lung tumor cells and human lungtumor xenografts in mice.  Inhibition of GLS markedly reduced cell viability, producing ED50 values for inhibition of colony formation of 9, 27 and 217 nM in A427, A549 and H460, resp.  Inhibition of GLS is accompanied by ~ 30% increased response to radiation, suggesting an important role of glutamine-derived GSH in protecting tumor cells against radiation-induced injury.  In subsequent mouse xenografts, short-term CB-839 treatments reduced serum GSH by greater than 50% and increased response to radiotherapy of H460-derived tumor xenografts by 30%.  The results support the proposed mechanistic link between GLS activity and GSH synthesis and suggest that GLS inhibitors are effective radiosensitizers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPvDZSFhCDZbVg90H21EOLACvtfcHk0lg5uUIHavf7zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSlt7c%253D&md5=169e20877892733fa6ce64fa55b07b36</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F09553002.2018.1558299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09553002.2018.1558299%26sid%3Dliteratum%253Aachs%26aulast%3DBoysen%26aufirst%3DG.%26aulast%3DJamshidi-Parsian%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DM.%2BA.%26aulast%3DSiegel%26aufirst%3DE.%2BR.%26aulast%3DSimecka%26aufirst%3DC.%2BM.%26aulast%3DKore%26aufirst%3DR.%2BA.%26aulast%3DDings%26aufirst%3DR.%2BP.%2BM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3DGlutaminase%2520inhibitor%2520CB-839%2520increases%2520radiation%2520sensitivity%2520of%2520lung%2520tumor%2520cells%2520and%2520human%2520tumor%2520xenografts%2520in%2520mice%26jtitle%3DInt.%2520J.%2520Rad.%2520Biol.%26date%3D2019%26volume%3D95%26spage%3D436%26epage%3D442%26doi%3D10.1080%2F09553002.2018.1558299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willis, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seegmiller, J. E.</span></span> <span> </span><span class="NLM_article-title">The inhibition by 6-diazo-5-oxo-<span class="smallcaps smallerCapital">L</span>-norleucine of glutamine catabolism of the cultured human lymphoblast</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1002/jcp.1040930308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1002%2Fjcp.1040930308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=22551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADyaE1cXkvVShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1977&pages=375-382&author=R.+C.+Willisauthor=J.+E.+Seegmiller&title=The+inhibition+by+6-diazo-5-oxo-L-norleucine+of+glutamine+catabolism+of+the+cultured+human+lymphoblast&doi=10.1002%2Fjcp.1040930308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibition by 6-diazo-5-oxo-L-norleucine of glutamine catabolism of the cultured human lymphoblast</span></div><div class="casAuthors">Willis, Randall C.; Seegmiller, J. Edwin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-82</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    </div><div class="casAbstract">The rapid catabolism of glutamine by the cultured human lymphoblast line WI-L2 was inhibited by >95% during incubation of cell suspensions with 6-diazo-5-oxo-L-norleucine (I).  The inhibition persisted for ≥4 h after the removal of I from the cell suspension.  The exposure of cells to I inhibited >95% of the glutaminase activity measured in lysates in the presence of either phosphate or maleate.  Similarly, γ-glutamyl transpeptidase, assayed with γ-glutamyl-p-nitroanilide as substrate and glycylglycine as acceptor, was inhibited >90%.  I-treated and control cells accumulated radioactive material from suspensions contg. L-glutamine-14C at similar initial rates.  The radioactive material accumulated by the I-treated cells was all recoverable as glutamine, whereas the radioactive material accumulated by untreated cells was principally recovered as glutamate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooEluRc1A7arVg90H21EOLACvtfcHk0litb1r_CMO92A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvVShtQ%253D%253D&md5=75a871601964879332b313079c9d61a2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fjcp.1040930308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.1040930308%26sid%3Dliteratum%253Aachs%26aulast%3DWillis%26aufirst%3DR.%2BC.%26aulast%3DSeegmiller%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520inhibition%2520by%25206-diazo-5-oxo-L-norleucine%2520of%2520glutamine%2520catabolism%2520of%2520the%2520cultured%2520human%2520lymphoblast%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D1977%26volume%3D93%26spage%3D375%26epage%3D382%26doi%3D10.1002%2Fjcp.1040930308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, R. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Bis[(carboxamidothiadiazolyl)ethyl] Sulfides and Ethers as Glutaminase Inhibitors</span>. U.S. Patent <span class="NLM_patent">US6451828</span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=R.+W.+Newcomb&title=Preparation+of+Bis%5B%28carboxamidothiadiazolyl%29ethyl%5D+Sulfides+and+Ethers+as+Glutaminase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNewcomb%26aufirst%3DR.%2BW.%26atitle%3DPreparation%2520of%2520Bis%255B%2528carboxamidothiadiazolyl%2529ethyl%255D%2520Sulfides%2520and%2520Ethers%2520as%2520Glutaminase%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinavahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosio, A. L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, S. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span> <span> </span><span class="NLM_article-title">Targeting mitochondrial glutaminase activity inhibits oncogenic transformation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2010.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.ccr.2010.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=20832749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGht7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=207-219&author=J.+B.+Wangauthor=J.+W.+Ericksonauthor=R.+Fujiauthor=S.+Ramachandranauthor=P.+Gaoauthor=R.+Dinavahiauthor=K.+F.+Wilsonauthor=A.+L.+B.+Ambrosioauthor=S.+M.+G.+Diasauthor=C.+V.+Dangauthor=R.+A.+Cerione&title=Targeting+mitochondrial+glutaminase+activity+inhibits+oncogenic+transformation&doi=10.1016%2Fj.ccr.2010.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation</span></div><div class="casAuthors">Wang, Jian-Bin; Erickson, Jon W.; Fuji, Reina; Ramachandran, Sekar; Gao, Ping; Dinavahi, Ramani; Wilson, Kristin F.; Ambrosio, Andre L. B.; Dias, Sandra M. G.; Dang, Chi-V.; Cerione, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-219</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Rho GTPases impact a no. of activities important for oncogenesis.  We describe a small mol. inhibitor that blocks oncogenic transformation induced by various Rho GTPases in fibroblasts, and the growth of human breast cancer and B lymphoma cells, without affecting normal cells.  We identify the target of this inhibitor to be the metabolic enzyme glutaminase, which catalyzes the hydrolysis of glutamine to glutamate.  We show that transformed fibroblasts and breast cancer cells exhibit elevated glutaminase activity that is dependent on Rho GTPases and NF-κB activity, and is blocked by the small mol. inhibitor.  These findings highlight a previously unappreciated connection between Rho GTPase activation and cellular metab. and demonstrate that targeting glutaminase activity can inhibit oncogenic transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTP6YsyzRd1LVg90H21EOLACvtfcHk0ljWXMPh60GGAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGht7bO&md5=67b64e99c992bbe6636ecfc04b83aac0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BB.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26aulast%3DFuji%26aufirst%3DR.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DDinavahi%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DK.%2BF.%26aulast%3DAmbrosio%26aufirst%3DA.%2BL.%2BB.%26aulast%3DDias%26aufirst%3DS.%2BM.%2BG.%26aulast%3DDang%26aufirst%3DC.%2BV.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26atitle%3DTargeting%2520mitochondrial%2520glutaminase%2520activity%2520inhibits%2520oncogenic%2520transformation%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D207%26epage%3D219%26doi%3D10.1016%2Fj.ccr.2010.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemberg, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vornov, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span> <span> </span><span class="NLM_article-title">We’re not “DON” yet: Optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1824</span>– <span class="NLM_lpage">1832</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-1148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1535-7163.MCT-17-1148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=30181331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12qt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1824-1832&author=K.+M.+Lembergauthor=J.+J.+Vornovauthor=R.+Raisauthor=B.+S.+Slusher&title=We%E2%80%99re+not+%E2%80%9CDON%E2%80%9D+yet%3A+Optimal+dosing+and+prodrug+delivery+of+6-diazo-5-oxo-L-norleucine&doi=10.1158%2F1535-7163.MCT-17-1148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">We're not "DON" yet: optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine</span></div><div class="casAuthors">Lemberg, Kathryn M.; Vornov, James J.; Rais, Rana; Slusher, Barbara S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1824-1832</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The broadly active glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) has been studied for 60 years as a potential anticancer therapeutic.  Clin. studies of DON in the 1950s using low daily doses suggested antitumor activity, but later phase I and II trials of DON given intermittently at high doses were hampered by dose-limiting nausea and vomiting.  Further clin. development of DON was abandoned.  Recently, the recognition that multiple tumor types are glutamine-dependent has renewed interest in metabolic inhibitors such as DON.  Here, we describe the prior experience with DON in humans.  Evaluation of past studies suggests that the major impediments to successful clin. use included unacceptable gastrointestinal (GI) toxicities, inappropriate dosing schedules for a metabolic inhibitor, and lack of targeted patient selection.  To circumvent GI toxicity, prodrug strategies for DON have been developed to enhance delivery of active compd. to tumor tissues, including the CNS.  When these prodrugs are administered in a low daily dosing regimen, appropriate for metabolic inhibition, they are robustly effective without significant toxicity.  Patients whose tumors have genetic, metabolic, or imaging biomarker evidence of glutamine dependence should be prioritized as candidates for future clin. evaluations of novel DON prodrugs, given either as monotherapy or in rationally directed pharmacol. combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm4X4Vtx-nTLVg90H21EOLACvtfcHk0liJDypMW-tjJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12qt7bK&md5=d83f232e399c8b1d6a4815d5f9a0c876</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-1148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-1148%26sid%3Dliteratum%253Aachs%26aulast%3DLemberg%26aufirst%3DK.%2BM.%26aulast%3DVornov%26aufirst%3DJ.%2BJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26atitle%3DWe%25E2%2580%2599re%2520not%2520%25E2%2580%259CDON%25E2%2580%259D%2520yet%253A%2520Optimal%2520dosing%2520and%2520prodrug%2520delivery%2520of%25206-diazo-5-oxo-L-norleucine%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1824%26epage%3D1832%26doi%3D10.1158%2F1535-7163.MCT-17-1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span> <span> </span><span class="NLM_article-title">Dibenzophenanthridinesas inhibitors of glutaminase C and cancer cell proliferation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1535-7163.MCT-11-0942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=22496480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1269-1277&author=W.+P.+Kattauthor=S.+Ramachandranauthor=J.+W.+Ericksonauthor=R.+A.+Cerione&title=Dibenzophenanthridinesas+inhibitors+of+glutaminase+C+and+cancer+cell+proliferation&doi=10.1158%2F1535-7163.MCT-11-0942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation</span></div><div class="casAuthors">Katt, William P.; Ramachandran, Sekar; Erickson, Jon W.; Cerione, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1269-1278</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">One hallmark of cancer cells is their adaptation to rely upon an altered metabolic scheme that includes changes in the glycolytic pathway, known as the Warburg effect, and elevated glutamine metab.  Glutaminase, a mitochondrial enzyme, plays a key role in the metab. of glutamine in cancer cells, and its inhibition could significantly impact malignant transformation.  The small mol. 968, a dibenzophenanthridine, was recently shown to inhibit recombinantly expressed glutaminase C, to block the proliferation and anchorage-independent colony formation of human cancer cells in culture, and to inhibit tumor formation in mouse xenograft models.  Here, we examine the structure-activity relationship that leads to 968-based inhibition of glutaminase and cancer cell proliferation, focusing upon a "hot-spot" ring previously identified as crit. to 968 activity.  We find that the hot-spot ring must be substituted with a large, nonplanar functionality (e.g., a t-Bu group) to bestow activity to the series, leading us to a model whereby the mol. binds glutaminase at a previously undescribed allosteric site.  We conduct docking studies to locate potential 968-binding sites and proceed to test a specific set of docking solns. via site-directed mutagenesis.  We verify the results from our initial assay of 968 and its analogs by cellular studies using MDA-MB-231 breast cancer cells.  Mol Cancer Ther; 11(6); 1269-78. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr56LeuCKRMMbVg90H21EOLACvtfcHk0liJDypMW-tjJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlCisLs%253D&md5=a6e11ed0a50ee567f0013e268e1b36e4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0942%26sid%3Dliteratum%253Aachs%26aulast%3DKatt%26aufirst%3DW.%2BP.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26atitle%3DDibenzophenanthridinesas%2520inhibitors%2520of%2520glutaminase%2520C%2520and%2520cancer%2520cell%2520proliferation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1269%26epage%3D1277%26doi%3D10.1158%2F1535-7163.MCT-11-0942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stalnecker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBrayer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. W.</span></span> <span> </span><span class="NLM_article-title">Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1073/pnas.1414056112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1073%2Fpnas.1414056112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=25548170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVak" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=394-399&author=C.+A.+Stalneckerauthor=S.+M.+Ulrichauthor=Y.+Liauthor=S.+Ramachandranauthor=M.+K.+McBrayerauthor=R.+J.+DeBerardinisauthor=R.+A.+Cerioneauthor=J.+W.+Erickson&title=Mechanism+by+which+a+recently+discovered+allosteric+inhibitor+blocks+glutamine+metabolism+in+transformed+cells&doi=10.1073%2Fpnas.1414056112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells</span></div><div class="casAuthors">Stalnecker, Clint A.; Ulrich, Scott M.; Li, Yunxing; Ramachandran, Sekar; McBrayer, Mary Kate; DeBerardinis, Ralph J.; Cerione, Richard A.; Erickson, Jon W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">394-399</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mitochondrial enzyme glutaminase C (GAC) catalyzes the hydrolysis of glutamine to glutamate plus ammonia, a key step in the metab. of glutamine by cancer cells.  Recently, we discovered a class of allosteric inhibitors of GAC that inhibit cancer cell growth without affecting their normal cellular counterparts, with the lead compd. being the bromo-benzophenanthridinone 968.  Here, we take advantage of mouse embryonic fibroblasts transformed by oncogenic Dbl, which hyperactivates Rho GTPases, together with 13C-labeled glutamine and stable-isotope tracing methods, to establish that 968 selectively blocks the enhancement in glutaminolysis necessary for satisfying the glutamine addiction of cancer cells.  We then det. how 968 inhibits the catalytic activity of GAC.  First, we developed a FRET assay to examine the effects of 968 on the ability of GAC to undergo the dimer-to-tetramer transition necessary for enzyme activation.  We next demonstrate how the fluorescence of a reporter group attached to GAC provides a direct read-out of the binding of 968 and related compds. to the enzyme.  By combining these fluorescence assays with newly developed GAC mutants trapped in either the monomeric or dimeric state, we show that 968 has the highest affinity for monomeric GAC and that the dose-dependent binding of 968 to GAC monomers directly matches its dose-dependent inhibition of enzyme activity and cellular transformation.  Together, these findings highlight the requirement of tetramer formation as the mechanism of GAC activation and shed new light on how a distinct class of allosteric GAC inhibitors impacts the metabolic program of transformed cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-MQlQRMdgt7Vg90H21EOLACvtfcHk0lhZ31-qXmbWzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVak&md5=a6920098b26d87012aa3f625804c22ed</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1414056112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1414056112%26sid%3Dliteratum%253Aachs%26aulast%3DStalnecker%26aufirst%3DC.%2BA.%26aulast%3DUlrich%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DMcBrayer%26aufirst%3DM.%2BK.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26atitle%3DMechanism%2520by%2520which%2520a%2520recently%2520discovered%2520allosteric%2520inhibitor%2520blocks%2520glutamine%2520metabolism%2520in%2520transformed%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D394%26epage%3D399%26doi%3D10.1073%2Fpnas.1414056112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lukey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cluntun, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druso, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span> <span> </span><span class="NLM_article-title">Liver-type glutaminase GLS2 is a druggable metabolic node in luminal-subtype breast cancer</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">76.e7</span>– <span class="NLM_lpage">88.e7</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.08.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.celrep.2019.08.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=76.e7-88.e7&author=M.+J.+Lukeyauthor=A.+A.+Cluntunauthor=W.+P.+Kattauthor=M.+J.+Linauthor=J.+E.+Drusoauthor=S.+Ramachandranauthor=J.+W.+Ericksonauthor=H.+H.+Leauthor=Z.-E.+Wangauthor=B.+Blankauthor=K.+S.+Greeneauthor=R.+A.+Cerione&title=Liver-type+glutaminase+GLS2+is+a+druggable+metabolic+node+in+luminal-subtype+breast+cancer&doi=10.1016%2Fj.celrep.2019.08.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.08.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.08.076%26sid%3Dliteratum%253Aachs%26aulast%3DLukey%26aufirst%3DM.%2BJ.%26aulast%3DCluntun%26aufirst%3DA.%2BA.%26aulast%3DKatt%26aufirst%3DW.%2BP.%26aulast%3DLin%26aufirst%3DM.%2BJ.%26aulast%3DDruso%26aufirst%3DJ.%2BE.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26aulast%3DLe%26aufirst%3DH.%2BH.%26aulast%3DWang%26aufirst%3DZ.-E.%26aulast%3DBlank%26aufirst%3DB.%26aulast%3DGreene%26aufirst%3DK.%2BS.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26atitle%3DLiver-type%2520glutaminase%2520GLS2%2520is%2520a%2520druggable%2520metabolic%2520node%2520in%2520luminal-subtype%2520breast%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D29%26spage%3D76.e7%26epage%3D88.e7%26doi%3D10.1016%2Fj.celrep.2019.08.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBryant, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curthoys, N. P.</span></span> <span> </span><span class="NLM_article-title">Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES)</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1042/BJ20070039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1042%2FBJ20070039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=17581113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BD2sXps1Wgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2007&pages=407-414&author=M.+M.+Robinsonauthor=S.+J.+McBryantauthor=T.+Tsukamotoauthor=C.+Rojasauthor=D.+V.+Ferrarisauthor=S.+K.+Hamiltonauthor=J.+C.+Hansenauthor=N.+P.+Curthoys&title=Novel+mechanism+of+inhibition+of+rat+kidney-type+glutaminase+by+bis-2-%285-phenylacetamido-1%2C2%2C4-thiadiazol-2-yl%29ethyl+sulfide+%28BPTES%29&doi=10.1042%2FBJ20070039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES)</span></div><div class="casAuthors">Robinson, Mary M.; McBryant, Steven J.; Tsukamoto, Takashi; Rojas, Camilo; Ferraris, Dana V.; Hamilton, Sean K.; Hansen, Jeffrey C.; Curthoys, Norman P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The release of GA (mitochondrial glutaminase) from neurons following acute ischemia or during chronic neurodegenerative diseases may contribute to the propagation of glutamate excitotoxicity.  Thus an inhibitor that selectively inactivates the released GA may limit the accumulation of excess glutamate and minimize the loss of neurol. function that accompanies brain injury.  The present study examines the mechanism of inactivation of rat KGA (kidney GA isoform) by the small-mol. inhibitor BPTES [bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide].  BPTES is a potent inhibitor of KGA, but not of the liver GA isoform, glutamate dehydrogenase or γ-glutamyl transpeptidase.  Kinetic studies indicate that, with respect to glutamine, BPTES has a Ki of approx. 3 μM.  Moreover, these studies suggest that BPTES inhibits the allosteric activation caused by phosphate binding and promotes the formation of an inactive complex.  Gel-filtration chromatog. and sedimentation-velocity anal. were used to examine the effect of BPTES on the phosphate-dependent oligomerization of KGA.  This established that BPTES prevents the formation of large phosphate-induced oligomers and instead promotes the formation of a single oligomeric species with distinct phys. properties.  Sedimentation-equil. studies detd. that the oligomer produced by BPTES is a stable tetramer.  Taken together, the present work indicates that BPTES is a unique and potent inhibitor of rat KGA and elucidates a novel mechanism of inactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR5Ncyq__sELVg90H21EOLACvtfcHk0lhZ31-qXmbWzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXps1Wgsb4%253D&md5=cde9754c0dedd000423226e2289b4690</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1042%2FBJ20070039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070039%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%2BM.%26aulast%3DMcBryant%26aufirst%3DS.%2BJ.%26aulast%3DTsukamoto%26aufirst%3DT.%26aulast%3DRojas%26aufirst%3DC.%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26aulast%3DHamilton%26aufirst%3DS.%2BK.%26aulast%3DHansen%26aufirst%3DJ.%2BC.%26aulast%3DCurthoys%26aufirst%3DN.%2BP.%26atitle%3DNovel%2520mechanism%2520of%2520inhibition%2520of%2520rat%2520kidney-type%2520glutaminase%2520by%2520bis-2-%25285-phenylacetamido-1%252C2%252C4-thiadiazol-2-yl%2529ethyl%2520sulfide%2520%2528BPTES%2529%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D406%26spage%3D407%26epage%3D414%26doi%3D10.1042%2FBJ20070039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeLaBarre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song J, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurov, J. B.</span></span> <span> </span><span class="NLM_article-title">Full-length human glutaminase in complex with an allosteric inhibitor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">10764</span>– <span class="NLM_lpage">10770</span>, <span class="refDoi"> DOI: 10.1021/bi201613d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi201613d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSks73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=10764-10770&author=B.+DeLaBarreauthor=S.+Grossauthor=C.+Fangauthor=Y.+Gaoauthor=A.+Jhaauthor=F.+Jiangauthor=J.+Song+Jauthor=W.+Weiauthor=J.+B.+Hurov&title=Full-length+human+glutaminase+in+complex+with+an+allosteric+inhibitor&doi=10.1021%2Fbi201613d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Full-Length Human Glutaminase in Complex with an Allosteric Inhibitor</span></div><div class="casAuthors">DeLaBarre, Byron; Gross, Stefan; Fang, Cheng; Gao, Yi; Jha, Abhishek; Jiang, Fan; Song J., Juanhua; Wei, Wentao; Hurov, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">10764-10770</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glutaminase (GLS1/2) catalyzes the conversion of L-glutamine to L-glutamate and ammonia.  The level of a splice variant of GLS1 (GAC) is elevated in certain cancers, and GAC is specifically inhibited by bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide (BPTES).  We report here the first full-length crystal structure of GAC in the presence and absence of BPTES mols.  Two BPTES mols. bind at an interface region of the GAC tetramer in a manner that appears to lock the GAC tetramer into a nonproductive conformation.  The importance of these loops with regard to overall enzymic activity of the tetramer was revealed by a series of GAC point mutants designed to create a BPTES resistant GAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrj21-Ko0HGLVg90H21EOLACvtfcHk0lj5UXeQUyj50A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSks73K&md5=bd94996062f54c4f51a138c8e9f5f99a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi201613d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi201613d%26sid%3Dliteratum%253Aachs%26aulast%3DDeLaBarre%26aufirst%3DB.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DJha%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DSong%2BJ%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DHurov%26aufirst%3DJ.%2BB.%26atitle%3DFull-length%2520human%2520glutaminase%2520in%2520complex%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D10764%26epage%3D10770%26doi%3D10.1021%2Fbi201613d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, T.</span></span> <span> </span><span class="NLM_article-title">Recent progress in the discovery of allosteric inhibitors of kidney-type glutaminase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ertLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=46-59&author=S.+C.+Zimmermannauthor=B.+Duvallauthor=T.+Tsukamoto&title=Recent+progress+in+the+discovery+of+allosteric+inhibitors+of+kidney-type+glutaminase&doi=10.1021%2Facs.jmedchem.8b00327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase</span></div><div class="casAuthors">Zimmermann, Sarah C.; Duvall, Bridget; Tsukamoto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-59</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kidney-type glutaminase (GLS), the first enzyme in the glutaminolysis pathway, catalyzes the hydrolysis of glutamine to glutamate.  GLS was found to be upregulated in many glutamine-dependent cancer cells.  Therefore, selective inhibition of GLS has gained substantial interest as a therapeutic approach targeting cancer metab.  Bis-2-[5-(phenylacetamido)-1,3,4-thiadiazol-2-yl]ethyl sulfide (BPTES), despite its poor physicochem. properties, has served as a key mol. template in subsequent efforts to identify more potent and drug-like allosteric GLS inhibitors.  This review article provides an overview of the progress made to date in the development of GLS inhibitors and highlights the remarkable transformation of the unfavorable lead into "druglike" compds. guided by systematic SAR studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSonxbDTrHLrVg90H21EOLACvtfcHk0lj5UXeQUyj50A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ertLrJ&md5=70d1c4cb85923362e2e5d92c2113f273</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00327%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DS.%2BC.%26aulast%3DDuvall%26aufirst%3DB.%26aulast%3DTsukamoto%26aufirst%3DT.%26atitle%3DRecent%2520progress%2520in%2520the%2520discovery%2520of%2520allosteric%2520inhibitors%2520of%2520kidney-type%2520glutaminase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D46%26epage%3D59%26doi%3D10.1021%2Facs.jmedchem.8b00327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delahanty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamato, T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazolyl-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10551</span>– <span class="NLM_lpage">10563</span>, <span class="refDoi"> DOI: 10.1021/jm301191p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301191p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ohs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10551-10563&author=K.+Shuklaauthor=D.+V.+Ferrarisauthor=A.+G.+Thomasauthor=M.+Stathisauthor=B.+Duvallauthor=G.+Delahantyauthor=J.+Altauthor=R.+Raisauthor=C.+Rojasauthor=P.+Gaoauthor=Y.+Xiangauthor=C.+V.+Dangauthor=B.+S.+Slusherauthor=T.+Tsukamato&title=Design%2C+synthesis+and+pharmacological+evaluation+of+bis-2-%285-phenylacetamido-1%2C2%2C4-thiadiazolyl-2-yl%29ethyl+sulfide+3+%28BPTES%29+analogs+as+glutaminase+inhibitors&doi=10.1021%2Fjm301191p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors</span></div><div class="casAuthors">Shukla, Krupa; Ferraris, Dana V.; Thomas, Ajit G.; Stathis, Marigo; Duvall, Bridget; Delahanty, Greg; Alt, Jesse; Rais, Rana; Rojas, Camilo; Gao, Ping; Xiang, Yan; Dang, Chi V.; Slusher, Barbara S.; Tsukamoto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10551-10563</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) that has served as a mol. probe to det. the therapeutic potential of GLS inhibition.  In an attempt to identify more potent GLS inhibitors with improved drug-like mol. properties, a series of BPTES analogs were synthesized and evaluated.  The structure-activity relationship (SAR) studies revealed that some truncated analogs retained the potency of BPTES, presenting an opportunity to improve its aq. soly.  The analog I exhibited similar potency and better soly. relative to BPTES and attenuated the growth of P493 human lymphoma B cells in vitro as well as in a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0N1SUSOaTCbVg90H21EOLACvtfcHk0lgGoovnNyQqxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ohs7zM&md5=7a54f0c8de3c211a65d5c9bbb4a6db62</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm301191p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301191p%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DK.%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26aulast%3DThomas%26aufirst%3DA.%2BG.%26aulast%3DStathis%26aufirst%3DM.%26aulast%3DDuvall%26aufirst%3DB.%26aulast%3DDelahanty%26aufirst%3DG.%26aulast%3DAlt%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DRojas%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DDang%26aufirst%3DC.%2BV.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DTsukamato%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%2520and%2520pharmacological%2520evaluation%2520of%2520bis-2-%25285-phenylacetamido-1%252C2%252C4-thiadiazolyl-2-yl%2529ethyl%2520sulfide%25203%2520%2528BPTES%2529%2520analogs%2520as%2520glutaminase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10551%26epage%3D10563%26doi%3D10.1021%2Fjm301191p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R.</span></span> <span> </span><span class="NLM_article-title">Design and evaluation of novel glutaminase inhibitors</span>. <i>Biorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">1839</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.bmc.2016.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=26988803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Wmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1819-1839&author=L.+A.+McDermottauthor=P.+Iyerauthor=L.+Vernettiauthor=S.+Rimerauthor=J.+Sunauthor=M.+Bobyauthor=T.+Yangauthor=M.+Fioravantiauthor=J.+O%E2%80%99Neillauthor=L.+Wangauthor=D.+Drakesauthor=W.+Kattauthor=Q.+Huangauthor=R.+Cerione&title=Design+and+evaluation+of+novel+glutaminase+inhibitors&doi=10.1016%2Fj.bmc.2016.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and evaluation of novel glutaminase inhibitors</span></div><div class="casAuthors">McDermott, Lee A.; Iyer, Prema; Vernetti, Larry; Rimer, Shawn; Sun, Jingran; Boby, Melissa; Yang, Tianyi; Fioravanti, Michael; O'Neill, Jason; Wang, Liwei; Drakes, Dylan; Katt, William; Huang, Qingqiu; Cerione, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1819-1839</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel set of GAC (kidney glutaminase isoform C) inhibitors able to inhibit the enzymic activity of GAC and the growth of the triple neg. MDA-MB-231 breast cancer cells with low nanomolar potency is described.  Compds. in this series have a reduced no. of rotatable bonds, improved C log Ps, microsomal stability and ligand efficiency when compared to the leading GAC inhibitors BPTES and CB-839.  Property improvements were achieved by the replacement of the flexible n-diethylthio or the Bu moiety present in the leading inhibitors by heteroatom substituted heterocycloalkanes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGfzNc9NMuhbVg90H21EOLACvtfcHk0lgGoovnNyQqxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Wmsbg%253D&md5=f335b5659f76e351b73c96954153127d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DL.%2BA.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DVernetti%26aufirst%3DL.%26aulast%3DRimer%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DBoby%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DFioravanti%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DDrakes%26aufirst%3DD.%26aulast%3DKatt%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DCerione%26aufirst%3DR.%26atitle%3DDesign%2520and%2520evaluation%2520of%2520novel%2520glutaminase%2520inhibitors%26jtitle%3DBiorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1819%26epage%3D1839%26doi%3D10.1016%2Fj.bmc.2016.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geedy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R.</span></span> <span> </span><span class="NLM_article-title">GAC inhibitors with a 4-hydroxypiperidine spacer: Requirements for potency</span>. <i>Biorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">126632</span> <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.bmcl.2019.126632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=31474484" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&author=L.+McDermottauthor=D.+Koesauthor=S.+Mohammedauthor=P.+Iyerauthor=M.+Bobyauthor=V.+Balasubramanianauthor=M.+Geedyauthor=W.+Kattauthor=R.+Cerione&title=GAC+inhibitors+with+a+4-hydroxypiperidine+spacer%3A+Requirements+for+potency&doi=10.1016%2Fj.bmcl.2019.126632"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126632%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DL.%26aulast%3DKoes%26aufirst%3DD.%26aulast%3DMohammed%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBoby%26aufirst%3DM.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DGeedy%26aufirst%3DM.%26aulast%3DKatt%26aufirst%3DW.%26aulast%3DCerione%26aufirst%3DR.%26atitle%3DGAC%2520inhibitors%2520with%2520a%25204-hydroxypiperidine%2520spacer%253A%2520Requirements%2520for%2520potency%26jtitle%3DBiorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26doi%3D10.1016%2Fj.bmcl.2019.126632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, B. H.</span></span> <span> </span><span class="NLM_article-title">Novel 1,3,4-selenadiazole-containing kidney-type glutaminase inhibitors showed improved cellular uptake and antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWju7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=589-603&author=Z.+Chenauthor=D.+Liauthor=N.+Xuauthor=J.+Fangauthor=Y.+Yuauthor=W.+Houauthor=H.+Ruanauthor=P.+Zhuauthor=R.+Maauthor=S.+Luauthor=D.+Caoauthor=R.+Wuauthor=M.+Niauthor=W.+Zhangauthor=W.+Suauthor=B.+H.+Ruan&title=Novel+1%2C3%2C4-selenadiazole-containing+kidney-type+glutaminase+inhibitors+showed+improved+cellular+uptake+and+antitumor+activity&doi=10.1021%2Facs.jmedchem.8b01198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity</span></div><div class="casAuthors">Chen, Zhao; Li, Di; Xu, Ning; Fang, Jinzhang; Yu, Yan; Hou, Wei; Ruan, Haoqiang; Zhu, Panpan; Ma, Renchao; Lu, Shiying; Cao, Danhui; Wu, Rui; Ni, Mowei; Zhang, Wei; Su, Weike; Ruan, Benfang Helen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">589-603</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kidney-type glutaminase [KGA/isoenzyme glutaminase C (GAC)] is becoming an important tumor metab. target in cancer chemotherapy.  Its allosteric inhibitor, CB839, showed early promise in cancer therapeutics but limited efficacy in in vivo cancer models.  To improve the in vivo activity, the authors explored a bioisostere replacement of the sulfur atom in bis-2-(5-phenylacetamido-1,2,4-thiadiazol)ethyl sulfide and CB839 analogs with selenium using a novel synthesis of the selenadiazole moiety from carboxylic acids or nitriles.  The resulting selenadiazole compds. showed enhanced KGA inhibition, more potent induction of reactive oxygen species, improved inhibition of cancer cells, and higher cellular and tumor accumulation than the corresponding sulfur-contg. mols.  However, both CB839 and its selenium analogs show incomplete inhibition of the tested cancer cells, and a partial redn. in tumor size was obsd. in both the glutamine-dependent HCT116 and aggressive H22 liver cancer xenograft models.  Despite this, tumor tissue damage and prolonged survival were obsd. in animals treated with the selenium analog of CB839.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7CHcIk6PcobVg90H21EOLACvtfcHk0lgFloW21l0ICQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWju7nL&md5=cbad84021fd466bfedb2592f84136afb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01198%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DW.%26aulast%3DRuan%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DW.%26aulast%3DRuan%26aufirst%3DB.%2BH.%26atitle%3DNovel%25201%252C3%252C4-selenadiazole-containing%2520kidney-type%2520glutaminase%2520inhibitors%2520showed%2520improved%2520cellular%2520uptake%2520and%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D589%26epage%3D603%26doi%3D10.1021%2Facs.jmedchem.8b01198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairnduff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheasty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekwuru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littleson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarron, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKelvie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raubo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter-Holt, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a thiadiazole-pyridazine-based allosteric glutaminase 1 inhibitor series that demonstrates oral bioavailability and activity in tumor xenograft models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6540</span>– <span class="NLM_lpage">6560</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFOks7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6540-6560&author=M.+R.+Finlayauthor=M.+Andertonauthor=A.+Baileyauthor=S.+Boydauthor=J.+Brookfieldauthor=C.+Cairnduffauthor=M.+Charlesauthor=A.+Cheastyauthor=S.+E.+Critchlowauthor=J.+Culshawauthor=T.+Ekwuruauthor=I.+Hollingsworthauthor=N.+Jonesauthor=F.+Lerouxauthor=M.+Littlesonauthor=H.+McCarronauthor=J.+McKelvieauthor=L.+Mooneyauthor=J.+W.+M.+Nissinkauthor=D.+Perkinsauthor=S.+Powellauthor=M.+J.+Quesadaauthor=P.+Rauboauthor=V.+Sabinauthor=J.+Smithauthor=P.+D.+Smithauthor=A.+Starkauthor=A.+Tingauthor=P.+Wangauthor=Z.+Wilsonauthor=J.+J.+Winter-Holtauthor=J.+M.+Woodauthor=G.+L.+Wrigleyauthor=G.+Yuauthor=P.+Zhang&title=Discovery+of+a+thiadiazole-pyridazine-based+allosteric+glutaminase+1+inhibitor+series+that+demonstrates+oral+bioavailability+and+activity+in+tumor+xenograft+models&doi=10.1021%2Facs.jmedchem.9b00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Bailey, Andrew; Boyd, Scott; Brookfield, Joanna; Cairnduff, Ceri; Charles, Mark; Cheasty, Anne; Critchlow, Susan E.; Culshaw, Janet; Ekwuru, Tennyson; Hollingsworth, Ian; Jones, Neil; Leroux, Fred; Littleson, Mairi; McCarron, Hollie; McKelvie, Jennifer; Mooney, Lorraine; Nissink, J. Willem M.; Perkins, David; Powell, Steve; Quesada, Mar Jimenez; Raubo, Piotr; Sabin, Verity; Smith, James; Smith, Peter D.; Stark, Andrew; Ting, Attilla; Wang, Peng; Wilson, Zena; Winter-Holt, Jon J.; Wood, J. Matthew; Wrigley, Gail L.; Yu, Guoqing; Zhang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6540-6560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumors have evolved a variety of methods to reprogram conventional metabolic pathways to favor their own nutritional needs, including glutaminolysis, the first step of which is the hydrolysis of glutamine to glutamate by the amidohydrolase glutaminase 1 (GLS1).  A GLS1 inhibitor could potentially target certain cancers by blocking the tumor cell's ability to produce glutamine-derived nutrients.  Starting from the known GLS1 inhibitor bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide, we describe the medicinal chem. evolution of a series from lipophilic inhibitors with suboptimal physicochem. and pharmacokinetic properties to cell potent examples with reduced mol. wt. and lipophilicity, leading to compds. with greatly improved oral exposure that demonstrate in vivo target engagement accompanied by activity in relevant disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo60TBet-ww7rVg90H21EOLACvtfcHk0lgFloW21l0ICQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFOks7zP&md5=ba80acfcafc8c312f64a8b55ca601724</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00260%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBoyd%26aufirst%3DS.%26aulast%3DBrookfield%26aufirst%3DJ.%26aulast%3DCairnduff%26aufirst%3DC.%26aulast%3DCharles%26aufirst%3DM.%26aulast%3DCheasty%26aufirst%3DA.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DCulshaw%26aufirst%3DJ.%26aulast%3DEkwuru%26aufirst%3DT.%26aulast%3DHollingsworth%26aufirst%3DI.%26aulast%3DJones%26aufirst%3DN.%26aulast%3DLeroux%26aufirst%3DF.%26aulast%3DLittleson%26aufirst%3DM.%26aulast%3DMcCarron%26aufirst%3DH.%26aulast%3DMcKelvie%26aufirst%3DJ.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DQuesada%26aufirst%3DM.%2BJ.%26aulast%3DRaubo%26aufirst%3DP.%26aulast%3DSabin%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DTing%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DWinter-Holt%26aufirst%3DJ.%2BJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520a%2520thiadiazole-pyridazine-based%2520allosteric%2520glutaminase%25201%2520inhibitor%2520series%2520that%2520demonstrates%2520oral%2520bioavailability%2520and%2520activity%2520in%2520tumor%2520xenograft%2520models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6540%26epage%3D6560%26doi%3D10.1021%2Facs.jmedchem.9b00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burns, A. C.</span>; <span class="NLM_string-name">Collins, M. R.</span>; <span class="NLM_string-name">Greasley, S. E.</span>; <span class="NLM_string-name">Hoffman, R. L.</span>; <span class="NLM_string-name">Huang, Q.</span>; <span class="NLM_string-name">Kania, R. S.</span>; <span class="NLM_string-name">Kung, P.</span>; <span class="NLM_string-name">Linton, M. A.</span>; <span class="NLM_string-name">Narasimhan, L. S.</span>; <span class="NLM_string-name">Richardson, P. F.</span>; <span class="NLM_string-name">Richter, D. T.</span>; <span class="NLM_string-name">Smith, G.</span></span> <span> </span><span class="NLM_article-title">Cycloalkyl-linked Diheterocycle Derivatives</span>. International Patent Application Number <span class="NLM_patent">WO2015/166373A1</span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+C.+Burns&author=M.+R.+Collins&author=S.+E.+Greasley&author=R.+L.+Hoffman&author=Q.+Huang&author=R.+S.+Kania&author=P.+Kung&author=M.+A.+Linton&author=L.+S.+Narasimhan&author=P.+F.+Richardson&author=D.+T.+Richter&author=G.+Smith&title=Cycloalkyl-linked+Diheterocycle+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DA.%2BC.%26atitle%3DCycloalkyl-linked%2520Diheterocycle%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span>; <span class="NLM_string-name">Lemieux, R. M.</span>; <span class="NLM_string-name">Cao, S.</span>; <span class="NLM_string-name">Ding, Y.</span>; <span class="NLM_string-name">Ye, Z.</span></span> <span> </span><span class="NLM_article-title">Compounds and Their Methods of Use</span>. International Patent Application Number <span class="NLM_patent">WO2015/143340 A1</span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=G.+Cianchetta&author=R.+M.+Lemieux&author=S.+Cao&author=Y.+Ding&author=Z.+Ye&title=Compounds+and+Their+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCianchetta%26aufirst%3DG.%26atitle%3DCompounds%2520and%2520Their%2520Methods%2520of%2520Use%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhavar, P. K.</span>; <span class="NLM_string-name">Vakkalanka, S. K.</span>; <span class="NLM_string-name">Viswanadha, S.</span>; <span class="NLM_string-name">Swaroop, M. G.</span>; <span class="NLM_string-name">Babu, G.</span></span> <span> </span><span class="NLM_article-title">Novel Glutaminase Inhibitors</span>. <span class="NLM_patent">WO2015/101958 A2</span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+K.+Bhavar&author=S.+K.+Vakkalanka&author=S.+Viswanadha&author=M.+G.+Swaroop&author=G.+Babu&title=Novel+Glutaminase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhavar%26aufirst%3DP.%2BK.%26atitle%3DNovel%2520Glutaminase%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Chen, L.</span>; <span class="NLM_string-name">Goyal, B.</span>; <span class="NLM_string-name">Laidig, G.</span>; <span class="NLM_string-name">Stanton, T. F.</span>; <span class="NLM_string-name">Sjogren, E. B.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Inhibitors of Glutaminase</span>. International Patent Application Number <span class="NLM_patent">WO2013/078123 A1</span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Li&author=L.+Chen&author=B.+Goyal&author=G.+Laidig&author=T.+F.+Stanton&author=E.+B.+Sjogren&title=Heterocyclic+Inhibitors+of+Glutaminase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DHeterocyclic%2520Inhibitors%2520of%2520Glutaminase%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogl, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orford, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">3059</span>, <span class="refDoi"> DOI: 10.1182/blood.V126.23.3059.3059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1182%2Fblood.V126.23.3059.3059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=3059&author=D.+T.+Voglauthor=A.+Younesauthor=K.+Stewartauthor=K.+W.+Orfordauthor=M.+Bennettauthor=D.+Siegelauthor=J.+G.+Berdeja&title=Phase+1+study+of+CB-839%2C+a+first-in-class%2C+glutaminase+inhibitor+in+patients+with+multiple+myeloma+and+lymphoma&doi=10.1182%2Fblood.V126.23.3059.3059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1182%2Fblood.V126.23.3059.3059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V126.23.3059.3059%26sid%3Dliteratum%253Aachs%26aulast%3DVogl%26aufirst%3DD.%2BT.%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DOrford%26aufirst%3DK.%2BW.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26atitle%3DPhase%25201%2520study%2520of%2520CB-839%252C%2520a%2520first-in-class%252C%2520glutaminase%2520inhibitor%2520in%2520patients%2520with%2520multiple%2520myeloma%2520and%2520lymphoma%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D3059%26doi%3D10.1182%2Fblood.V126.23.3059.3059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalinsky, K.</span>; <span class="NLM_string-name">Harding, J. J.</span>; <span class="NLM_string-name">DeMichele, A.</span>; <span class="NLM_string-name">Infante, J. R.</span>; <span class="NLM_string-name">Gogineni, K.</span>; <span class="NLM_string-name">Owonikoko, T. K.</span>; <span class="NLM_string-name">Isakoff, S.</span>; <span class="NLM_string-name">Iliopuolos, O.</span>; <span class="NLM_string-name">Patel, N. R.</span>; <span class="NLM_string-name">Munster, P.</span>; <span class="NLM_string-name">Telli, M. L.</span>; <span class="NLM_string-name">Jenkins, Y.</span>; <span class="NLM_string-name">Fiji, G. P.</span>; <span class="NLM_string-name">Whiting, S. H.</span>; <span class="NLM_string-name">Meric-Bernstam, F.</span></span> In  <i>Phase 1 study of CB-839, a First-in-Class Inhibitor of Glutaminase, in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR</i>, Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5–9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res. 2018, 78(4 Suppl), Abstract no. PD3-13, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.+Kalinsky&author=J.+J.+Harding&author=A.+DeMichele&author=J.+R.+Infante&author=K.+Gogineni&author=T.+K.+Owonikoko&author=S.+Isakoff&author=O.+Iliopuolos&author=N.+R.+Patel&author=P.+Munster&author=M.+L.+Telli&author=Y.+Jenkins&author=G.+P.+Fiji&author=S.+H.+Whiting&author=F.+Meric-Bernstam&title=Phase+1+study+of+CB-839%2C+a+First-in-Class+Inhibitor+of+Glutaminase%2C+in+Combination+with+Paclitaxel+in+Patients+with+Advanced+Triple+Negative+Breast+Cancer+%5Babstract%5D.+In%3A+Proceedings+of+the+2017+San+Antonio+Breast+Cancer+Symposium%3B+2017+Dec+5-9%3B+San+Antonio%2C+TX.+Philadelphia+%28PA%29%3A+AACR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKalinsky%26aufirst%3DK.%26jtitle%3DPhase%25201%2520study%2520of%2520CB-839%252C%2520a%2520First-in-Class%2520Inhibitor%2520of%2520Glutaminase%252C%2520in%2520Combination%2520with%2520Paclitaxel%2520in%2520Patients%2520with%2520Advanced%2520Triple%2520Negative%2520Breast%2520Cancer%2520%255Babstract%255D.%2520In%253A%2520Proceedings%2520of%2520the%25202017%2520San%2520Antonio%2520Breast%2520Cancer%2520Symposium%253B%25202017%2520Dec%25205-9%253B%2520San%2520Antonio%252C%2520TX.%2520Philadelphia%2520%2528PA%2529%253A%2520AACR%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carthon, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliopoulos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannir, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span> <span> </span><span class="NLM_article-title">CB-839, a glutaminase inhibitor, in combination with cabozantanib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase 1 study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>, <span class="NLM_elocation-id">549</span> <span class="refDoi"> DOI: 10.1200/JCO.2019.37.7_suppl.549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1200%2FJCO.2019.37.7_suppl.549" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&author=F.+Meric-Bernstamauthor=R.+J.+Leeauthor=B.+C.+Carthonauthor=O.+Iliopoulosauthor=J.+W.+Mierauthor=M.+R.+Patelauthor=N.+M.+Tannirauthor=T.+K.+Owonikokoauthor=N.+B.+Haasauthor=M.+H.+Vossauthor=J.+J.+Hardingauthor=R.+Srinivasanauthor=G.+Shapiroauthor=M.+L.+Telliauthor=P.+N.+Munsterauthor=R.+D.+Carvajalauthor=Y.+Jenkinsauthor=S.+H.+Whitingauthor=J.+C.+Bendellauthor=T.+M.+Bauer&title=CB-839%2C+a+glutaminase+inhibitor%2C+in+combination+with+cabozantanib+in+patients+with+clear+cell+and+papillary+metastatic+renal+cell+cancer+%28mRCC%29%3A+Results+of+a+phase+1+study&doi=10.1200%2FJCO.2019.37.7_suppl.549"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.7_suppl.549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.7_suppl.549%26sid%3Dliteratum%253Aachs%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DCarthon%26aufirst%3DB.%2BC.%26aulast%3DIliopoulos%26aufirst%3DO.%26aulast%3DMier%26aufirst%3DJ.%2BW.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DTannir%26aufirst%3DN.%2BM.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DHaas%26aufirst%3DN.%2BB.%26aulast%3DVoss%26aufirst%3DM.%2BH.%26aulast%3DHarding%26aufirst%3DJ.%2BJ.%26aulast%3DSrinivasan%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DTelli%26aufirst%3DM.%2BL.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DJenkins%26aufirst%3DY.%26aulast%3DWhiting%26aufirst%3DS.%2BH.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26atitle%3DCB-839%252C%2520a%2520glutaminase%2520inhibitor%252C%2520in%2520combination%2520with%2520cabozantanib%2520in%2520patients%2520with%2520clear%2520cell%2520and%2520papillary%2520metastatic%2520renal%2520cell%2520cancer%2520%2528mRCC%2529%253A%2520Results%2520of%2520a%2520phase%25201%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26doi%3D10.1200%2FJCO.2019.37.7_suppl.549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeLaBarre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurov, J. B.</span></span> <span> </span><span class="NLM_article-title">Full-length human glutaminase in complex with an allosteric inhibitor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">10764</span>– <span class="NLM_lpage">10770</span>, <span class="refDoi"> DOI: 10.1021/bi201613d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi201613d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSks73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=10764-10770&author=B.+DeLaBarreauthor=S.+Grossauthor=C.+Fangauthor=Y.+Gaoauthor=A.+Jhaauthor=F.+Jiangauthor=J.+J.+Songauthor=W.+Weiauthor=J.+B.+Hurov&title=Full-length+human+glutaminase+in+complex+with+an+allosteric+inhibitor&doi=10.1021%2Fbi201613d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Full-Length Human Glutaminase in Complex with an Allosteric Inhibitor</span></div><div class="casAuthors">DeLaBarre, Byron; Gross, Stefan; Fang, Cheng; Gao, Yi; Jha, Abhishek; Jiang, Fan; Song J., Juanhua; Wei, Wentao; Hurov, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">10764-10770</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glutaminase (GLS1/2) catalyzes the conversion of L-glutamine to L-glutamate and ammonia.  The level of a splice variant of GLS1 (GAC) is elevated in certain cancers, and GAC is specifically inhibited by bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide (BPTES).  We report here the first full-length crystal structure of GAC in the presence and absence of BPTES mols.  Two BPTES mols. bind at an interface region of the GAC tetramer in a manner that appears to lock the GAC tetramer into a nonproductive conformation.  The importance of these loops with regard to overall enzymic activity of the tetramer was revealed by a series of GAC point mutants designed to create a BPTES resistant GAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrj21-Ko0HGLVg90H21EOLACvtfcHk0lgTrMCJYuOlQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSks73K&md5=bd94996062f54c4f51a138c8e9f5f99a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fbi201613d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi201613d%26sid%3Dliteratum%253Aachs%26aulast%3DDeLaBarre%26aufirst%3DB.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DJha%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DHurov%26aufirst%3DJ.%2BB.%26atitle%3DFull-length%2520human%2520glutaminase%2520in%2520complex%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D10764%26epage%3D10770%26doi%3D10.1021%2Fbi201613d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M. J.</span>; <span class="NLM_string-name">Le, K.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Kovacs, J. J.</span>; <span class="NLM_string-name">Burke, J. P.</span>; <span class="NLM_string-name">Bardenhagen, J. P.</span>; <span class="NLM_string-name">Bristow, C. A.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Carroll, C. L.</span>; <span class="NLM_string-name">Di Francesco, M. E.</span>; <span class="NLM_string-name">Hamilton, M. M.</span>; <span class="NLM_string-name">Geck Do, M.</span>; <span class="NLM_string-name">Harris, A.</span>; <span class="NLM_string-name">Giuliani, V.</span>; <span class="NLM_string-name">Huang, S.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Johnson, T.</span>; <span class="NLM_string-name">Kang, Z.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">McAfoos, T.</span>; <span class="NLM_string-name">Miller, M.</span>; <span class="NLM_string-name">Morlacchi, P.</span>; <span class="NLM_string-name">Palmer, W. S.</span>; <span class="NLM_string-name">Pang, J.</span>; <span class="NLM_string-name">Rogers, N.</span>; <span class="NLM_string-name">Shepard, H. E.</span>; <span class="NLM_string-name">Spencer, N. D.</span>; <span class="NLM_string-name">Theroff, J.</span>; <span class="NLM_string-name">Xu, Q.</span>; <span class="NLM_string-name">Yau, A.</span>; <span class="NLM_string-name">Draetta, G.</span>; <span class="NLM_string-name">Toniatti, C.</span>; <span class="NLM_string-name">Nazarenko, N.</span>; <span class="NLM_string-name">Heffernan, T. P.</span>; <span class="NLM_string-name">Jones, P.</span></span> In  <i>First-time Disclosure of IPN60090, a Potent and Selective GLS1 Inhibitor with Excellent Edit Reference</i>; Abstracts of Papers, 259th ACS National Meeting and Exposition, Philadelphia, PA, United States. <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">March 22–26, 2020</span>; MEDI  <span class="NLM_fpage">0288</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=March+22%E2%80%9326%2C+2020&pages=0288&author=M.+J.+Soth&author=K.+Le&author=G.+Liu&author=J.+J.+Kovacs&author=J.+P.+Burke&author=J.+P.+Bardenhagen&author=C.+A.+Bristow&author=B.+Czako&author=C.+L.+Carroll&author=M.+E.+Di+Francesco&author=M.+M.+Hamilton&author=M.+Geck+Do&author=A.+Harris&author=V.+Giuliani&author=S.+Huang&author=Y.+Jiang&author=T.+Johnson&author=Z.+Kang&author=Z.+Liu&author=T.+McAfoos&author=M.+Miller&author=P.+Morlacchi&author=W.+S.+Palmer&author=J.+Pang&author=N.+Rogers&author=H.+E.+Shepard&author=N.+D.+Spencer&author=J.+Theroff&author=Q.+Xu&author=A.+Yau&author=G.+Draetta&author=C.+Toniatti&author=N.+Nazarenko&author=T.+P.+Heffernan&author=P.+Jones&title=First-time+Disclosure+of+IPN60090%2C+a+Potent+and+Selective+GLS1+Inhibitor+with+Excellent+Edit+Reference"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSoth%26aufirst%3DM.%2BJ.%26btitle%3DFirst-time%2520Disclosure%2520of%2520IPN60090%252C%2520a%2520Potent%2520and%2520Selective%2520GLS1%2520Inhibitor%2520with%2520Excellent%2520Edit%2520Reference%26pub%3DAmerican%2520Chemical%2520Society%26date%3DMarch%252022%25E2%2580%259326%252C%25202020%26spage%3D0288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilbourn, M. R.</span></span> <span> </span><span class="NLM_article-title">Thiophenes as phenyl bio-isosteres: Application in radiopharmaceutical design-I. Dopamine uptake antagonists</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.1016/0883-2897(89)90138-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2F0883-2897%2889%2990138-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADyaK3cXntlSjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1989&pages=681-686&author=M.+R.+Kilbourn&title=Thiophenes+as+phenyl+bio-isosteres%3A+Application+in+radiopharmaceutical+design-I.+Dopamine+uptake+antagonists&doi=10.1016%2F0883-2897%2889%2990138-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Thiophenes as phenyl bio-isosteres:  application in radiopharmaceutical design.  I.  Dopamine uptake antagonists</span></div><div class="casAuthors">Kilbourn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">681-6</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    </div><div class="casAbstract">Possible applications of thiophenes in radiopharmaceutical chem. were explored.  Thiophene for benzene ring substitution was applied to the synthesis of thienyl-[18F]GBR 13119 (I), an analog of the potent and selective dopamine uptake inhibitor [18F]GBR 13119.  I was prepd. by the exchange reaction of Bu4N+18F- with (4-fluorophenyl) (2-thienyl)methanone followed by LiAlH4 redn., chloro substitution and reaction with N-(2-hydroxyethyl)-N-(3-phenylpropyl)piperazine.  In vivo regional brain distribution in mice shows essentially identical results for the thienyl and Ph compds. (striatum/cerebellum ratios of >4 at 60 min), suggesting successful substitution by the thiophene ring.  The extension of this concept to the synthesis of no-carrier-added, high specific activity [18F]fluorothiophenes was examd.: 5-[18F]fluoro-2-2-thiophenecarboxaldehyde was prepd. in 10-20% yields by an unprecedented [18F]fluoride-for-bromo substitution of 5-bromo-2-thiophenecarboxaldehyde.  The possible advantages of thiophenes (lower log P, altered metab.) in radiopharmaceutical chem. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYdMxG0Eqox7Vg90H21EOLACvtfcHk0ljiHZTLmFEJwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXntlSjtA%253D%253D&md5=50fd9c852d8d98162bdcc4a0aeeffdf3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0883-2897%2889%2990138-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2897%252889%252990138-4%26sid%3Dliteratum%253Aachs%26aulast%3DKilbourn%26aufirst%3DM.%2BR.%26atitle%3DThiophenes%2520as%2520phenyl%2520bio-isosteres%253A%2520Application%2520in%2520radiopharmaceutical%2520design-I.%2520Dopamine%2520uptake%2520antagonists%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D1989%26volume%3D16%26spage%3D681%26epage%3D686%26doi%3D10.1016%2F0883-2897%2889%2990138-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thangavelu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uttamchandani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaraman, J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">7705</span>– <span class="NLM_lpage">7710</span>, <span class="refDoi"> DOI: 10.1073/pnas.1116573109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1073%2Fpnas.1116573109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=22538822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Knsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=7705-7710&author=K.+Thangaveluauthor=C.+Q.+Panauthor=T.+Karlbergauthor=G.+Balajiauthor=M.+Uttamchandaniauthor=V.+Sureshauthor=H.+Sch%C3%BClerauthor=B.+C.+Lowauthor=J.+Sivaraman&title=Structural+basis+for+the+allosteric+inhibitory+mechanism+of+human+kidney-type+glutaminase+%28KGA%29+and+its+regulation+by+Raf-Mek-Erk+signaling+in+cancer+cell+metabolism&doi=10.1073%2Fpnas.1116573109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism</span></div><div class="casAuthors">Thangavelu, K.; Pan, Catherine Qiurong; Karlberg, Tobias; Balaji, Ganapathy; Uttamchandani, Mahesh; Suresh, Valiyaveettil; Schuler, Herwig; Low, Boon Chuan; Sivaraman, J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7705-7710, S7705/1-S7705/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Besides thriving on altered glucose metab., cancer cells undergo glutaminolysis to meet their energy demands.  As the first enzyme in catalyzing glutaminolysis, human kidney-type glutaminase isoform (KGA) is becoming an attractive target for small mols. such as BPTES [bis-2-(5 phenylacetamido-1,2,4-thiadiazol-2-yl) Et sulfide], although the regulatory mechanism of KGA remains unknown.  On the basis of crystal structures, we reveal that BPTES binds to an allosteric pocket at the dimer interface of KGA, triggering a dramatic conformational change of the key loop (Glu312-Pro329) near the catalytic site. and rendering it inactive.  The binding mode of BPTES on the hydrophobic pocket explains its specificity to KGA.  Interestingly, KGA activity in cells is stimulated by EGF, and KGA assocs. with all three kinase components of the Raf-1/Mek2/Erk signaling module.  However, the enhanced activity is abrogated by kinase-dead, dominant neg. mutants of Raf-1 (Raf-1-K375M) and Mek2 (Mek2-K101A), protein phosphatase PP2A, and Mek-inhibitor U0126, indicative of phosphorylation-dependent regulation.  Furthermore, treating cells that coexpressed Mek2-K101A and KGA with suboptimal level of BPTES leads to synergistic inhibition on cell proliferation.  Consequently, mutating the crucial hydrophobic residues at this key loop abrogates KGA activity and cell proliferation, despite the binding of constitutive active Mek2-S222/226D.  These studies therefore offer insights into (i) allosteric inhibition of KGA by BPTES, revealing the dynamic nature of KGA's active and inhibitory sites, and (ii) cross-talk and regulation of KGA activities by EGF-mediated Raf-Mek-Erk signaling.  These findings will help in the design of better inhibitors and strategies for the treatment of cancers addicted with glutamine metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosvIi87QxUvrVg90H21EOLACvtfcHk0ljiHZTLmFEJwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Knsbw%253D&md5=b628ca742b8d3b03c17db79a59d3e3b3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1116573109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1116573109%26sid%3Dliteratum%253Aachs%26aulast%3DThangavelu%26aufirst%3DK.%26aulast%3DPan%26aufirst%3DC.%2BQ.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DBalaji%26aufirst%3DG.%26aulast%3DUttamchandani%26aufirst%3DM.%26aulast%3DSuresh%26aufirst%3DV.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DLow%26aufirst%3DB.%2BC.%26aulast%3DSivaraman%26aufirst%3DJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520allosteric%2520inhibitory%2520mechanism%2520of%2520human%2520kidney-type%2520glutaminase%2520%2528KGA%2529%2520and%2520its%2520regulation%2520by%2520Raf-Mek-Erk%2520signaling%2520in%2520cancer%2520cell%2520metabolism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D7705%26epage%3D7710%26doi%3D10.1073%2Fpnas.1116573109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eYs33obGTc3prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lg9AjcyOXs4XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span> </span><span class="NLM_article-title">This fluorine
substitution was inspired by unpublished work in our group on an earlier,
structurally related chemical series containing the same four carbon
linker. Metabolite identification studies on an analog identified
an internal carbon as a site of metabolism, and microsomal stability
was improved by adding a fluorine to this carbon.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=This+fluorine%0Asubstitution+was+inspired+by+unpublished+work+in+our+group+on+an+earlier%2C%0Astructurally+related+chemical+series+containing+the+same+four+carbon%0Alinker.+Metabolite+identification+studies+on+an+analog+identified%0Aan+internal+carbon+as+a+site+of+metabolism%2C+and+microsomal+stability%0Awas+improved+by+adding+a+fluorine+to+this+carbon."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DThis%2520fluorine%250Asubstitution%2520was%2520inspired%2520by%2520unpublished%2520work%2520in%2520our%2520group%2520on%2520an%2520earlier%252C%250Astructurally%2520related%2520chemical%2520series%2520containing%2520the%2520same%2520four%2520carbon%250Alinker.%2520Metabolite%2520identification%2520studies%2520on%2520an%2520analog%2520identified%250Aan%2520internal%2520carbon%2520as%2520a%2520site%2520of%2520metabolism%252C%2520and%2520microsomal%2520stability%250Awas%2520improved%2520by%2520adding%2520a%2520fluorine%2520to%2520this%2520carbon." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span> </span><span class="NLM_article-title">The 100
mg/kg
BID dose of compound 27 was determined to be the maximally tolerated
dose in an earlier model study(unpublished), and we used it as our
default dose for subsequent studies, including the ones in this manuscript.
The 250 mg/kg BID dose of compound 4 (CB-839) was taken from in-house
studies showing consistent maximal in vivo target engagement at this
dose, and is slightly higher than the 200 mg/kg BID dose used by Calithera
in reference 9</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+100%0Amg%2Fkg%0ABID+dose+of+compound+27+was+determined+to+be+the+maximally+tolerated%0Adose+in+an+earlier+model+study%28unpublished%29%2C+and+we+used+it+as+our%0Adefault+dose+for+subsequent+studies%2C+including+the+ones+in+this+manuscript.%0AThe+250+mg%2Fkg+BID+dose+of+compound+4+%28CB-839%29+was+taken+from+in-house%0Astudies+showing+consistent+maximal+in+vivo+target+engagement+at+this%0Adose%2C+and+is+slightly+higher+than+the+200+mg%2Fkg+BID+dose+used+by+Calithera%0Ain+reference+9."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520100%250Amg%252Fkg%250ABID%2520dose%2520of%2520compound%252027%2520was%2520determined%2520to%2520be%2520the%2520maximally%2520tolerated%250Adose%2520in%2520an%2520earlier%2520model%2520study%2528unpublished%2529%252C%2520and%2520we%2520used%2520it%2520as%2520our%250Adefault%2520dose%2520for%2520subsequent%2520studies%252C%2520including%2520the%2520ones%2520in%2520this%2520manuscript.%250AThe%2520250%2520mg%252Fkg%2520BID%2520dose%2520of%2520compound%25204%2520%2528CB-839%2529%2520was%2520taken%2520from%2520in-house%250Astudies%2520showing%2520consistent%2520maximal%2520in%2520vivo%2520target%2520engagement%2520at%2520this%250Adose%252C%2520and%2520is%2520slightly%2520higher%2520than%2520the%2520200%2520mg%252Fkg%2520BID%2520dose%2520used%2520by%2520Calithera%250Ain%2520reference%25209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dientsmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span> <span> </span><span class="NLM_article-title">Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1535-7163.MCT-13-0639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=24748656" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1021-1031&author=R.+Dientsmannauthor=J.+Rodonauthor=V.+Serraauthor=J.+Tabernero&title=Picking+the+point+of+inhibition%3A+A+comparative+review+of+PI3K%2FAKT%2FmTOR+pathway+inhibitors&doi=10.1158%2F1535-7163.MCT-13-0639"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0639%26sid%3Dliteratum%253Aachs%26aulast%3DDientsmann%26aufirst%3DR.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DPicking%2520the%2520point%2520of%2520inhibition%253A%2520A%2520comparative%2520review%2520of%2520PI3K%252FAKT%252FmTOR%2520pathway%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1021%26epage%3D1031%26doi%3D10.1158%2F1535-7163.MCT-13-0639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. J.</span>; <span class="NLM_string-name">Spencer, N. D.</span>; <span class="NLM_string-name">Bristow, C. A.</span>; <span class="NLM_string-name">Giuliani, V.</span>; <span class="NLM_string-name">Miller, M. A.</span>; <span class="NLM_string-name">Soth, M. J.</span>; <span class="NLM_string-name">Harris, A. L.</span>; <span class="NLM_string-name">Le, K.</span>; <span class="NLM_string-name">Burke, J. P.</span>; <span class="NLM_string-name">Carugo, A.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Xu, Q. A.</span>; <span class="NLM_string-name">Bardenhagen, J. P.</span>; <span class="NLM_string-name">Carrillo, C. C.</span>; <span class="NLM_string-name">Carroll, C. L.</span>; <span class="NLM_string-name">Chang, Q.</span>; <span class="NLM_string-name">Cross, J. B.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Feng, N.</span>; <span class="NLM_string-name">Gao, G.</span>; <span class="NLM_string-name">Garvey, J. R.</span>; <span class="NLM_string-name">Gay, J. P.</span>; <span class="NLM_string-name">Geck Do, M. K.</span>; <span class="NLM_string-name">Gera, S.</span>; <span class="NLM_string-name">Gogi, K.</span>; <span class="NLM_string-name">Greer, J.</span>; <span class="NLM_string-name">Hamilton, M.</span>; <span class="NLM_string-name">Han, M.</span>; <span class="NLM_string-name">Herrera, Z. J.</span>; <span class="NLM_string-name">Huang, S.</span>; <span class="NLM_string-name">Johnson, S. B.</span>; <span class="NLM_string-name">Johnson, T.</span>; <span class="NLM_string-name">Kang, Z.</span>; <span class="NLM_string-name">Kost-Alimova, M.</span>; <span class="NLM_string-name">Lewis, R. T.</span>; <span class="NLM_string-name">Linares, J.</span>; <span class="NLM_string-name">Liu, C.-Y.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Liu, J.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Yan Ma, X.</span>; <span class="NLM_string-name">McAfoos, T.</span>; <span class="NLM_string-name">Miao, L.</span>; <span class="NLM_string-name">Minelli, R.</span>; <span class="NLM_string-name">Molina, J.</span>; <span class="NLM_string-name">Morlacchi, P.</span>; <span class="NLM_string-name">Mseeh, F.</span>; <span class="NLM_string-name">Mullinax, R. A.</span>; <span class="NLM_string-name">Palmer, W.</span>; <span class="NLM_string-name">Pang, J.</span>; <span class="NLM_string-name">Parker, C. A.</span>; <span class="NLM_string-name">Peoples, M. D.</span>; <span class="NLM_string-name">Petrocchi, A.</span>; <span class="NLM_string-name">Quill, T. M.</span>; <span class="NLM_string-name">Ramamoorthy, V.</span>; <span class="NLM_string-name">Rogers, N.</span>; <span class="NLM_string-name">Shepard, H. E.</span>; <span class="NLM_string-name">Suarez, C.</span>; <span class="NLM_string-name">Sun, Y.</span>; <span class="NLM_string-name">Suzuki, E.</span>; <span class="NLM_string-name">Tan, L.</span>; <span class="NLM_string-name">Theroff, J. P.</span>; <span class="NLM_string-name">Wu, Q.</span>; <span class="NLM_string-name">Yau, A.</span>; <span class="NLM_string-name">Zhao, S.</span>; <span class="NLM_string-name">Zuniga, A. M.</span>; <span class="NLM_string-name">Weinstein, J. N.</span>; <span class="NLM_string-name">Lorenzi, P. L.</span>; <span class="NLM_string-name">de Stanchina, E.</span>; <span class="NLM_string-name">Rudin, C. M.</span>; <span class="NLM_string-name">Toniatti, C.</span>; <span class="NLM_string-name">Di Francesco, M. E.</span>; <span class="NLM_string-name">Marszalek, J. R.</span>; <span class="NLM_string-name">Draetta, G.</span>; <span class="NLM_string-name">Yap, T. A.</span>; <span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Heffernan, T. P.</span></span>, unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kovacs%2C+J.+J.%3B+Spencer%2C+N.+D.%3B+Bristow%2C+C.+A.%3B+Giuliani%2C+V.%3B+Miller%2C+M.+A.%3B+Soth%2C+M.+J.%3B+Harris%2C+A.+L.%3B+Le%2C+K.%3B+Burke%2C+J.+P.%3B+Carugo%2C+A.%3B+Jiang%2C+Y.%3B+Xu%2C+Q.+A.%3B+Bardenhagen%2C+J.+P.%3B+Carrillo%2C+C.+C.%3B+Carroll%2C+C.+L.%3B+Chang%2C+Q.%3B+Cross%2C+J.+B.%3B+Czako%2C+B.%3B+Feng%2C+N.%3B+Gao%2C+G.%3B+Garvey%2C+J.+R.%3B+Gay%2C+J.+P.%3B+Geck+Do%2C+M.+K.%3B+Gera%2C+S.%3B+Gogi%2C+K.%3B+Greer%2C+J.%3B+Hamilton%2C+M.%3B+Han%2C+M.%3B+Herrera%2C+Z.+J.%3B+Huang%2C+S.%3B+Johnson%2C+S.+B.%3B+Johnson%2C+T.%3B+Kang%2C+Z.%3B+Kost-Alimova%2C+M.%3B+Lewis%2C+R.+T.%3B+Linares%2C+J.%3B+Liu%2C+C.-Y.%3B+Liu%2C+G.%3B+Liu%2C+J.%3B+Liu%2C+Z.%3B+Yan+Ma%2C+X.%3B+McAfoos%2C+T.%3B+Miao%2C+L.%3B+Minelli%2C+R.%3B+Molina%2C+J.%3B+Morlacchi%2C+P.%3B+Mseeh%2C+F.%3B+Mullinax%2C+R.+A.%3B+Palmer%2C+W.%3B+Pang%2C+J.%3B+Parker%2C+C.+A.%3B+Peoples%2C+M.+D.%3B+Petrocchi%2C+A.%3B+Quill%2C+T.+M.%3B+Ramamoorthy%2C+V.%3B+Rogers%2C+N.%3B+Shepard%2C+H.+E.%3B+Suarez%2C+C.%3B+Sun%2C+Y.%3B+Suzuki%2C+E.%3B+Tan%2C+L.%3B+Theroff%2C+J.+P.%3B+Wu%2C+Q.%3B+Yau%2C+A.%3B+Zhao%2C+S.%3B+Zuniga%2C+A.+M.%3B+Weinstein%2C+J.+N.%3B+Lorenzi%2C+P.+L.%3B+de+Stanchina%2C+E.%3B+Rudin%2C+C.+M.%3B+Toniatti%2C+C.%3B+Di+Francesco%2C+M.+E.%3B+Marszalek%2C+J.+R.%3B+Draetta%2C+G.%3B+Yap%2C+T.+A.%3B+Jones%2C+P.%3B+Heffernan%2C+T.+P.%2C+unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DKovacs%26aufirst%3DJ.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="null"><span><span> </span><span class="NLM_article-title">The 5 day/2 off
schedule was standard for the research group running the study, chosen
for convenience of dosing. In other studies, including the H2122 study
contained in the supporting information, continuous every day schedules
were well-tolerated</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+5+day%2F2+off%0Aschedule+was+standard+for+the+research+group+running+the+study%2C+chosen%0Afor+convenience+of+dosing.+In+other+studies%2C+including+the+H2122+study%0Acontained+in+the+supporting+information%2C+continuous+every+day+schedules%0Awere+well-tolerated."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DThe%25205%2520day%252F2%2520off%250Aschedule%2520was%2520standard%2520for%2520the%2520research%2520group%2520running%2520the%2520study%252C%2520chosen%250Afor%2520convenience%2520of%2520dosing.%2520In%2520other%2520studies%252C%2520including%2520the%2520H2122%2520study%250Acontained%2520in%2520the%2520supporting%2520information%252C%2520continuous%2520every%2520day%2520schedules%250Awere%2520well-tolerated" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, S. R.</span></span> <span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination on in vitro half-life approach and nonspecific binding to microsomes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=S.+R.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+An+examination+on+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0lgllO4ndo7nxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DS.%2BR.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520An%2520examination%2520on%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['null'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xi Xu, Jubo Wang, Min Wang, Xinyu Yuan, Lei Li, Chao Zhang, Huidan Huang, Tian Jing, Chenchen Wang, Chao Tong, Liwen Zhou, Ying Meng, Pengfei Xu, Junping Kou, Zhixia Qiu, Zhiyu Li, <span class="NLM_string-name hlFld-ContribAuthor">Jinlei Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4588-4611. <a href="https://doi.org/10.1021/acs.jmedchem.0c02044" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02044%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Enabled%252BDiscovery%252Bof%252BNovel%252BMacrocyclic%252BInhibitors%252BTargeting%252BGlutaminase%252B1%252BAllosteric%252BBinding%252BSite%26aulast%3DXu%26aufirst%3DXi%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D25112020%26date%3D01042021%26volume%3D64%26issue%3D8%26spage%3D4588%26epage%3D4611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hadia  Moindjie</span>, <span class="hlFld-ContribAuthor ">Sylvie  Rodrigues-Ferreira</span>, <span class="hlFld-ContribAuthor ">Clara  Nahmias</span>. </span><span class="cited-content_cbyCitation_article-title">Mitochondrial Metabolism in Carcinogenesis and Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (13)
                                     , 3311. <a href="https://doi.org/10.3390/cancers13133311" title="DOI URL">https://doi.org/10.3390/cancers13133311</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13133311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13133311%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DMitochondrial%252BMetabolism%252Bin%252BCarcinogenesis%252Band%252BCancer%252BTherapy%26aulast%3DMoindjie%26aufirst%3DHadia%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D13%26spage%3D3311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel R.  Schmidt</span>, <span class="hlFld-ContribAuthor ">Rutulkumar  Patel</span>, <span class="hlFld-ContribAuthor ">David G.  Kirsch</span>, <span class="hlFld-ContribAuthor ">Caroline A.  Lewis</span>, <span class="hlFld-ContribAuthor ">Matthew G.  Vander Heiden</span>, <span class="hlFld-ContribAuthor ">Jason W.  Locasale</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolomics in cancer research and emerging applications in clinical oncology. </span><span class="cited-content_cbyCitation_journal-name">CA: A Cancer Journal for Clinicians</span><span> <strong>2021,</strong> <em>71 </em>
                                    (4)
                                     , 333-358. <a href="https://doi.org/10.3322/caac.21670" title="DOI URL">https://doi.org/10.3322/caac.21670</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3322/caac.21670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3322%2Fcaac.21670%26sid%3Dliteratum%253Aachs%26jtitle%3DCA%253A%2520A%2520Cancer%2520Journal%2520for%2520Clinicians%26atitle%3DMetabolomics%252Bin%252Bcancer%252Bresearch%252Band%252Bemerging%252Bapplications%252Bin%252Bclinical%252Boncology%26aulast%3DSchmidt%26aufirst%3DDaniel%2BR.%26date%3D2021%26date%3D2021%26volume%3D71%26issue%3D4%26spage%3D333%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Glutamine metabolism through GLS-1. GLS-1 converts glutamine to glutamate and ammonia. The produced glutamate can be further converted by the cellular machinery to glutathione (which regulates reactive oxygen species (ROS)) or α-ketoglutarate (α-KG) (key building block in the tricarboxylic acid (TCA) cycle). The produced ammonia is a building block for cellular protein syntheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of known GLS inhibitors DON (<b>1</b>), BPTES (<b>2</b>), “compound 968” (<b>3</b>), and CB-839 (<b>4</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Proposed binding of series example <b>5</b> in the GLS-1 tetramer, modeled using PDB 3UO9.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Hydrogen-bonding motifs of amidotriazoles overlay well onto those of aminopyridazines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Summary of potencies, selectivities, and pharmacokinetic properties of compound <b>27</b>. <sup>a</sup>All IC<sub>50</sub> values are reported as the mean of at least two determinations. <sup>b</sup>Inhibition of purified recombinant human GLS-1 (GAC isoform) assessed via a dual-coupled enzyme assay. IC<sub>50</sub> value is the mean ± standard deviation for 36 determinations. <sup>c</sup>Inhibition of purified recombinant human GLS-2 assessed via a dual-coupled enzyme assay. <sup>d</sup>Inhibition of proliferation of A549 cells. IC<sub>50</sub> value is the mean ± standard deviation for 36 determinations. <sup>e</sup>Inhibition of cellular glutaminase assessed via direct measurement of glutamine and glutamate levels in the cellular media. IC<sub>50</sub> value is the mean ± standard deviation for four determinations. <sup>f</sup>hERG QPatch assay, CHO cell line. <sup>g</sup>Inhibition of metabolism of known substrates for the indicated cytochrome P450 enzymes. <sup>h</sup>Eurofins CEREP profiling service; details are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>. <sup>i</sup>Eurofins DiscoverX KINOMEscan profiling service, scanEDGE product; details are in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf" class="ext-link">Supporting Information</a>. <sup>j</sup>Liver microsomal intrinsic clearance (mL/min/kg protein). <sup>k</sup>Liver hepatocyte intrinsic clearance (mL/min/kg protein). <sup>l</sup>Plasma protein binding determined by equilibrium dialysis. <sup>m</sup>Dosed as a bis-hydrochloride salt to female CD-1 mice, male Sprague Dawley rats, male cynomolgus monkeys, and male beagle dogs. Doses were 0.3 mg/kg IV (intravenous) and 3 mpk PO (per os), except for mouse (3 mpk IV, 10 mpk PO). <i>C</i><sub>max</sub>, AUC<sub>last</sub>, and <i>F</i>% were determined from the oral dose, and CL, Vd<sub>ss</sub>, and <i>t</i><sub>1/2</sub> were determined from the IV dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Ascending dose oral PK of compound <b>27</b> (bis-hydrochloride salt) in mouse, rat, and dog dosed in 0.5% aqueous methylcellulose vehicle. Values are the means with standard deviation for three animals except for mouse AUC values, which are composite determinations, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo target engagement and concentrations of compound <b>27</b> in an H460 NSG mouse xenograft model. Compound <b>27</b> (<i>bis</i>-hydrochloride) was administered orally at the indicated doses in a 0.5% aqueous methylcellulose vehicle. There were six animals per group. (a) Glutamate/glutamine ratios at 8 and 24 h after each dose, with standard deviation bars; (b) free plasma concentrations, with standard deviations, of compound <b>27</b> at 8 and 24 h for each dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacies in an Ru337 PDX subcutaneous mouse tumor model of compound <b>27</b> as monotherapy and in combination with dual TORC inhibitor TAK-228. Compound <b>27</b> (neutral compound) was administered orally twice daily at 100 mg/kg in an 0.5% aqueous methylcellulose vehicle; TAK-228 was dosed orally once daily at 1 mg/kg in an 0.5% aqueous methylcellulose, 5% sucrose vehicle. Both compounds were dosed on a schedule of 5 days on/2 days off,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and there were eight animals per group. (a) Tumor volumes plotted as mean ± standard deviation; (b) average % bodyweights relative to day 0 plotted as mean ± standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Compounds <b>5</b>–<b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) copper sulfate, ascorbic acid, <i>tert</i>-butanol/water (54%); (ii) <i>bis</i>(triphenylphosphine) palladium(II) dichloride, copper iodide, triethylamine, tetrahydrofuran (THF), 60 °C (84%); (iii) Raney nickel, hydrogen, methanol (89%); (iv) R-CO<sub>2</sub>H, propanephosphonic acid anhydride, pyridine (25–78%); (v) (a) trifluoroacetic acid (TFA), dichloromethane (DCM), (b) R-NH<sub>2</sub>, amide coupling reagent, solvent (15–98%).</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Compounds <b>14</b>–<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) (a) trifluoroacetic acid, dichloromethane, (b) methylamine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA), 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate, tetrahydrofuran/<i>N</i>,<i>N</i>-dimethylformamide (29%); (ii) R-CO<sub>2</sub>H, amide coupling reagent, solvent (5–82%).</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Intermediate Iodide <b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) sodium azide, ammonium chloride, methanol/water (91%); (ii) <i>tert</i>-butyl propiolate, <i>N</i>,<i>N</i>-diisopropylethylamine, acetic acid, dichloromethane (82% crude); (iii) (diethylamino)sulfur trifluoride (DAST), pyridine, dichloromethane (45%); (iv) 10% palladium hydroxide on carbon, hydrogen, ethyl acetate (101% crude); (v) 4-toluenesulfonyl chloride, 4-dimethylaminopyridine (DMAP), dichloromethane (84% crude); sodium iodide, acetone (91%).</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. General Synthesis of Compounds <b>21</b>–<b>23</b>, <b>25</b>, and <b>26</b><sup>a</sup><sup>,</sup><sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) (a) 55% aqueous hydrogen iodide, 90 °C (90%), (b) di-<i>tert</i>-butyl propanedioate, sodium hydride, tetrahydrofuran, 65 °C (78%); (ii) intermediate <b>32</b>, potassium carbonate, <i>N</i>,<i>N</i>-dimethylformamide (75%); (iii) (a) trifluoroacetic acid, dichloromethane, 40 °C, (b) methylamine, <i>N</i>,<i>N</i>-diisopropylethylamine, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate, tetrahydrofuran/<i>N</i>,<i>N</i>-dimethylformamide (56%); (iv) R-CONH<sub>2</sub>, palladium-catalyzed coupling, solvent (15–57%).</p><p class="last"><span class="fn-label"><sup>b</sup></span>Compound <b>22</b>, the enantiomer of compound <b>21</b>, was made using the same synthetic route including preparation of starting material shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, but starting from (<i>S</i>)-2-((benzyloxy)methyl)oxirane in place of (<i>R</i>)-2-((benzyloxy)methyl)oxirane.</p></p></figure><figure data-id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/medium/jm0c01398_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0014.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. General Synthesis of Compounds <b>24</b>, <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01398/20201105/images/large/jm0c01398_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01398&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) R-CONH<sub>2,</sub> palladium-catalyzed coupling, solvent (34–86%); (ii) hydrogen chloride, dioxane; (iii) methylamine, <i>N</i>,<i>N</i>-diisopropylethylamine, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate, tetrahydrofuran/<i>N</i>,<i>N</i>-dimethylformamide (two-step 56–68%).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i73">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13255" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13255" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Overview of the development of glutaminase inhibitors: Achievements and future directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1096</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00961</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00961" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyqtbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1096-1115&author=X.+Xuauthor=Y.+Mengauthor=L.+Liauthor=P.+Xuauthor=J.+Wangauthor=Z.+Liauthor=J.+Bian&title=Overview+of+the+development+of+glutaminase+inhibitors%3A+Achievements+and+future+directions&doi=10.1021%2Facs.jmedchem.8b00961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions</span></div><div class="casAuthors">Xu, Xi; Meng, Ying; Li, Lei; Xu, Pengfei; Wang, Jubo; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1096-1115</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">It has been demonstrated that glutamine metab. has become the main energy and building blocks supply for the growth and viability of a potentially large subset of malignant tumors.  The glutamine metab. often depends upon mitochondrial glutaminase (GLS) activity, which converts glutamine to glutamate and serves as a significant role for bioenergetic processes.  Thus, recently, the GLS has become a key target for small mol. therapeutic intervention.  Numerous medicinal chem. studies are currently aimed at the design of novel and potent inhibitors for GLS, however, to date, only one compd. (named CB-839) have entered clin. trials for the treatment of advanced solid tumors and hematol. malignancies.  The perspective summarizes the progress in the discovery and development of GLS inhibitors, including the potential binding site, biochem. techniques for inhibitor identification, and approaches for identifying small-mol. inhibitors, as well as future therapeutic perspectives in glutamine metab. are also put forward in order to provide ref. and rational for the drug discovery of novel and potent glutamine metab. modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrwroUUbG7grVg90H21EOLACvtfcHk0ljy0XUmWx73PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyqtbjE&md5=799044e083ce769a67c0adfdd248e3f8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00961%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DOverview%2520of%2520the%2520development%2520of%2520glutaminase%2520inhibitors%253A%2520Achievements%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1096%26epage%3D1115%26doi%3D10.1021%2Facs.jmedchem.8b00961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span> <span> </span><span class="NLM_article-title">Glutaminase regulation in cancer cells: a druggable chain of events</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.drudis.2013.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=24140288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSls7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=450-457&author=W.+P.+Kattauthor=R.+A.+Cerione&title=Glutaminase+regulation+in+cancer+cells%3A+a+druggable+chain+of+events&doi=10.1016%2Fj.drudis.2013.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Glutaminase regulation in cancer cells: a druggable chain of events</span></div><div class="casAuthors">Katt, William P.; Cerione, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">450-457</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Metab. is the process by which cells convert relatively simple extracellular nutrients into energy and building blocks necessary for their growth and survival.  In cancer cells, metab. is dramatically altered compared with normal cells.  These alterations are known as the Warburg effect.  One consequence of these changes is cellular addiction to glutamine.  Because of this, in recent years the enzyme glutaminase has become a key target for small mol. therapeutic intervention.  Like many oncotargets, however, glutaminase has a no. of upstream partners that might offer addnl. druggable targets.  This review summarizes the work from the current decade surrounding glutaminase and its regulation, and suggests strategies for therapeutic intervention in relevant cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY9cKMRSje5LVg90H21EOLACvtfcHk0ljXCJUGwFA3rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSls7vF&md5=01b37117a2665312031d0cf5af24b7e9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DKatt%26aufirst%3DW.%2BP.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26atitle%3DGlutaminase%2520regulation%2520in%2520cancer%2520cells%253A%2520a%2520druggable%2520chain%2520of%2520events%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D450%26epage%3D457%26doi%3D10.1016%2Fj.drudis.2013.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasti, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span> <span> </span><span class="NLM_article-title">Glutamine and cancer: cell biology, physiology, and clinical opportunities</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">3678</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1172/JCI69600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1172%2FJCI69600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=23999442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=3678-3684&author=C.+T.+Hensleyauthor=A.+T.+Wastiauthor=R.+J.+DeBerardinis&title=Glutamine+and+cancer%3A+cell+biology%2C+physiology%2C+and+clinical+opportunities&doi=10.1172%2FJCI69600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine and cancer: cell biology, physiology, and clinical opportunities</span></div><div class="casAuthors">Hensley, Christopher T.; Wasti, Ajla T.; DeBerardinis, Ralph J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3678-3684</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Glutamine is an abundant and versatile nutrient that participates in energy formation, redox homeostasis, macromol. synthesis, and signaling in cancer cells.  These characteristics make glutamine metab. an appealing target for new clin. strategies to detect, monitor, and treat cancer.  Here the authors review the metabolic functions of glutamine as a super nutrient and the surprising roles of glutamine in supporting the biol. hallmarks of malignancy.  The authors also review recent efforts in imaging and therapeutics to exploit tumor cell glutamine dependence, discuss some of the challenges in this arena, and suggest a disease-focused paradigm to deploy these emerging approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocNnK_GlTtRrVg90H21EOLACvtfcHk0lh4zHB5ARMHdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bL&md5=fb704a7773710a20add6edbf0da08616</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1172%2FJCI69600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69600%26sid%3Dliteratum%253Aachs%26aulast%3DHensley%26aufirst%3DC.%2BT.%26aulast%3DWasti%26aufirst%3DA.%2BT.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26atitle%3DGlutamine%2520and%2520cancer%253A%2520cell%2520biology%252C%2520physiology%252C%2520and%2520clinical%2520opportunities%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D3678%26epage%3D3684%26doi%3D10.1172%2FJCI69600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wise, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">Glutamine addiction: a new therapeutic target in cancer</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2010.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.tibs.2010.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=20570523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=427-433&author=D.+R.+Wiseauthor=C.+B.+Thompson&title=Glutamine+addiction%3A+a+new+therapeutic+target+in+cancer&doi=10.1016%2Fj.tibs.2010.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine addiction: A new therapeutic target in cancer</span></div><div class="casAuthors">Wise, David R.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">427-433</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Most cancers depend on a high rate of aerobic glycolysis for their continued growth and survival.  Paradoxically, some cancer cell lines also display addiction to glutamine despite the fact that glutamine is a nonessential amino acid that can be synthesized from glucose.  The high rate of glutamine uptake exhibited by glutamine-dependent cells does not appear to result solely from its role as a nitrogen donor in nucleotide and amino acid biosynthesis.  Instead, glutamine plays a required role in the uptake of essential amino acids and in maintaining activation of TOR (target of rapamycin) kinase.  Moreover, in many cancer cells, glutamine is the primary mitochondrial substrate and is required for maintenance of mitochondrial membrane potential and integrity and for support of the NADPH prodn. needed for redox control and macromol. synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Gv_LsNdulLVg90H21EOLACvtfcHk0liWe1hOj5nOqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKqs7s%253D&md5=915fa51996bc1c9b3ec3970b2dae7163</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2010.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2010.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DGlutamine%2520addiction%253A%2520a%2520new%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2010%26volume%3D35%26spage%3D427%26epage%3D433%26doi%3D10.1016%2Fj.tibs.2010.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodiriquez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackinnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span> <span> </span><span class="NLM_article-title">Abstract 2329: glutaminase inhibition with CB-839 enhances anti-tumor activity of PD-1 and PD-L1 antibodies by overcoming a metabolic checkpoint blocking T cell activation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>, <span class="NLM_elocation-id">2329</span> <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1538-7445.AM2016-2329" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&author=M.+Grossauthor=J.+Chenauthor=J.+Englertauthor=J.+Janesauthor=R.+Leoneauthor=M.+Rodiriquezauthor=A.+Mackinnonauthor=F.+Parlatiauthor=P.+Shwonekauthor=J.+Powell&title=Abstract+2329%3A+glutaminase+inhibition+with+CB-839+enhances+anti-tumor+activity+of+PD-1+and+PD-L1+antibodies+by+overcoming+a+metabolic+checkpoint+blocking+T+cell+activation&doi=10.1158%2F1538-7445.AM2016-2329"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-2329%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DEnglert%26aufirst%3DJ.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DLeone%26aufirst%3DR.%26aulast%3DRodiriquez%26aufirst%3DM.%26aulast%3DMackinnon%26aufirst%3DA.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DShwonek%26aufirst%3DP.%26aulast%3DPowell%26aufirst%3DJ.%26atitle%3DAbstract%25202329%253A%2520glutaminase%2520inhibition%2520with%2520CB-839%2520enhances%2520anti-tumor%2520activity%2520of%2520PD-1%2520and%2520PD-L1%2520antibodies%2520by%2520overcoming%2520a%2520metabolic%2520checkpoint%2520blocking%2520T%2520cell%2520activation%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26doi%3D10.1158%2F1538-7445.AM2016-2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, I.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arwood, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettencourt, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blosser, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prchalova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1126/science.aav2588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1126%2Fscience.aav2588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=31699883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1anu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2019&pages=1013-1021&author=R.+D.+Leoneauthor=L.+Zhaoauthor=J.+M.+Englertauthor=I.-M.+Sunauthor=M.-H.+Ohauthor=I.-H.+Sunauthor=M.+L.+Arwoodauthor=I.+A.+Bettencourtauthor=C.+H.+Patelauthor=J.+Wenauthor=A.+Tamauthor=R.+L.+Blosserauthor=P.+Prchalovaauthor=J.+Altauthor=R.+Raisauthor=B.+S.+Slusherauthor=J.+D.+Powell&title=Glutamine+blockade+induces+divergent+metabolic+programs+to+overcome+tumor+immune+evasion&doi=10.1126%2Fscience.aav2588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion</span></div><div class="casAuthors">Leone, Robert D.; Zhao, Liang; Englert, Judson M.; Sun, Im-Meng; Oh, Min-Hee; Sun, Im-Hong; Arwood, Matthew L.; Bettencourt, Ian A.; Patel, Chirag H.; Wen, Jiayu; Tam, Ada; Blosser, Richard L.; Prchalova, Eva; Alt, Jesse; Rais, Rana; Slusher, Barbara S.; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">6468</span>),
    <span class="NLM_cas:pages">1013-1021</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Glutamine is essential for tumor growth and has long been an attractive therapeutic target for cancer researchers.  Some attempts at blocking glutamine metab. in cancer patients resulted in toxicity, prompting Leone et al. to develop an innovative approach to reduce general side effects.  They designed a prodrug form (JHU083) of the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON), which is administered in an inert state but then preferentially activated by enzymes enriched in the tumor microenvironment.  JHU083 simultaneously shut down glycolysis and oxidative phosphorylation in mouse cancer cells while enhancing T cell oxidative phosphorylation and anticancer immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohlhLbE1xLvLVg90H21EOLACvtfcHk0ljbO9ivDmW1tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1anu7rE&md5=cdc7642118e455d547bb8d2723797e6d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.aav2588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aav2588%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DR.%2BD.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DEnglert%26aufirst%3DJ.%2BM.%26aulast%3DSun%26aufirst%3DI.-M.%26aulast%3DOh%26aufirst%3DM.-H.%26aulast%3DSun%26aufirst%3DI.-H.%26aulast%3DArwood%26aufirst%3DM.%2BL.%26aulast%3DBettencourt%26aufirst%3DI.%2BA.%26aulast%3DPatel%26aufirst%3DC.%2BH.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DBlosser%26aufirst%3DR.%2BL.%26aulast%3DPrchalova%26aufirst%3DP.%26aulast%3DAlt%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DGlutamine%2520blockade%2520induces%2520divergent%2520metabolic%2520programs%2520to%2520overcome%2520tumor%2520immune%2520evasion%26jtitle%3DScience%26date%3D2019%26volume%3D366%26spage%3D1013%26epage%3D1021%26doi%3D10.1126%2Fscience.aav2588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T.</span>; <span class="NLM_string-name">Toniatti, C.</span>; <span class="NLM_string-name">Kovacs, J.</span>; <span class="NLM_string-name">Giuliani, V.</span>; <span class="NLM_string-name">Spencer, N.</span>; <span class="NLM_string-name">Di Francesco, M. E.</span>; <span class="NLM_string-name">Bristow, C. A.</span></span> <span> </span><span class="NLM_article-title">GlutaminaseInhibitor Therapy for Cancer</span>. International Patent Application Number <span class="NLM_patent">WO2016/004418A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Heffernan&author=C.+Toniatti&author=J.+Kovacs&author=V.+Giuliani&author=N.+Spencer&author=M.+E.+Di+Francesco&author=C.+A.+Bristow&title=GlutaminaseInhibitor+Therapy+for+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeffernan%26aufirst%3DT.%26atitle%3DGlutaminaseInhibitor%2520Therapy%2520for%2520Cancer%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayin, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBoeuf, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakousi, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Rivera, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbaraj, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prigge, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goparaju, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgalev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heguy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaj, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papgiannakopoulos, T.</span></span> <span> </span><span class="NLM_article-title">Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1362</span>– <span class="NLM_lpage">1368</span>, <span class="refDoi"> DOI: 10.1038/nm.4407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1038%2Fnm.4407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=28967920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFylurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=1362-1368&author=R.+Romeroauthor=V.+I.+Sayinauthor=S.+M.+Davidsonauthor=M.+R.+Bauerauthor=S.+X.+Singhauthor=S.+E.+LeBoeufauthor=T.+R.+Karakousiauthor=D.+C.+Ellisauthor=A.+Bhutkarauthor=F.+J.+S%C3%A1nchez-Riveraauthor=L.+Subbarajauthor=B.+Martinezauthor=R.+T.+Bronsonauthor=J.+R.+Priggeauthor=E.+E.+Schmidtauthor=C.+J.+Thomasauthor=C.+Goparajuauthor=A.+Daviesauthor=I.+Dolgalevauthor=A.+Heguyauthor=V.+Allajauthor=J.+T.+Poirierauthor=A.+L.+Moreiraauthor=C.+M.+Rudinauthor=H.+I.+Passauthor=M.+G.+Vander+Heidenauthor=T.+Jacksauthor=T.+Papgiannakopoulos&title=Keap1+loss+promotes+Kras-driven+lung+cancer+and+results+in+dependence+on+glutaminolysis&doi=10.1038%2Fnm.4407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis</span></div><div class="casAuthors">Romero, Rodrigo; Sayin, Volkan I.; Davidson, Shawn M.; Bauer, Matthew R.; Singh, Simranjit X.; Le Boeuf, Sarah E.; Karakousi, Triantafyllia R.; Ellis, Donald C.; Bhutkar, Arjun; Sanchez-Rivera, Francisco J.; Subbaraj, Lakshmipriya; Martinez, Britney; Bronson, Roderick T.; Prigge, Justin R.; Schmidt, Edward E.; Thomas, Craig J.; Goparaju, Chandra; Davies, Angela; Dolgalev, Igor; Heguy, Adriana; Allaj, Viola; Poirier, John T.; Moreira, Andre L.; Rudin, Charles M.; Pass, Harvey I.; Vander Heiden, Matthew G.; Jacks, Tyler; Papagiannakopoulos, Thales</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1362-1368</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties assocd. with directly inhibiting the KRAS oncoprotein.  One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselves may lead to therapeutic vulnerabilities in tumors.  Approx. 20% of KRAS-mutant LUAD tumors carry loss-of-function mutations in the KEAP1 gene encoding Kelch-like ECH-assocd. protein 1 (refs. 2, 3, 4), a neg. regulator of nuclear factor erythroid 2-like 2 (NFE2L2; hereafter NRF2), which is the master transcriptional regulator of the endogenous antioxidant response.  The high frequency of mutations in KEAP1 suggests an important role for the oxidative stress response in lung tumorigenesis.  Using a CRISPR-Cas9-based approach in a mouse model of KRAS-driven LUAD, we examd. the effects of Keap1 loss in lung cancer progression.  We show that loss of Keap1 hyperactivates NRF2 and promotes KRAS-driven LUAD in mice.  Through a combination of CRISPR-Cas9-based genetic screening and metabolomic analyses, we show that Keap1- or Nrf2-mutant cancers are dependent on increased glutaminolysis, and this property can be therapeutically exploited through the pharmacol. inhibition of glutaminase.  Finally, we provide a rationale for stratification of human patients with lung cancer harboring KRAS/KEAP1- or KRAS/NRF2-mutant lung tumors as likely to respond to glutaminase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofWgHF0gdsW7Vg90H21EOLACvtfcHk0liMGf4k4rFqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFylurrK&md5=2bc4122a4c757cc3a5fdab3eb62b26e3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnm.4407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4407%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DR.%26aulast%3DSayin%26aufirst%3DV.%2BI.%26aulast%3DDavidson%26aufirst%3DS.%2BM.%26aulast%3DBauer%26aufirst%3DM.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BX.%26aulast%3DLeBoeuf%26aufirst%3DS.%2BE.%26aulast%3DKarakousi%26aufirst%3DT.%2BR.%26aulast%3DEllis%26aufirst%3DD.%2BC.%26aulast%3DBhutkar%26aufirst%3DA.%26aulast%3DS%25C3%25A1nchez-Rivera%26aufirst%3DF.%2BJ.%26aulast%3DSubbaraj%26aufirst%3DL.%26aulast%3DMartinez%26aufirst%3DB.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DPrigge%26aufirst%3DJ.%2BR.%26aulast%3DSchmidt%26aufirst%3DE.%2BE.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DGoparaju%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DDolgalev%26aufirst%3DI.%26aulast%3DHeguy%26aufirst%3DA.%26aulast%3DAllaj%26aufirst%3DV.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DMoreira%26aufirst%3DA.%2BL.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DPass%26aufirst%3DH.%2BI.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DPapgiannakopoulos%26aufirst%3DT.%26atitle%3DKeap1%2520loss%2520promotes%2520Kras-driven%2520lung%2520cancer%2520and%2520results%2520in%2520dependence%2520on%2520glutaminolysis%26jtitle%3DNat.%2520Med.%26date%3D2017%26volume%3D23%26spage%3D1362%26epage%3D1368%26doi%3D10.1038%2Fnm.4407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennison, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernov-Rogan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidig, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKinnon, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjogren, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. K.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1535-7163.MCT-13-0870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=24523301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=890-901&author=M.+I.+Grossauthor=S.+D.+Demoauthor=J.+B.+Dennisonauthor=L.+Chenauthor=T.+Chernov-Roganauthor=B.+Goyalauthor=J.+R.+Janesauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=J.+Liauthor=A.+L.+MacKinnonauthor=F.+Parlatiauthor=M.+L.+M.+Rodriguezauthor=P.+J.+Shwonekauthor=E.+B.+Sjogrenauthor=T.+F.+Stantonauthor=T.+Wangauthor=J.+Yangauthor=F.+Zhaoauthor=M.+K.+Bennett&title=Antitumor+activity+of+the+glutaminase+inhibitor+CB-839+in+triple-negative+breast+cancer&doi=10.1158%2F1535-7163.MCT-13-0870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Gross, Matt I.; Demo, Susan D.; Dennison, Jennifer B.; Chen, Lijing; Chernov-Rogan, Tania; Goyal, Bindu; Janes, Julie R.; Laidig, Guy J.; Lewis, Evan R.; Li, Jim; MacKinnon, Andrew L.; Parlati, Francesco; Rodriguez, Mirna L. M.; Shwonek, Peter J.; Sjogren, Eric B.; Stanton, Timothy F.; Wang, Taotao; Yang, Jinfu; Zhao, Frances; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">890-901</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glutamine serves as an important source of energy and building blocks for many tumor cells.  The first step in glutamine utilization is its conversion to glutamate by the mitochondrial enzyme glutaminase.  CB-839 is a potent, selective, and orally bioavailable inhibitor of both splice variants of glutaminase (KGA and GAC).  CB-839 had antiproliferative activity in a triple-neg. breast cancer (TNBC) cell line, HCC-1806, that was assocd. with a marked decrease in glutamine consumption, glutamate prodn., oxygen consumption, and the steady-state levels of glutathione and several tricarboxylic acid cycle intermediates.  In contrast, no antiproliferative activity was obsd. in an estrogen receptor-pos. cell line, T47D, and only modest effects on glutamine consumption and downstream metabolites were obsd.  Across a panel of breast cancer cell lines, GAC protein expression and glutaminase activity were elevated in the majority of TNBC cell lines relative to receptor pos. cells.  Furthermore, the TNBC subtype displayed the greatest sensitivity to CB-839 treatment and this sensitivity was correlated with (i) dependence on extracellular glutamine for growth, (ii) intracellular glutamate and glutamine levels, and (iii) GAC (but not KGA) expression, a potential biomarker for sensitivity.  CB-839 displayed significant antitumor activity in two xenograft models: as a single agent in a patient-derived TNBC model and in a basal like HER2+ cell line model, JIMT-1, both as a single agent and in combination with paclitaxel.  Together, these data provide a strong rationale for the clin. investigation of CB-839 as a targeted therapeutic in patients with TNBC and other glutamine-dependent tumors.  Mol Cancer Ther; 13(4); 890-901.2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDfUGWU-VZObVg90H21EOLACvtfcHk0lhDKE_0__zGMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurg%253D&md5=5b9ddb35c56409b58ce2b889bbbbc33f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0870%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DM.%2BI.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DDennison%26aufirst%3DJ.%2BB.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChernov-Rogan%26aufirst%3DT.%26aulast%3DGoyal%26aufirst%3DB.%26aulast%3DJanes%26aufirst%3DJ.%2BR.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMacKinnon%26aufirst%3DA.%2BL.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRodriguez%26aufirst%3DM.%2BL.%2BM.%26aulast%3DShwonek%26aufirst%3DP.%2BJ.%26aulast%3DSjogren%26aufirst%3DE.%2BB.%26aulast%3DStanton%26aufirst%3DT.%2BF.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520glutaminase%2520inhibitor%2520CB-839%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D890%26epage%3D901%26doi%3D10.1158%2F1535-7163.MCT-13-0870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csibi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">E21</span>– <span class="NLM_lpage">E29</span>, <span class="refDoi"> DOI: 10.1073/pnas.1417015112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1073%2Fpnas.1417015112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=25524627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E21-E29&author=J.+Liauthor=A.+Csibiauthor=S.+Yangauthor=G.+R.+Hoffmanauthor=C.+Liauthor=E.+Zhangauthor=J.+J.+Yuauthor=J.+Blenis&title=Synthetic+lethality+of+combined+glutaminase+and+Hsp90+inhibition+in+mTORC1-driven+tumor+cells&doi=10.1073%2Fpnas.1417015112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells</span></div><div class="casAuthors">Li, Jing; Csibi, Alfredo; Yang, Sun; Hoffman, Gregory R.; Li, Chenggang; Zhang, Erik; Yu, Jane J.; Blenis, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">E21-E29</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin complex 1 (mTORC1) integrates multiple signals from growth factors, nutrients, and cellular energy status to control a wide range of metabolic processes, including mRNA biogenesis; protein, nucleotide, and lipid synthesis; and autophagy.  Deregulation of the mTORC1 pathway is found in cancer as well as genetic disorders such as tuberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis.  Recent studies have shown that the mTORC1 inhibitor rapamycin and its analogs generally suppress proliferation rather than induce apoptosis.  Therefore, it is crit. to use alternative strategies to induce death of cells with activated mTORC1.  In this study, a small-mol. screen has revealed that the combination of glutaminase (GLS) and heat shock protein 90 (Hsp90) inhibitors selectively triggers death of TSC2-deficient cells.  At a mechanistic level, high mTORC1-driven translation rates in TSC1/2-deficient cells, unlike wild-type cells, sensitizes these cells to endoplasmic reticulum (ER) stress.  Thus, Hsp90 inhibition drives accumulation of unfolded protein and ER stress.  When combining proteotoxic stress with oxidative stress by depletion of the intracellular antioxidant glutathione by GLS inhibition, acute cell death is obsd. in cells with activated mTORC1 signaling.  This study suggests that this combination strategy may have the potential to be developed into a therapeutic use for the treatment of mTORC1-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_GzMngCRwAbVg90H21EOLACvtfcHk0liVFQjrdOQVDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrt73K&md5=a543aa696f8d1601549fda8dc4b51c24</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1417015112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1417015112%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCsibi%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DG.%2BR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DYu%26aufirst%3DJ.%2BJ.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DSynthetic%2520lethality%2520of%2520combined%2520glutaminase%2520and%2520Hsp90%2520inhibition%2520in%2520mTORC1-driven%2520tumor%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3DE21%26epage%3DE29%26doi%3D10.1073%2Fpnas.1417015112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elgogary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poore, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neisser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semenza, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A.</span></span> <span> </span><span class="NLM_article-title">Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E5328</span>– <span class="NLM_lpage">E5336</span>, <span class="refDoi"> DOI: 10.1073/pnas.1611406113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1073%2Fpnas.1611406113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=27559084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2ktbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E5328-E5336&author=A.+Elgogaryauthor=Q.+Xuauthor=B.+Pooreauthor=J.+Altauthor=S.+C.+Zimmermannauthor=L.+Zhaoauthor=J.+Fuauthor=B.+Chenauthor=S.+Xiaauthor=Y.+Liuauthor=M.+Neisserauthor=C.+Nguyenauthor=R.+Leeauthor=J.+K.+Parkauthor=J.+Reyesauthor=T.+Hartungauthor=C.+Rojasauthor=R.+Raisauthor=T.+Tsukamotoauthor=G.+L.+Semenzaauthor=J.+Hanesauthor=B.+Slusherauthor=A.+Le&title=Combination+therapy+with+BPTES+nanoparticles+and+metformin+targets+the+metabolic+heterogeneity+of+pancreatic+cancer&doi=10.1073%2Fpnas.1611406113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer</span></div><div class="casAuthors">Elgogary, Amira; Xu, Qingguo; Poore, Brad; Alt, Jesse; Zimmermann, Sarah C.; Zhao, Liang; Fu, Jie; Chen, Baiwei; Xia, Shiyu; Liu, Yanfei; Neisser, Marc; Nguyen, Christopher; Lee, Ramon; Park, Joshua K.; Reyes, Juvenal; Hartung, Thomas; Rojas, Camilo; Rais, Rana; Tsukamoto, Takashi; Semenza, Gregg L.; Hanes, Justin; Slusher, Barbara S.; Le, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">E5328-E5336</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Targeting glutamine metab. via pharmacol. inhibition of glutaminase has been translated into clin. trials as a novel cancer therapy, but available drugs lack optimal safety and efficacy.  In this study, we used a proprietary emulsification process to encapsulate bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), a selective but relatively insol. glutaminase inhibitor, in nanoparticles.  BPTES nanoparticles demonstrated improved pharmacokinetics and efficacy compared with unencapsulated BPTES.  In addn., BPTES nanoparticles had no effect on the plasma levels of liver enzymes in contrast to CB-839, a glutaminase inhibitor that is currently in clin. trials.  In a mouse model using orthotopic transplantation of patient-derived pancreatic tumor tissue, BPTES nanoparticle monotherapy led to modest antitumor effects.  Using the HypoxCR reporter in vivo, we found that glutaminase inhibition reduced tumor growth by specifically targeting proliferating cancer cells but did not affect hypoxic, noncycling cells.  Metabolomics analyses revealed that surviving tumor cells following glutaminase inhibition were reliant on glycolysis and glycogen synthesis.  Based on these findings, metformin was selected for combination therapy with BPTES nanoparticles, which resulted in significantly greater pancreatic tumor redn. than either treatment alone.  Thus, targeting of multiple metabolic pathways, including effective inhibition of glutaminase by nanoparticle drug delivery, holds promise as a novel therapy for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEO264JigFOLVg90H21EOLACvtfcHk0ljMxlTS1OcQ4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2ktbbM&md5=2765c0794c6ed0e5068079d5912a0468</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1611406113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1611406113%26sid%3Dliteratum%253Aachs%26aulast%3DElgogary%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DPoore%26aufirst%3DB.%26aulast%3DAlt%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DS.%2BC.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DXia%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DNeisser%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DReyes%26aufirst%3DJ.%26aulast%3DHartung%26aufirst%3DT.%26aulast%3DRojas%26aufirst%3DC.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DTsukamoto%26aufirst%3DT.%26aulast%3DSemenza%26aufirst%3DG.%2BL.%26aulast%3DHanes%26aufirst%3DJ.%26aulast%3DSlusher%26aufirst%3DB.%26aulast%3DLe%26aufirst%3DA.%26atitle%3DCombination%2520therapy%2520with%2520BPTES%2520nanoparticles%2520and%2520metformin%2520targets%2520the%2520metabolic%2520heterogeneity%2520of%2520pancreatic%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3DE5328%26epage%3DE5336%26doi%3D10.1073%2Fpnas.1611406113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronchetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decroocq, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciel, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospital, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujobert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moura, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouscary, D.</span></span> <span> </span><span class="NLM_article-title">Targeting glutaminase has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1346</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-01-621870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1182%2Fblood-2015-01-621870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=26186940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1WisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=1346-1356&author=N.+Jacqueauthor=A.+M.+Ronchettiauthor=C.+Larrueauthor=G.+Meunierauthor=R.+Birsenauthor=L.+Willemsauthor=E.+Salandauthor=J.+Decroocqauthor=T.+T.+Macielauthor=M.+Lambertauthor=L.+Poulainauthor=M.+A.+Hospitalauthor=P.+Sujobertauthor=L.+Josephauthor=N.+Chapuisauthor=C.+Lacombeauthor=I.+C.+Mouraauthor=S.+Demoauthor=J.+E.+Sarryauthor=C.+Recherauthor=P.+Mayeuxauthor=J.+Tamburiniauthor=D.+Bouscary&title=Targeting+glutaminase+has+antileukemic+activity+in+acute+myeloid+leukemia+and+synergizes+with+BCL-2+inhibition&doi=10.1182%2Fblood-2015-01-621870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition</span></div><div class="casAuthors">Jacque, Nathalie; Ronchetti, Anne Marie; Larrue, Clement; Meunier, Godelieve; Birsen, Rudy; Willems, Lise; Saland, Estelle; Decroocq, Justine; Macie, Thiago Trovati; Lambert, Mireille; Poulain, Laury; Hospital, Marie Anne; Sujobert, Pierre; Joseph, Laure; Chapuis, Nicolas; Lacombe, Catherine; Moura, Ivan Cruz; Demo, Susan; Sarry, Jean Emmanuel; Recher, Christian; Mayeux, Patrick; Tamburini, Jerome; Bouscary, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1346-1356</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Cancer cells require glutamine to adapt to increased biosynthetic activity.  The limiting step in intracellular glutamine catabolism involves its conversion to glutamate by glutaminase (GA).  Different GA isoforms are encoded by the genes GLS1 and GLS2 in humans.  Herein, we show that glutamine levels control mitochondrial oxidative phosphorylation (OXPHOS) in acute myeloid leukemia (AML) cells.  Glutaminase C (GAC) is the GA isoform that is most abundantly expressed in AML.  Both knockdown of GLS1 expression and pharmacol. GLS1 inhibition by the drug CB-839 can reduce OXPHOS, leading to leukemic cell proliferation arrest and apoptosis without causing cytotoxic activity against normal human CD34+ progenitors.  Strikingly, GLS1 knockdown dramatically inhibited AML development in NSG mice.  The antileukemic activity of CB-839 was abrogated by both the expression of a hyperactive GACK320A allele and the addn. of the tricarboxyclic acid cycle product α-ketoglutarate, indicating the crit. function of GLS1 in AML cell survival.  Finally, glutaminolysis inhibition activated mitochondrial apoptosis and synergistically sensitized leukemic cells to priming with the BCL-2 inhibitor ABT-199.  These findings show that targeting glutamine addiction via GLS1 inhibition offers a potential novel therapeutic strategy for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_p-hOsAD2CbVg90H21EOLACvtfcHk0lgw8RbRXdiZ7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1WisLs%253D&md5=b4530d3ae6fd6d6c3e74fdcbf8967f76</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-01-621870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-01-621870%26sid%3Dliteratum%253Aachs%26aulast%3DJacque%26aufirst%3DN.%26aulast%3DRonchetti%26aufirst%3DA.%2BM.%26aulast%3DLarrue%26aufirst%3DC.%26aulast%3DMeunier%26aufirst%3DG.%26aulast%3DBirsen%26aufirst%3DR.%26aulast%3DWillems%26aufirst%3DL.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3DDecroocq%26aufirst%3DJ.%26aulast%3DMaciel%26aufirst%3DT.%2BT.%26aulast%3DLambert%26aufirst%3DM.%26aulast%3DPoulain%26aufirst%3DL.%26aulast%3DHospital%26aufirst%3DM.%2BA.%26aulast%3DSujobert%26aufirst%3DP.%26aulast%3DJoseph%26aufirst%3DL.%26aulast%3DChapuis%26aufirst%3DN.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DMoura%26aufirst%3DI.%2BC.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DBouscary%26aufirst%3DD.%26atitle%3DTargeting%2520glutaminase%2520has%2520antileukemic%2520activity%2520in%2520acute%2520myeloid%2520leukemia%2520and%2520synergizes%2520with%2520BCL-2%2520inhibition%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D1346%26epage%3D1356%26doi%3D10.1182%2Fblood-2015-01-621870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Momcilovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbein, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magyar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graebor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czernin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emberley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackinnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Works, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walser, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinett, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, D. B.</span></span> <span> </span><span class="NLM_article-title">Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.celrep.2016.12.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=28099841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ChsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=601-610&author=M.+Momcilovicauthor=S.+T.+Baileyauthor=J.+T.+Leeauthor=M.+C.+Fishbeinauthor=C.+Magyarauthor=D.+Braasauthor=T.+Graeborauthor=N.+J.+Jacksonauthor=J.+Czerninauthor=E.+Emberleyauthor=M.+Grossauthor=J.+Janesauthor=A.+Mackinnonauthor=A.+Panauthor=M.+Rodriguezauthor=M.+Worksauthor=W.+Zhangauthor=F.+Parlatiauthor=S.+Demoauthor=E.+Garonauthor=K.+Krysanauthor=T.+C.+Walserauthor=S.+M.+Dubinettauthor=S.+Sadeghiauthor=H.+R.+Christofkauthor=D.+B.+Shackelford&title=Targeted+inhibition+of+EGFR+and+glutaminase+induces+metabolic+crisis+in+EGFR+mutant+lung+cancer&doi=10.1016%2Fj.celrep.2016.12.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer</span></div><div class="casAuthors">Momcilovic, Milica; Bailey, Sean T.; Lee, Jason T.; Fishbein, Michael C.; Magyar, Clara; Braas, Daniel; Graeber, Thomas; Jackson, Nicholas J.; Czernin, Johannes; Emberley, Ethan; Gross, Matthew; Janes, Julie; MacKinnon, Andy; Pan, Alison; Rodriguez, Mirna; Works, Melissa; Zhang, Winter; Parlati, Francesco; Demo, Susan; Garon, Edward; Krysan, Kostyantyn; Walser, Tonya C.; Dubinett, Steven M.; Sadeghi, Saman; Christofk, Heather R.; Shackelford, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">601-610</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cancer cells exhibit increased use of nutrients, including glucose and glutamine, to support the bioenergetic and biosynthetic demands of proliferation.  We tested the small-mol. inhibitor of glutaminase CB-839 in combination with erlotinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) as a therapeutic strategy to simultaneously impair cancer glucose and glutamine utilization and thereby suppress tumor growth.  Here, we show that CB-839 cooperates with erlotinib to drive energetic stress and activate the AMP-activated protein kinase (AMPK) pathway in EGFR (del19) lung tumors.  Tumor cells undergo metabolic crisis and cell death, resulting in rapid tumor regression in vivo in mouse NSCLC xenografts.  Consistently, positron emission tomog. (PET) imaging with 18F-fluoro-2-deoxyglucose (18F-FDG) and 11C-glutamine (11C-Gln) of xenografts indicated reduced glucose and glutamine uptake in tumors following treatment with CB-839 + erlotinib.  Therefore, PET imaging with 18F-FDG and 11C-Gln tracers can be used to non-invasively measure metabolic response to CB-839 and erlotinib combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDi9ghbRHBG7Vg90H21EOLACvtfcHk0lhyFvX4gzn_Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ChsL4%253D&md5=b335b9e4ba83b1d462f8baceae85074f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.061%26sid%3Dliteratum%253Aachs%26aulast%3DMomcilovic%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DS.%2BT.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DFishbein%26aufirst%3DM.%2BC.%26aulast%3DMagyar%26aufirst%3DC.%26aulast%3DBraas%26aufirst%3DD.%26aulast%3DGraebor%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DN.%2BJ.%26aulast%3DCzernin%26aufirst%3DJ.%26aulast%3DEmberley%26aufirst%3DE.%26aulast%3DGross%26aufirst%3DM.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DMackinnon%26aufirst%3DA.%26aulast%3DPan%26aufirst%3DA.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DWorks%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DGaron%26aufirst%3DE.%26aulast%3DKrysan%26aufirst%3DK.%26aulast%3DWalser%26aufirst%3DT.%2BC.%26aulast%3DDubinett%26aufirst%3DS.%2BM.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DShackelford%26aufirst%3DD.%2BB.%26atitle%3DTargeted%2520inhibition%2520of%2520EGFR%2520and%2520glutaminase%2520induces%2520metabolic%2520crisis%2520in%2520EGFR%2520mutant%2520lung%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D601%26epage%3D610%26doi%3D10.1016%2Fj.celrep.2016.12.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ospina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Escheverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederschain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, L.</span></span> <span> </span><span class="NLM_article-title">Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0185092</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0185092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1371%2Fjournal.pone.0185092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=28950000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotV2nsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=M.+Lampaauthor=H.+Arltauthor=T.+Heauthor=B.+Ospinaauthor=J.+Reevesauthor=B.+Zhangauthor=J.+Murtieauthor=G.+Dengauthor=C.+Barberisauthor=D.+Hoffmannauthor=H.+Chengauthor=J.+Pollardauthor=C.+Winterauthor=V.+Richonauthor=C.+Garcia-Escheverriaauthor=F.+Adrianauthor=D.+Wiederschainauthor=L.+Srinivasan&title=Glutaminase+is+essential+for+the+growth+of+triple-negative+breast+cancer+cells+with+a+deregulated+glutamine+metabolism+pathway+and+its+suppression+synergizes+with+mTOR+inhibition&doi=10.1371%2Fjournal.pone.0185092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition</span></div><div class="casAuthors">Lampa, Michael; Arlt, Heike; He, Timothy; Ospina, Beatriz; Reeves, Jason; Zhang, Bailin; Murtie, Joshua; Deng, Gejing; Barberis, Claude; Hoffmann, Dietmar; Cheng, Hong; Pollard, Jack; Winter, Christopher; Richon, Victoria; Garcia-Escheverria, Carlos; Adrian, Francisco; Wiederschain, Dmitri; Srinivasan, Lakshmi</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0185092/1-e0185092/24</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tumor cells display fundamental changes in metab. and nutrient uptake in order to utilize addnl. nutrient sources to meet their enhanced bioenergetic requirements.  Glutamine (Gln) is one such nutrient that is rapidly taken up by tumor cells to fulfill this increased metabolic demand.  A vital step in the catabolism of glutamine is its conversion to glutamate by the mitochondrial enzyme glutaminase (GLS).  This study has identified GLS a potential therapeutic target in breast cancer, specifically in the basal subtype that exhibits a deregulated glutaminolysis pathway.  Using inducible shRNA mediated gene knockdown, we discovered that loss of GLS function in triple-neg. breast cancer (TNBC) cell lines with a deregulated glutaminolysis pathway led to profound tumor growth inhibition in vitro and in vivo.  GLS knockdown had no effect on growth and metabolite levels in non-TNBC cell lines.  We rescued the anti-tumor effect of GLS knockdown using shRNA resistant cDNAs encoding both GLS isoforms and by addn. of an a-ketoglutarate (αKG) analog thus confirming the crit. role of GLS in TNBC.  Pharmacol. inhibition of GLS with the small mol. inhibitor CB-839 reduced cell growth and led to a decrease in mammalian target of rapamycin (mTOR) activity and an increase in the stress response pathway driven by activating transcription factor 4 (ATF4).  Finally, we found that GLS inhibition synergizes with mTOR inhibition, which introduces the possibility of a novel therapeutic strategy for TNBC.  Our study revealed that GLS is essential for the survival of TNBC with a deregulated glutaminolysis pathway.  The synergistic activity of GLS and mTOR inhibitors in TNBC cell lines suggests therapeutic potential of this combination for the treatment of vulnerable subpopulations of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxPfQ2FostHrVg90H21EOLACvtfcHk0liUK7ohYNUk9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotV2nsLg%253D&md5=6b68e9038486853cd3612ffd8ef7f918</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0185092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0185092%26sid%3Dliteratum%253Aachs%26aulast%3DLampa%26aufirst%3DM.%26aulast%3DArlt%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DOspina%26aufirst%3DB.%26aulast%3DReeves%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMurtie%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DBarberis%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DGarcia-Escheverria%26aufirst%3DC.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DWiederschain%26aufirst%3DD.%26aulast%3DSrinivasan%26aufirst%3DL.%26atitle%3DGlutaminase%2520is%2520essential%2520for%2520the%2520growth%2520of%2520triple-negative%2520breast%2520cancer%2520cells%2520with%2520a%2520deregulated%2520glutamine%2520metabolism%2520pathway%2520and%2520its%2520suppression%2520synergizes%2520with%2520mTOR%2520inhibition%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0185092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sappington, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi-Parsian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boysen, G.</span></span> <span> </span><span class="NLM_article-title">Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1860</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">843</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2016.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.bbagen.2016.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=26825773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs12gsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1860&publication_year=2016&pages=836-843&author=D.+R.+Sappingtonauthor=E.+R.+Siegelauthor=G.+Hiattauthor=A.+Desaiauthor=R.+B.+Penneyauthor=A.+Jamshidi-Parsianauthor=R.+J.+Griffinauthor=G.+Boysen&title=Glutamine+drives+glutathione+synthesis+and+contributes+to+radiation+sensitivity+of+A549+and+H460+lung+cancer+cell+lines&doi=10.1016%2Fj.bbagen.2016.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines</span></div><div class="casAuthors">Sappington, Daniel R.; Siegel, Eric R.; Hiatt, Gloria; Desai, Abhishek; Penney, Rosalind B.; Jamshidi-Parsian, Azemat; Griffin, Robert J.; Boysen, Gunnar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1860</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">836-843</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Increased glutamine uptake is known to drive cancer cell proliferation, making tumor cells glutamine-dependent.  Glutamine provides addnl. carbon and nitrogen sources for cell growth.  The first step in glutamine utilization is its conversion to glutamate by glutaminase (GLS).  Glutamate is a precursor for glutathione synthesis, and we investigated the hypothesis that glutamine drives glutathione synthesis and thereby contributes to cellular defense systems.The importance of glutamine for glutathione synthesis was studied in H460 and A549 lung cancer cell lines using glutamine-free medium and bis-2-(5-phenyl-acetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) a GLS inhibitor.  Metabolic activities were detd. by targeted mass spectrometry.A significant correlation between glutamine consumption and glutathione excretion was demonstrated in H460 and A549 tumor cells.  Culturing in the presence of [13C5]glutamine demonstrated that by 12 h > 50% of excreted glutathione was derived from glutamine.  Culturing in glutamine-free medium or treatment with BPTES, a GLS-specific inhibitor, reduced cell proliferation and viability and abolished glutathione excretion.  Treatment with glutathione-ester prevented BPTES-induced cytotoxicity.  Inhibition of GLS markedly radiosensitized the lung tumor cell lines, suggesting an important role of glutamine-derived glutathione in detg. radiation sensitivity.We demonstrate here for the first time that a significant amt. of extracellular glutathione is directly derived from glutamine.  This finding adds yet another important function to the already known glutamine dependence of tumor cells and probably tumors as well.Glutamine is essential for synthesis and excretion of glutathione to promote cell growth and viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFRlEk2tVJrVg90H21EOLACvtfcHk0lgU9Y5xB61swA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs12gsrY%253D&md5=50b758d3f4c5203f63cf91b08a77ab4a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2016.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2016.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DSappington%26aufirst%3DD.%2BR.%26aulast%3DSiegel%26aufirst%3DE.%2BR.%26aulast%3DHiatt%26aufirst%3DG.%26aulast%3DDesai%26aufirst%3DA.%26aulast%3DPenney%26aufirst%3DR.%2BB.%26aulast%3DJamshidi-Parsian%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DBoysen%26aufirst%3DG.%26atitle%3DGlutamine%2520drives%2520glutathione%2520synthesis%2520and%2520contributes%2520to%2520radiation%2520sensitivity%2520of%2520A549%2520and%2520H460%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2016%26volume%3D1860%26spage%3D836%26epage%3D843%26doi%3D10.1016%2Fj.bbagen.2016.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boysen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi-Parsian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simecka, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kore, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dings, R. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span> <span> </span><span class="NLM_article-title">Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human tumor xenografts in mice</span>. <i>Int. J. Rad. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1080/09553002.2018.1558299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1080%2F09553002.2018.1558299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=30557074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2019&pages=436-442&author=G.+Boysenauthor=A.+Jamshidi-Parsianauthor=M.+A.+Davisauthor=E.+R.+Siegelauthor=C.+M.+Simeckaauthor=R.+A.+Koreauthor=R.+P.+M.+Dingsauthor=R.+J.+Griffin&title=Glutaminase+inhibitor+CB-839+increases+radiation+sensitivity+of+lung+tumor+cells+and+human+tumor+xenografts+in+mice&doi=10.1080%2F09553002.2018.1558299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice</span></div><div class="casAuthors">Boysen, Gunnar; Jamshidi-Parsian, Azemat; Davis, Mary A.; Siegel, Eric R.; Simecka, Christine M.; Kore, Rajshekhar A.; Dings, Ruud P. M.; Griffin, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">436-442</span>CODEN:
                <span class="NLM_cas:coden">IJRBE7</span>;
        ISSN:<span class="NLM_cas:issn">0955-3002</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The purpose of this study was to translate our in vitro therapy approach to an in vivo model.  Increased glutamine uptake is known to drive cancer cell proliferation, making tumor cells glutamine-dependent.  Studying lymph-node aspirates contg. malignant lung tumor cells showed a strong correlation between glutamine consumption and glutathione (GSH) excretion.  Subsequent expts. with A549 and H460 lung tumor cell lines provided addnl. evidence for glutamine's role in driving synthesis and excretion of GSH.  Using stable-isotope-labeled glutamine as a tracer metabolite, we demonstrated that the glutamate group in GSH is directly derived from glutamine, linking glutamine utilization intimately to GSH syntheses.  To understand the possible mechanistic link between glutamine consumption and GSH excretion, we studied GSH metab. in more detail.  Inhibition of glutaminase (GLS) with BPTES, a GLS-specific inhibitor, effectively abolished GSH synthesis and excretion.  Since our previous work, several novel GLS inhibitors became available and we report herein effects of CB-839 in A427, H460 and A549 lung tumor cells and human lungtumor xenografts in mice.  Inhibition of GLS markedly reduced cell viability, producing ED50 values for inhibition of colony formation of 9, 27 and 217 nM in A427, A549 and H460, resp.  Inhibition of GLS is accompanied by ~ 30% increased response to radiation, suggesting an important role of glutamine-derived GSH in protecting tumor cells against radiation-induced injury.  In subsequent mouse xenografts, short-term CB-839 treatments reduced serum GSH by greater than 50% and increased response to radiotherapy of H460-derived tumor xenografts by 30%.  The results support the proposed mechanistic link between GLS activity and GSH synthesis and suggest that GLS inhibitors are effective radiosensitizers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPvDZSFhCDZbVg90H21EOLACvtfcHk0ljNCiFvJQHZIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSlt7c%253D&md5=169e20877892733fa6ce64fa55b07b36</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F09553002.2018.1558299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09553002.2018.1558299%26sid%3Dliteratum%253Aachs%26aulast%3DBoysen%26aufirst%3DG.%26aulast%3DJamshidi-Parsian%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DM.%2BA.%26aulast%3DSiegel%26aufirst%3DE.%2BR.%26aulast%3DSimecka%26aufirst%3DC.%2BM.%26aulast%3DKore%26aufirst%3DR.%2BA.%26aulast%3DDings%26aufirst%3DR.%2BP.%2BM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3DGlutaminase%2520inhibitor%2520CB-839%2520increases%2520radiation%2520sensitivity%2520of%2520lung%2520tumor%2520cells%2520and%2520human%2520tumor%2520xenografts%2520in%2520mice%26jtitle%3DInt.%2520J.%2520Rad.%2520Biol.%26date%3D2019%26volume%3D95%26spage%3D436%26epage%3D442%26doi%3D10.1080%2F09553002.2018.1558299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willis, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seegmiller, J. E.</span></span> <span> </span><span class="NLM_article-title">The inhibition by 6-diazo-5-oxo-<span class="smallcaps smallerCapital">L</span>-norleucine of glutamine catabolism of the cultured human lymphoblast</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1002/jcp.1040930308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1002%2Fjcp.1040930308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=22551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADyaE1cXkvVShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1977&pages=375-382&author=R.+C.+Willisauthor=J.+E.+Seegmiller&title=The+inhibition+by+6-diazo-5-oxo-L-norleucine+of+glutamine+catabolism+of+the+cultured+human+lymphoblast&doi=10.1002%2Fjcp.1040930308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibition by 6-diazo-5-oxo-L-norleucine of glutamine catabolism of the cultured human lymphoblast</span></div><div class="casAuthors">Willis, Randall C.; Seegmiller, J. Edwin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-82</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    </div><div class="casAbstract">The rapid catabolism of glutamine by the cultured human lymphoblast line WI-L2 was inhibited by >95% during incubation of cell suspensions with 6-diazo-5-oxo-L-norleucine (I).  The inhibition persisted for ≥4 h after the removal of I from the cell suspension.  The exposure of cells to I inhibited >95% of the glutaminase activity measured in lysates in the presence of either phosphate or maleate.  Similarly, γ-glutamyl transpeptidase, assayed with γ-glutamyl-p-nitroanilide as substrate and glycylglycine as acceptor, was inhibited >90%.  I-treated and control cells accumulated radioactive material from suspensions contg. L-glutamine-14C at similar initial rates.  The radioactive material accumulated by the I-treated cells was all recoverable as glutamine, whereas the radioactive material accumulated by untreated cells was principally recovered as glutamate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooEluRc1A7arVg90H21EOLACvtfcHk0lgyIVNf1cNAdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvVShtQ%253D%253D&md5=75a871601964879332b313079c9d61a2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fjcp.1040930308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.1040930308%26sid%3Dliteratum%253Aachs%26aulast%3DWillis%26aufirst%3DR.%2BC.%26aulast%3DSeegmiller%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520inhibition%2520by%25206-diazo-5-oxo-L-norleucine%2520of%2520glutamine%2520catabolism%2520of%2520the%2520cultured%2520human%2520lymphoblast%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D1977%26volume%3D93%26spage%3D375%26epage%3D382%26doi%3D10.1002%2Fjcp.1040930308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, R. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Bis[(carboxamidothiadiazolyl)ethyl] Sulfides and Ethers as Glutaminase Inhibitors</span>. U.S. Patent <span class="NLM_patent">US6451828</span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=R.+W.+Newcomb&title=Preparation+of+Bis%5B%28carboxamidothiadiazolyl%29ethyl%5D+Sulfides+and+Ethers+as+Glutaminase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNewcomb%26aufirst%3DR.%2BW.%26atitle%3DPreparation%2520of%2520Bis%255B%2528carboxamidothiadiazolyl%2529ethyl%255D%2520Sulfides%2520and%2520Ethers%2520as%2520Glutaminase%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinavahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosio, A. L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, S. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span> <span> </span><span class="NLM_article-title">Targeting mitochondrial glutaminase activity inhibits oncogenic transformation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2010.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.ccr.2010.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=20832749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGht7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=207-219&author=J.+B.+Wangauthor=J.+W.+Ericksonauthor=R.+Fujiauthor=S.+Ramachandranauthor=P.+Gaoauthor=R.+Dinavahiauthor=K.+F.+Wilsonauthor=A.+L.+B.+Ambrosioauthor=S.+M.+G.+Diasauthor=C.+V.+Dangauthor=R.+A.+Cerione&title=Targeting+mitochondrial+glutaminase+activity+inhibits+oncogenic+transformation&doi=10.1016%2Fj.ccr.2010.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation</span></div><div class="casAuthors">Wang, Jian-Bin; Erickson, Jon W.; Fuji, Reina; Ramachandran, Sekar; Gao, Ping; Dinavahi, Ramani; Wilson, Kristin F.; Ambrosio, Andre L. B.; Dias, Sandra M. G.; Dang, Chi-V.; Cerione, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-219</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Rho GTPases impact a no. of activities important for oncogenesis.  We describe a small mol. inhibitor that blocks oncogenic transformation induced by various Rho GTPases in fibroblasts, and the growth of human breast cancer and B lymphoma cells, without affecting normal cells.  We identify the target of this inhibitor to be the metabolic enzyme glutaminase, which catalyzes the hydrolysis of glutamine to glutamate.  We show that transformed fibroblasts and breast cancer cells exhibit elevated glutaminase activity that is dependent on Rho GTPases and NF-κB activity, and is blocked by the small mol. inhibitor.  These findings highlight a previously unappreciated connection between Rho GTPase activation and cellular metab. and demonstrate that targeting glutaminase activity can inhibit oncogenic transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTP6YsyzRd1LVg90H21EOLACvtfcHk0lgyIVNf1cNAdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGht7bO&md5=67b64e99c992bbe6636ecfc04b83aac0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BB.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26aulast%3DFuji%26aufirst%3DR.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DDinavahi%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DK.%2BF.%26aulast%3DAmbrosio%26aufirst%3DA.%2BL.%2BB.%26aulast%3DDias%26aufirst%3DS.%2BM.%2BG.%26aulast%3DDang%26aufirst%3DC.%2BV.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26atitle%3DTargeting%2520mitochondrial%2520glutaminase%2520activity%2520inhibits%2520oncogenic%2520transformation%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D207%26epage%3D219%26doi%3D10.1016%2Fj.ccr.2010.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemberg, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vornov, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span> <span> </span><span class="NLM_article-title">We’re not “DON” yet: Optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1824</span>– <span class="NLM_lpage">1832</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-1148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1535-7163.MCT-17-1148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=30181331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12qt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1824-1832&author=K.+M.+Lembergauthor=J.+J.+Vornovauthor=R.+Raisauthor=B.+S.+Slusher&title=We%E2%80%99re+not+%E2%80%9CDON%E2%80%9D+yet%3A+Optimal+dosing+and+prodrug+delivery+of+6-diazo-5-oxo-L-norleucine&doi=10.1158%2F1535-7163.MCT-17-1148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">We're not "DON" yet: optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine</span></div><div class="casAuthors">Lemberg, Kathryn M.; Vornov, James J.; Rais, Rana; Slusher, Barbara S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1824-1832</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The broadly active glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) has been studied for 60 years as a potential anticancer therapeutic.  Clin. studies of DON in the 1950s using low daily doses suggested antitumor activity, but later phase I and II trials of DON given intermittently at high doses were hampered by dose-limiting nausea and vomiting.  Further clin. development of DON was abandoned.  Recently, the recognition that multiple tumor types are glutamine-dependent has renewed interest in metabolic inhibitors such as DON.  Here, we describe the prior experience with DON in humans.  Evaluation of past studies suggests that the major impediments to successful clin. use included unacceptable gastrointestinal (GI) toxicities, inappropriate dosing schedules for a metabolic inhibitor, and lack of targeted patient selection.  To circumvent GI toxicity, prodrug strategies for DON have been developed to enhance delivery of active compd. to tumor tissues, including the CNS.  When these prodrugs are administered in a low daily dosing regimen, appropriate for metabolic inhibition, they are robustly effective without significant toxicity.  Patients whose tumors have genetic, metabolic, or imaging biomarker evidence of glutamine dependence should be prioritized as candidates for future clin. evaluations of novel DON prodrugs, given either as monotherapy or in rationally directed pharmacol. combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm4X4Vtx-nTLVg90H21EOLACvtfcHk0ljbxG9ZFdATng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12qt7bK&md5=d83f232e399c8b1d6a4815d5f9a0c876</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-1148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-1148%26sid%3Dliteratum%253Aachs%26aulast%3DLemberg%26aufirst%3DK.%2BM.%26aulast%3DVornov%26aufirst%3DJ.%2BJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26atitle%3DWe%25E2%2580%2599re%2520not%2520%25E2%2580%259CDON%25E2%2580%259D%2520yet%253A%2520Optimal%2520dosing%2520and%2520prodrug%2520delivery%2520of%25206-diazo-5-oxo-L-norleucine%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1824%26epage%3D1832%26doi%3D10.1158%2F1535-7163.MCT-17-1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span> <span> </span><span class="NLM_article-title">Dibenzophenanthridinesas inhibitors of glutaminase C and cancer cell proliferation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1535-7163.MCT-11-0942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=22496480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1269-1277&author=W.+P.+Kattauthor=S.+Ramachandranauthor=J.+W.+Ericksonauthor=R.+A.+Cerione&title=Dibenzophenanthridinesas+inhibitors+of+glutaminase+C+and+cancer+cell+proliferation&doi=10.1158%2F1535-7163.MCT-11-0942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation</span></div><div class="casAuthors">Katt, William P.; Ramachandran, Sekar; Erickson, Jon W.; Cerione, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1269-1278</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">One hallmark of cancer cells is their adaptation to rely upon an altered metabolic scheme that includes changes in the glycolytic pathway, known as the Warburg effect, and elevated glutamine metab.  Glutaminase, a mitochondrial enzyme, plays a key role in the metab. of glutamine in cancer cells, and its inhibition could significantly impact malignant transformation.  The small mol. 968, a dibenzophenanthridine, was recently shown to inhibit recombinantly expressed glutaminase C, to block the proliferation and anchorage-independent colony formation of human cancer cells in culture, and to inhibit tumor formation in mouse xenograft models.  Here, we examine the structure-activity relationship that leads to 968-based inhibition of glutaminase and cancer cell proliferation, focusing upon a "hot-spot" ring previously identified as crit. to 968 activity.  We find that the hot-spot ring must be substituted with a large, nonplanar functionality (e.g., a t-Bu group) to bestow activity to the series, leading us to a model whereby the mol. binds glutaminase at a previously undescribed allosteric site.  We conduct docking studies to locate potential 968-binding sites and proceed to test a specific set of docking solns. via site-directed mutagenesis.  We verify the results from our initial assay of 968 and its analogs by cellular studies using MDA-MB-231 breast cancer cells.  Mol Cancer Ther; 11(6); 1269-78. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr56LeuCKRMMbVg90H21EOLACvtfcHk0ljbxG9ZFdATng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlCisLs%253D&md5=a6e11ed0a50ee567f0013e268e1b36e4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0942%26sid%3Dliteratum%253Aachs%26aulast%3DKatt%26aufirst%3DW.%2BP.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26atitle%3DDibenzophenanthridinesas%2520inhibitors%2520of%2520glutaminase%2520C%2520and%2520cancer%2520cell%2520proliferation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1269%26epage%3D1277%26doi%3D10.1158%2F1535-7163.MCT-11-0942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stalnecker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBrayer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. W.</span></span> <span> </span><span class="NLM_article-title">Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1073/pnas.1414056112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1073%2Fpnas.1414056112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=25548170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVak" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=394-399&author=C.+A.+Stalneckerauthor=S.+M.+Ulrichauthor=Y.+Liauthor=S.+Ramachandranauthor=M.+K.+McBrayerauthor=R.+J.+DeBerardinisauthor=R.+A.+Cerioneauthor=J.+W.+Erickson&title=Mechanism+by+which+a+recently+discovered+allosteric+inhibitor+blocks+glutamine+metabolism+in+transformed+cells&doi=10.1073%2Fpnas.1414056112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells</span></div><div class="casAuthors">Stalnecker, Clint A.; Ulrich, Scott M.; Li, Yunxing; Ramachandran, Sekar; McBrayer, Mary Kate; DeBerardinis, Ralph J.; Cerione, Richard A.; Erickson, Jon W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">394-399</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mitochondrial enzyme glutaminase C (GAC) catalyzes the hydrolysis of glutamine to glutamate plus ammonia, a key step in the metab. of glutamine by cancer cells.  Recently, we discovered a class of allosteric inhibitors of GAC that inhibit cancer cell growth without affecting their normal cellular counterparts, with the lead compd. being the bromo-benzophenanthridinone 968.  Here, we take advantage of mouse embryonic fibroblasts transformed by oncogenic Dbl, which hyperactivates Rho GTPases, together with 13C-labeled glutamine and stable-isotope tracing methods, to establish that 968 selectively blocks the enhancement in glutaminolysis necessary for satisfying the glutamine addiction of cancer cells.  We then det. how 968 inhibits the catalytic activity of GAC.  First, we developed a FRET assay to examine the effects of 968 on the ability of GAC to undergo the dimer-to-tetramer transition necessary for enzyme activation.  We next demonstrate how the fluorescence of a reporter group attached to GAC provides a direct read-out of the binding of 968 and related compds. to the enzyme.  By combining these fluorescence assays with newly developed GAC mutants trapped in either the monomeric or dimeric state, we show that 968 has the highest affinity for monomeric GAC and that the dose-dependent binding of 968 to GAC monomers directly matches its dose-dependent inhibition of enzyme activity and cellular transformation.  Together, these findings highlight the requirement of tetramer formation as the mechanism of GAC activation and shed new light on how a distinct class of allosteric GAC inhibitors impacts the metabolic program of transformed cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-MQlQRMdgt7Vg90H21EOLACvtfcHk0ljEQsQHsh26FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVak&md5=a6920098b26d87012aa3f625804c22ed</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1414056112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1414056112%26sid%3Dliteratum%253Aachs%26aulast%3DStalnecker%26aufirst%3DC.%2BA.%26aulast%3DUlrich%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DMcBrayer%26aufirst%3DM.%2BK.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26atitle%3DMechanism%2520by%2520which%2520a%2520recently%2520discovered%2520allosteric%2520inhibitor%2520blocks%2520glutamine%2520metabolism%2520in%2520transformed%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D394%26epage%3D399%26doi%3D10.1073%2Fpnas.1414056112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lukey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cluntun, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druso, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R. A.</span></span> <span> </span><span class="NLM_article-title">Liver-type glutaminase GLS2 is a druggable metabolic node in luminal-subtype breast cancer</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">76.e7</span>– <span class="NLM_lpage">88.e7</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.08.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.celrep.2019.08.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=76.e7-88.e7&author=M.+J.+Lukeyauthor=A.+A.+Cluntunauthor=W.+P.+Kattauthor=M.+J.+Linauthor=J.+E.+Drusoauthor=S.+Ramachandranauthor=J.+W.+Ericksonauthor=H.+H.+Leauthor=Z.-E.+Wangauthor=B.+Blankauthor=K.+S.+Greeneauthor=R.+A.+Cerione&title=Liver-type+glutaminase+GLS2+is+a+druggable+metabolic+node+in+luminal-subtype+breast+cancer&doi=10.1016%2Fj.celrep.2019.08.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.08.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.08.076%26sid%3Dliteratum%253Aachs%26aulast%3DLukey%26aufirst%3DM.%2BJ.%26aulast%3DCluntun%26aufirst%3DA.%2BA.%26aulast%3DKatt%26aufirst%3DW.%2BP.%26aulast%3DLin%26aufirst%3DM.%2BJ.%26aulast%3DDruso%26aufirst%3DJ.%2BE.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26aulast%3DLe%26aufirst%3DH.%2BH.%26aulast%3DWang%26aufirst%3DZ.-E.%26aulast%3DBlank%26aufirst%3DB.%26aulast%3DGreene%26aufirst%3DK.%2BS.%26aulast%3DCerione%26aufirst%3DR.%2BA.%26atitle%3DLiver-type%2520glutaminase%2520GLS2%2520is%2520a%2520druggable%2520metabolic%2520node%2520in%2520luminal-subtype%2520breast%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D29%26spage%3D76.e7%26epage%3D88.e7%26doi%3D10.1016%2Fj.celrep.2019.08.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBryant, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curthoys, N. P.</span></span> <span> </span><span class="NLM_article-title">Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES)</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1042/BJ20070039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1042%2FBJ20070039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=17581113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BD2sXps1Wgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2007&pages=407-414&author=M.+M.+Robinsonauthor=S.+J.+McBryantauthor=T.+Tsukamotoauthor=C.+Rojasauthor=D.+V.+Ferrarisauthor=S.+K.+Hamiltonauthor=J.+C.+Hansenauthor=N.+P.+Curthoys&title=Novel+mechanism+of+inhibition+of+rat+kidney-type+glutaminase+by+bis-2-%285-phenylacetamido-1%2C2%2C4-thiadiazol-2-yl%29ethyl+sulfide+%28BPTES%29&doi=10.1042%2FBJ20070039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES)</span></div><div class="casAuthors">Robinson, Mary M.; McBryant, Steven J.; Tsukamoto, Takashi; Rojas, Camilo; Ferraris, Dana V.; Hamilton, Sean K.; Hansen, Jeffrey C.; Curthoys, Norman P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The release of GA (mitochondrial glutaminase) from neurons following acute ischemia or during chronic neurodegenerative diseases may contribute to the propagation of glutamate excitotoxicity.  Thus an inhibitor that selectively inactivates the released GA may limit the accumulation of excess glutamate and minimize the loss of neurol. function that accompanies brain injury.  The present study examines the mechanism of inactivation of rat KGA (kidney GA isoform) by the small-mol. inhibitor BPTES [bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide].  BPTES is a potent inhibitor of KGA, but not of the liver GA isoform, glutamate dehydrogenase or γ-glutamyl transpeptidase.  Kinetic studies indicate that, with respect to glutamine, BPTES has a Ki of approx. 3 μM.  Moreover, these studies suggest that BPTES inhibits the allosteric activation caused by phosphate binding and promotes the formation of an inactive complex.  Gel-filtration chromatog. and sedimentation-velocity anal. were used to examine the effect of BPTES on the phosphate-dependent oligomerization of KGA.  This established that BPTES prevents the formation of large phosphate-induced oligomers and instead promotes the formation of a single oligomeric species with distinct phys. properties.  Sedimentation-equil. studies detd. that the oligomer produced by BPTES is a stable tetramer.  Taken together, the present work indicates that BPTES is a unique and potent inhibitor of rat KGA and elucidates a novel mechanism of inactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR5Ncyq__sELVg90H21EOLACvtfcHk0ljEQsQHsh26FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXps1Wgsb4%253D&md5=cde9754c0dedd000423226e2289b4690</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1042%2FBJ20070039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070039%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%2BM.%26aulast%3DMcBryant%26aufirst%3DS.%2BJ.%26aulast%3DTsukamoto%26aufirst%3DT.%26aulast%3DRojas%26aufirst%3DC.%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26aulast%3DHamilton%26aufirst%3DS.%2BK.%26aulast%3DHansen%26aufirst%3DJ.%2BC.%26aulast%3DCurthoys%26aufirst%3DN.%2BP.%26atitle%3DNovel%2520mechanism%2520of%2520inhibition%2520of%2520rat%2520kidney-type%2520glutaminase%2520by%2520bis-2-%25285-phenylacetamido-1%252C2%252C4-thiadiazol-2-yl%2529ethyl%2520sulfide%2520%2528BPTES%2529%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D406%26spage%3D407%26epage%3D414%26doi%3D10.1042%2FBJ20070039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeLaBarre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song J, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurov, J. B.</span></span> <span> </span><span class="NLM_article-title">Full-length human glutaminase in complex with an allosteric inhibitor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">10764</span>– <span class="NLM_lpage">10770</span>, <span class="refDoi"> DOI: 10.1021/bi201613d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi201613d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSks73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=10764-10770&author=B.+DeLaBarreauthor=S.+Grossauthor=C.+Fangauthor=Y.+Gaoauthor=A.+Jhaauthor=F.+Jiangauthor=J.+Song+Jauthor=W.+Weiauthor=J.+B.+Hurov&title=Full-length+human+glutaminase+in+complex+with+an+allosteric+inhibitor&doi=10.1021%2Fbi201613d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Full-Length Human Glutaminase in Complex with an Allosteric Inhibitor</span></div><div class="casAuthors">DeLaBarre, Byron; Gross, Stefan; Fang, Cheng; Gao, Yi; Jha, Abhishek; Jiang, Fan; Song J., Juanhua; Wei, Wentao; Hurov, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">10764-10770</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glutaminase (GLS1/2) catalyzes the conversion of L-glutamine to L-glutamate and ammonia.  The level of a splice variant of GLS1 (GAC) is elevated in certain cancers, and GAC is specifically inhibited by bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide (BPTES).  We report here the first full-length crystal structure of GAC in the presence and absence of BPTES mols.  Two BPTES mols. bind at an interface region of the GAC tetramer in a manner that appears to lock the GAC tetramer into a nonproductive conformation.  The importance of these loops with regard to overall enzymic activity of the tetramer was revealed by a series of GAC point mutants designed to create a BPTES resistant GAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrj21-Ko0HGLVg90H21EOLACvtfcHk0ljEQsQHsh26FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSks73K&md5=bd94996062f54c4f51a138c8e9f5f99a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi201613d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi201613d%26sid%3Dliteratum%253Aachs%26aulast%3DDeLaBarre%26aufirst%3DB.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DJha%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DSong%2BJ%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DHurov%26aufirst%3DJ.%2BB.%26atitle%3DFull-length%2520human%2520glutaminase%2520in%2520complex%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D10764%26epage%3D10770%26doi%3D10.1021%2Fbi201613d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, T.</span></span> <span> </span><span class="NLM_article-title">Recent progress in the discovery of allosteric inhibitors of kidney-type glutaminase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ertLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=46-59&author=S.+C.+Zimmermannauthor=B.+Duvallauthor=T.+Tsukamoto&title=Recent+progress+in+the+discovery+of+allosteric+inhibitors+of+kidney-type+glutaminase&doi=10.1021%2Facs.jmedchem.8b00327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase</span></div><div class="casAuthors">Zimmermann, Sarah C.; Duvall, Bridget; Tsukamoto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-59</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kidney-type glutaminase (GLS), the first enzyme in the glutaminolysis pathway, catalyzes the hydrolysis of glutamine to glutamate.  GLS was found to be upregulated in many glutamine-dependent cancer cells.  Therefore, selective inhibition of GLS has gained substantial interest as a therapeutic approach targeting cancer metab.  Bis-2-[5-(phenylacetamido)-1,3,4-thiadiazol-2-yl]ethyl sulfide (BPTES), despite its poor physicochem. properties, has served as a key mol. template in subsequent efforts to identify more potent and drug-like allosteric GLS inhibitors.  This review article provides an overview of the progress made to date in the development of GLS inhibitors and highlights the remarkable transformation of the unfavorable lead into "druglike" compds. guided by systematic SAR studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSonxbDTrHLrVg90H21EOLACvtfcHk0li3VCGD6Tmhmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ertLrJ&md5=70d1c4cb85923362e2e5d92c2113f273</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00327%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DS.%2BC.%26aulast%3DDuvall%26aufirst%3DB.%26aulast%3DTsukamoto%26aufirst%3DT.%26atitle%3DRecent%2520progress%2520in%2520the%2520discovery%2520of%2520allosteric%2520inhibitors%2520of%2520kidney-type%2520glutaminase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D46%26epage%3D59%26doi%3D10.1021%2Facs.jmedchem.8b00327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delahanty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamato, T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazolyl-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10551</span>– <span class="NLM_lpage">10563</span>, <span class="refDoi"> DOI: 10.1021/jm301191p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301191p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ohs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10551-10563&author=K.+Shuklaauthor=D.+V.+Ferrarisauthor=A.+G.+Thomasauthor=M.+Stathisauthor=B.+Duvallauthor=G.+Delahantyauthor=J.+Altauthor=R.+Raisauthor=C.+Rojasauthor=P.+Gaoauthor=Y.+Xiangauthor=C.+V.+Dangauthor=B.+S.+Slusherauthor=T.+Tsukamato&title=Design%2C+synthesis+and+pharmacological+evaluation+of+bis-2-%285-phenylacetamido-1%2C2%2C4-thiadiazolyl-2-yl%29ethyl+sulfide+3+%28BPTES%29+analogs+as+glutaminase+inhibitors&doi=10.1021%2Fjm301191p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors</span></div><div class="casAuthors">Shukla, Krupa; Ferraris, Dana V.; Thomas, Ajit G.; Stathis, Marigo; Duvall, Bridget; Delahanty, Greg; Alt, Jesse; Rais, Rana; Rojas, Camilo; Gao, Ping; Xiang, Yan; Dang, Chi V.; Slusher, Barbara S.; Tsukamoto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10551-10563</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) that has served as a mol. probe to det. the therapeutic potential of GLS inhibition.  In an attempt to identify more potent GLS inhibitors with improved drug-like mol. properties, a series of BPTES analogs were synthesized and evaluated.  The structure-activity relationship (SAR) studies revealed that some truncated analogs retained the potency of BPTES, presenting an opportunity to improve its aq. soly.  The analog I exhibited similar potency and better soly. relative to BPTES and attenuated the growth of P493 human lymphoma B cells in vitro as well as in a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0N1SUSOaTCbVg90H21EOLACvtfcHk0li3VCGD6Tmhmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ohs7zM&md5=7a54f0c8de3c211a65d5c9bbb4a6db62</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm301191p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301191p%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DK.%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26aulast%3DThomas%26aufirst%3DA.%2BG.%26aulast%3DStathis%26aufirst%3DM.%26aulast%3DDuvall%26aufirst%3DB.%26aulast%3DDelahanty%26aufirst%3DG.%26aulast%3DAlt%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DRojas%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DDang%26aufirst%3DC.%2BV.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DTsukamato%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%2520and%2520pharmacological%2520evaluation%2520of%2520bis-2-%25285-phenylacetamido-1%252C2%252C4-thiadiazolyl-2-yl%2529ethyl%2520sulfide%25203%2520%2528BPTES%2529%2520analogs%2520as%2520glutaminase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10551%26epage%3D10563%26doi%3D10.1021%2Fjm301191p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R.</span></span> <span> </span><span class="NLM_article-title">Design and evaluation of novel glutaminase inhibitors</span>. <i>Biorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">1839</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.bmc.2016.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=26988803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Wmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1819-1839&author=L.+A.+McDermottauthor=P.+Iyerauthor=L.+Vernettiauthor=S.+Rimerauthor=J.+Sunauthor=M.+Bobyauthor=T.+Yangauthor=M.+Fioravantiauthor=J.+O%E2%80%99Neillauthor=L.+Wangauthor=D.+Drakesauthor=W.+Kattauthor=Q.+Huangauthor=R.+Cerione&title=Design+and+evaluation+of+novel+glutaminase+inhibitors&doi=10.1016%2Fj.bmc.2016.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and evaluation of novel glutaminase inhibitors</span></div><div class="casAuthors">McDermott, Lee A.; Iyer, Prema; Vernetti, Larry; Rimer, Shawn; Sun, Jingran; Boby, Melissa; Yang, Tianyi; Fioravanti, Michael; O'Neill, Jason; Wang, Liwei; Drakes, Dylan; Katt, William; Huang, Qingqiu; Cerione, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1819-1839</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel set of GAC (kidney glutaminase isoform C) inhibitors able to inhibit the enzymic activity of GAC and the growth of the triple neg. MDA-MB-231 breast cancer cells with low nanomolar potency is described.  Compds. in this series have a reduced no. of rotatable bonds, improved C log Ps, microsomal stability and ligand efficiency when compared to the leading GAC inhibitors BPTES and CB-839.  Property improvements were achieved by the replacement of the flexible n-diethylthio or the Bu moiety present in the leading inhibitors by heteroatom substituted heterocycloalkanes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGfzNc9NMuhbVg90H21EOLACvtfcHk0li3VCGD6Tmhmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Wmsbg%253D&md5=f335b5659f76e351b73c96954153127d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DL.%2BA.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DVernetti%26aufirst%3DL.%26aulast%3DRimer%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DBoby%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DFioravanti%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DDrakes%26aufirst%3DD.%26aulast%3DKatt%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DCerione%26aufirst%3DR.%26atitle%3DDesign%2520and%2520evaluation%2520of%2520novel%2520glutaminase%2520inhibitors%26jtitle%3DBiorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1819%26epage%3D1839%26doi%3D10.1016%2Fj.bmc.2016.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geedy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerione, R.</span></span> <span> </span><span class="NLM_article-title">GAC inhibitors with a 4-hydroxypiperidine spacer: Requirements for potency</span>. <i>Biorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">126632</span> <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2Fj.bmcl.2019.126632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=31474484" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&author=L.+McDermottauthor=D.+Koesauthor=S.+Mohammedauthor=P.+Iyerauthor=M.+Bobyauthor=V.+Balasubramanianauthor=M.+Geedyauthor=W.+Kattauthor=R.+Cerione&title=GAC+inhibitors+with+a+4-hydroxypiperidine+spacer%3A+Requirements+for+potency&doi=10.1016%2Fj.bmcl.2019.126632"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126632%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DL.%26aulast%3DKoes%26aufirst%3DD.%26aulast%3DMohammed%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBoby%26aufirst%3DM.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DGeedy%26aufirst%3DM.%26aulast%3DKatt%26aufirst%3DW.%26aulast%3DCerione%26aufirst%3DR.%26atitle%3DGAC%2520inhibitors%2520with%2520a%25204-hydroxypiperidine%2520spacer%253A%2520Requirements%2520for%2520potency%26jtitle%3DBiorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26doi%3D10.1016%2Fj.bmcl.2019.126632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, B. H.</span></span> <span> </span><span class="NLM_article-title">Novel 1,3,4-selenadiazole-containing kidney-type glutaminase inhibitors showed improved cellular uptake and antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWju7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=589-603&author=Z.+Chenauthor=D.+Liauthor=N.+Xuauthor=J.+Fangauthor=Y.+Yuauthor=W.+Houauthor=H.+Ruanauthor=P.+Zhuauthor=R.+Maauthor=S.+Luauthor=D.+Caoauthor=R.+Wuauthor=M.+Niauthor=W.+Zhangauthor=W.+Suauthor=B.+H.+Ruan&title=Novel+1%2C3%2C4-selenadiazole-containing+kidney-type+glutaminase+inhibitors+showed+improved+cellular+uptake+and+antitumor+activity&doi=10.1021%2Facs.jmedchem.8b01198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity</span></div><div class="casAuthors">Chen, Zhao; Li, Di; Xu, Ning; Fang, Jinzhang; Yu, Yan; Hou, Wei; Ruan, Haoqiang; Zhu, Panpan; Ma, Renchao; Lu, Shiying; Cao, Danhui; Wu, Rui; Ni, Mowei; Zhang, Wei; Su, Weike; Ruan, Benfang Helen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">589-603</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kidney-type glutaminase [KGA/isoenzyme glutaminase C (GAC)] is becoming an important tumor metab. target in cancer chemotherapy.  Its allosteric inhibitor, CB839, showed early promise in cancer therapeutics but limited efficacy in in vivo cancer models.  To improve the in vivo activity, the authors explored a bioisostere replacement of the sulfur atom in bis-2-(5-phenylacetamido-1,2,4-thiadiazol)ethyl sulfide and CB839 analogs with selenium using a novel synthesis of the selenadiazole moiety from carboxylic acids or nitriles.  The resulting selenadiazole compds. showed enhanced KGA inhibition, more potent induction of reactive oxygen species, improved inhibition of cancer cells, and higher cellular and tumor accumulation than the corresponding sulfur-contg. mols.  However, both CB839 and its selenium analogs show incomplete inhibition of the tested cancer cells, and a partial redn. in tumor size was obsd. in both the glutamine-dependent HCT116 and aggressive H22 liver cancer xenograft models.  Despite this, tumor tissue damage and prolonged survival were obsd. in animals treated with the selenium analog of CB839.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7CHcIk6PcobVg90H21EOLACvtfcHk0lgj15Cyf9OA_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWju7nL&md5=cbad84021fd466bfedb2592f84136afb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01198%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DW.%26aulast%3DRuan%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DW.%26aulast%3DRuan%26aufirst%3DB.%2BH.%26atitle%3DNovel%25201%252C3%252C4-selenadiazole-containing%2520kidney-type%2520glutaminase%2520inhibitors%2520showed%2520improved%2520cellular%2520uptake%2520and%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D589%26epage%3D603%26doi%3D10.1021%2Facs.jmedchem.8b01198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairnduff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheasty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekwuru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littleson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarron, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKelvie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raubo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter-Holt, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a thiadiazole-pyridazine-based allosteric glutaminase 1 inhibitor series that demonstrates oral bioavailability and activity in tumor xenograft models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6540</span>– <span class="NLM_lpage">6560</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFOks7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6540-6560&author=M.+R.+Finlayauthor=M.+Andertonauthor=A.+Baileyauthor=S.+Boydauthor=J.+Brookfieldauthor=C.+Cairnduffauthor=M.+Charlesauthor=A.+Cheastyauthor=S.+E.+Critchlowauthor=J.+Culshawauthor=T.+Ekwuruauthor=I.+Hollingsworthauthor=N.+Jonesauthor=F.+Lerouxauthor=M.+Littlesonauthor=H.+McCarronauthor=J.+McKelvieauthor=L.+Mooneyauthor=J.+W.+M.+Nissinkauthor=D.+Perkinsauthor=S.+Powellauthor=M.+J.+Quesadaauthor=P.+Rauboauthor=V.+Sabinauthor=J.+Smithauthor=P.+D.+Smithauthor=A.+Starkauthor=A.+Tingauthor=P.+Wangauthor=Z.+Wilsonauthor=J.+J.+Winter-Holtauthor=J.+M.+Woodauthor=G.+L.+Wrigleyauthor=G.+Yuauthor=P.+Zhang&title=Discovery+of+a+thiadiazole-pyridazine-based+allosteric+glutaminase+1+inhibitor+series+that+demonstrates+oral+bioavailability+and+activity+in+tumor+xenograft+models&doi=10.1021%2Facs.jmedchem.9b00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Bailey, Andrew; Boyd, Scott; Brookfield, Joanna; Cairnduff, Ceri; Charles, Mark; Cheasty, Anne; Critchlow, Susan E.; Culshaw, Janet; Ekwuru, Tennyson; Hollingsworth, Ian; Jones, Neil; Leroux, Fred; Littleson, Mairi; McCarron, Hollie; McKelvie, Jennifer; Mooney, Lorraine; Nissink, J. Willem M.; Perkins, David; Powell, Steve; Quesada, Mar Jimenez; Raubo, Piotr; Sabin, Verity; Smith, James; Smith, Peter D.; Stark, Andrew; Ting, Attilla; Wang, Peng; Wilson, Zena; Winter-Holt, Jon J.; Wood, J. Matthew; Wrigley, Gail L.; Yu, Guoqing; Zhang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6540-6560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumors have evolved a variety of methods to reprogram conventional metabolic pathways to favor their own nutritional needs, including glutaminolysis, the first step of which is the hydrolysis of glutamine to glutamate by the amidohydrolase glutaminase 1 (GLS1).  A GLS1 inhibitor could potentially target certain cancers by blocking the tumor cell's ability to produce glutamine-derived nutrients.  Starting from the known GLS1 inhibitor bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide, we describe the medicinal chem. evolution of a series from lipophilic inhibitors with suboptimal physicochem. and pharmacokinetic properties to cell potent examples with reduced mol. wt. and lipophilicity, leading to compds. with greatly improved oral exposure that demonstrate in vivo target engagement accompanied by activity in relevant disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo60TBet-ww7rVg90H21EOLACvtfcHk0lgj15Cyf9OA_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFOks7zP&md5=ba80acfcafc8c312f64a8b55ca601724</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00260%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBoyd%26aufirst%3DS.%26aulast%3DBrookfield%26aufirst%3DJ.%26aulast%3DCairnduff%26aufirst%3DC.%26aulast%3DCharles%26aufirst%3DM.%26aulast%3DCheasty%26aufirst%3DA.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DCulshaw%26aufirst%3DJ.%26aulast%3DEkwuru%26aufirst%3DT.%26aulast%3DHollingsworth%26aufirst%3DI.%26aulast%3DJones%26aufirst%3DN.%26aulast%3DLeroux%26aufirst%3DF.%26aulast%3DLittleson%26aufirst%3DM.%26aulast%3DMcCarron%26aufirst%3DH.%26aulast%3DMcKelvie%26aufirst%3DJ.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DQuesada%26aufirst%3DM.%2BJ.%26aulast%3DRaubo%26aufirst%3DP.%26aulast%3DSabin%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DTing%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DWinter-Holt%26aufirst%3DJ.%2BJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520a%2520thiadiazole-pyridazine-based%2520allosteric%2520glutaminase%25201%2520inhibitor%2520series%2520that%2520demonstrates%2520oral%2520bioavailability%2520and%2520activity%2520in%2520tumor%2520xenograft%2520models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6540%26epage%3D6560%26doi%3D10.1021%2Facs.jmedchem.9b00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burns, A. C.</span>; <span class="NLM_string-name">Collins, M. R.</span>; <span class="NLM_string-name">Greasley, S. E.</span>; <span class="NLM_string-name">Hoffman, R. L.</span>; <span class="NLM_string-name">Huang, Q.</span>; <span class="NLM_string-name">Kania, R. S.</span>; <span class="NLM_string-name">Kung, P.</span>; <span class="NLM_string-name">Linton, M. A.</span>; <span class="NLM_string-name">Narasimhan, L. S.</span>; <span class="NLM_string-name">Richardson, P. F.</span>; <span class="NLM_string-name">Richter, D. T.</span>; <span class="NLM_string-name">Smith, G.</span></span> <span> </span><span class="NLM_article-title">Cycloalkyl-linked Diheterocycle Derivatives</span>. International Patent Application Number <span class="NLM_patent">WO2015/166373A1</span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+C.+Burns&author=M.+R.+Collins&author=S.+E.+Greasley&author=R.+L.+Hoffman&author=Q.+Huang&author=R.+S.+Kania&author=P.+Kung&author=M.+A.+Linton&author=L.+S.+Narasimhan&author=P.+F.+Richardson&author=D.+T.+Richter&author=G.+Smith&title=Cycloalkyl-linked+Diheterocycle+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DA.%2BC.%26atitle%3DCycloalkyl-linked%2520Diheterocycle%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span>; <span class="NLM_string-name">Lemieux, R. M.</span>; <span class="NLM_string-name">Cao, S.</span>; <span class="NLM_string-name">Ding, Y.</span>; <span class="NLM_string-name">Ye, Z.</span></span> <span> </span><span class="NLM_article-title">Compounds and Their Methods of Use</span>. International Patent Application Number <span class="NLM_patent">WO2015/143340 A1</span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=G.+Cianchetta&author=R.+M.+Lemieux&author=S.+Cao&author=Y.+Ding&author=Z.+Ye&title=Compounds+and+Their+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCianchetta%26aufirst%3DG.%26atitle%3DCompounds%2520and%2520Their%2520Methods%2520of%2520Use%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhavar, P. K.</span>; <span class="NLM_string-name">Vakkalanka, S. K.</span>; <span class="NLM_string-name">Viswanadha, S.</span>; <span class="NLM_string-name">Swaroop, M. G.</span>; <span class="NLM_string-name">Babu, G.</span></span> <span> </span><span class="NLM_article-title">Novel Glutaminase Inhibitors</span>. <span class="NLM_patent">WO2015/101958 A2</span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+K.+Bhavar&author=S.+K.+Vakkalanka&author=S.+Viswanadha&author=M.+G.+Swaroop&author=G.+Babu&title=Novel+Glutaminase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhavar%26aufirst%3DP.%2BK.%26atitle%3DNovel%2520Glutaminase%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Chen, L.</span>; <span class="NLM_string-name">Goyal, B.</span>; <span class="NLM_string-name">Laidig, G.</span>; <span class="NLM_string-name">Stanton, T. F.</span>; <span class="NLM_string-name">Sjogren, E. B.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Inhibitors of Glutaminase</span>. International Patent Application Number <span class="NLM_patent">WO2013/078123 A1</span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Li&author=L.+Chen&author=B.+Goyal&author=G.+Laidig&author=T.+F.+Stanton&author=E.+B.+Sjogren&title=Heterocyclic+Inhibitors+of+Glutaminase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DHeterocyclic%2520Inhibitors%2520of%2520Glutaminase%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogl, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orford, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">3059</span>, <span class="refDoi"> DOI: 10.1182/blood.V126.23.3059.3059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1182%2Fblood.V126.23.3059.3059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=3059&author=D.+T.+Voglauthor=A.+Younesauthor=K.+Stewartauthor=K.+W.+Orfordauthor=M.+Bennettauthor=D.+Siegelauthor=J.+G.+Berdeja&title=Phase+1+study+of+CB-839%2C+a+first-in-class%2C+glutaminase+inhibitor+in+patients+with+multiple+myeloma+and+lymphoma&doi=10.1182%2Fblood.V126.23.3059.3059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1182%2Fblood.V126.23.3059.3059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V126.23.3059.3059%26sid%3Dliteratum%253Aachs%26aulast%3DVogl%26aufirst%3DD.%2BT.%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DOrford%26aufirst%3DK.%2BW.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26atitle%3DPhase%25201%2520study%2520of%2520CB-839%252C%2520a%2520first-in-class%252C%2520glutaminase%2520inhibitor%2520in%2520patients%2520with%2520multiple%2520myeloma%2520and%2520lymphoma%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D3059%26doi%3D10.1182%2Fblood.V126.23.3059.3059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalinsky, K.</span>; <span class="NLM_string-name">Harding, J. J.</span>; <span class="NLM_string-name">DeMichele, A.</span>; <span class="NLM_string-name">Infante, J. R.</span>; <span class="NLM_string-name">Gogineni, K.</span>; <span class="NLM_string-name">Owonikoko, T. K.</span>; <span class="NLM_string-name">Isakoff, S.</span>; <span class="NLM_string-name">Iliopuolos, O.</span>; <span class="NLM_string-name">Patel, N. R.</span>; <span class="NLM_string-name">Munster, P.</span>; <span class="NLM_string-name">Telli, M. L.</span>; <span class="NLM_string-name">Jenkins, Y.</span>; <span class="NLM_string-name">Fiji, G. P.</span>; <span class="NLM_string-name">Whiting, S. H.</span>; <span class="NLM_string-name">Meric-Bernstam, F.</span></span> In  <i>Phase 1 study of CB-839, a First-in-Class Inhibitor of Glutaminase, in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR</i>, Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5–9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res. 2018, 78(4 Suppl), Abstract no. PD3-13, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.+Kalinsky&author=J.+J.+Harding&author=A.+DeMichele&author=J.+R.+Infante&author=K.+Gogineni&author=T.+K.+Owonikoko&author=S.+Isakoff&author=O.+Iliopuolos&author=N.+R.+Patel&author=P.+Munster&author=M.+L.+Telli&author=Y.+Jenkins&author=G.+P.+Fiji&author=S.+H.+Whiting&author=F.+Meric-Bernstam&title=Phase+1+study+of+CB-839%2C+a+First-in-Class+Inhibitor+of+Glutaminase%2C+in+Combination+with+Paclitaxel+in+Patients+with+Advanced+Triple+Negative+Breast+Cancer+%5Babstract%5D.+In%3A+Proceedings+of+the+2017+San+Antonio+Breast+Cancer+Symposium%3B+2017+Dec+5-9%3B+San+Antonio%2C+TX.+Philadelphia+%28PA%29%3A+AACR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKalinsky%26aufirst%3DK.%26jtitle%3DPhase%25201%2520study%2520of%2520CB-839%252C%2520a%2520First-in-Class%2520Inhibitor%2520of%2520Glutaminase%252C%2520in%2520Combination%2520with%2520Paclitaxel%2520in%2520Patients%2520with%2520Advanced%2520Triple%2520Negative%2520Breast%2520Cancer%2520%255Babstract%255D.%2520In%253A%2520Proceedings%2520of%2520the%25202017%2520San%2520Antonio%2520Breast%2520Cancer%2520Symposium%253B%25202017%2520Dec%25205-9%253B%2520San%2520Antonio%252C%2520TX.%2520Philadelphia%2520%2528PA%2529%253A%2520AACR%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carthon, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliopoulos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannir, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span> <span> </span><span class="NLM_article-title">CB-839, a glutaminase inhibitor, in combination with cabozantanib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase 1 study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>, <span class="NLM_elocation-id">549</span> <span class="refDoi"> DOI: 10.1200/JCO.2019.37.7_suppl.549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1200%2FJCO.2019.37.7_suppl.549" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&author=F.+Meric-Bernstamauthor=R.+J.+Leeauthor=B.+C.+Carthonauthor=O.+Iliopoulosauthor=J.+W.+Mierauthor=M.+R.+Patelauthor=N.+M.+Tannirauthor=T.+K.+Owonikokoauthor=N.+B.+Haasauthor=M.+H.+Vossauthor=J.+J.+Hardingauthor=R.+Srinivasanauthor=G.+Shapiroauthor=M.+L.+Telliauthor=P.+N.+Munsterauthor=R.+D.+Carvajalauthor=Y.+Jenkinsauthor=S.+H.+Whitingauthor=J.+C.+Bendellauthor=T.+M.+Bauer&title=CB-839%2C+a+glutaminase+inhibitor%2C+in+combination+with+cabozantanib+in+patients+with+clear+cell+and+papillary+metastatic+renal+cell+cancer+%28mRCC%29%3A+Results+of+a+phase+1+study&doi=10.1200%2FJCO.2019.37.7_suppl.549"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.7_suppl.549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.7_suppl.549%26sid%3Dliteratum%253Aachs%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DCarthon%26aufirst%3DB.%2BC.%26aulast%3DIliopoulos%26aufirst%3DO.%26aulast%3DMier%26aufirst%3DJ.%2BW.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DTannir%26aufirst%3DN.%2BM.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DHaas%26aufirst%3DN.%2BB.%26aulast%3DVoss%26aufirst%3DM.%2BH.%26aulast%3DHarding%26aufirst%3DJ.%2BJ.%26aulast%3DSrinivasan%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DTelli%26aufirst%3DM.%2BL.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DJenkins%26aufirst%3DY.%26aulast%3DWhiting%26aufirst%3DS.%2BH.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26atitle%3DCB-839%252C%2520a%2520glutaminase%2520inhibitor%252C%2520in%2520combination%2520with%2520cabozantanib%2520in%2520patients%2520with%2520clear%2520cell%2520and%2520papillary%2520metastatic%2520renal%2520cell%2520cancer%2520%2528mRCC%2529%253A%2520Results%2520of%2520a%2520phase%25201%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26doi%3D10.1200%2FJCO.2019.37.7_suppl.549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeLaBarre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurov, J. B.</span></span> <span> </span><span class="NLM_article-title">Full-length human glutaminase in complex with an allosteric inhibitor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">10764</span>– <span class="NLM_lpage">10770</span>, <span class="refDoi"> DOI: 10.1021/bi201613d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi201613d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSks73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=10764-10770&author=B.+DeLaBarreauthor=S.+Grossauthor=C.+Fangauthor=Y.+Gaoauthor=A.+Jhaauthor=F.+Jiangauthor=J.+J.+Songauthor=W.+Weiauthor=J.+B.+Hurov&title=Full-length+human+glutaminase+in+complex+with+an+allosteric+inhibitor&doi=10.1021%2Fbi201613d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Full-Length Human Glutaminase in Complex with an Allosteric Inhibitor</span></div><div class="casAuthors">DeLaBarre, Byron; Gross, Stefan; Fang, Cheng; Gao, Yi; Jha, Abhishek; Jiang, Fan; Song J., Juanhua; Wei, Wentao; Hurov, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">10764-10770</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glutaminase (GLS1/2) catalyzes the conversion of L-glutamine to L-glutamate and ammonia.  The level of a splice variant of GLS1 (GAC) is elevated in certain cancers, and GAC is specifically inhibited by bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide (BPTES).  We report here the first full-length crystal structure of GAC in the presence and absence of BPTES mols.  Two BPTES mols. bind at an interface region of the GAC tetramer in a manner that appears to lock the GAC tetramer into a nonproductive conformation.  The importance of these loops with regard to overall enzymic activity of the tetramer was revealed by a series of GAC point mutants designed to create a BPTES resistant GAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrj21-Ko0HGLVg90H21EOLACvtfcHk0ljXD0E22xfyGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSks73K&md5=bd94996062f54c4f51a138c8e9f5f99a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fbi201613d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi201613d%26sid%3Dliteratum%253Aachs%26aulast%3DDeLaBarre%26aufirst%3DB.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DJha%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DHurov%26aufirst%3DJ.%2BB.%26atitle%3DFull-length%2520human%2520glutaminase%2520in%2520complex%2520with%2520an%2520allosteric%2520inhibitor%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D10764%26epage%3D10770%26doi%3D10.1021%2Fbi201613d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M. J.</span>; <span class="NLM_string-name">Le, K.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Kovacs, J. J.</span>; <span class="NLM_string-name">Burke, J. P.</span>; <span class="NLM_string-name">Bardenhagen, J. P.</span>; <span class="NLM_string-name">Bristow, C. A.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Carroll, C. L.</span>; <span class="NLM_string-name">Di Francesco, M. E.</span>; <span class="NLM_string-name">Hamilton, M. M.</span>; <span class="NLM_string-name">Geck Do, M.</span>; <span class="NLM_string-name">Harris, A.</span>; <span class="NLM_string-name">Giuliani, V.</span>; <span class="NLM_string-name">Huang, S.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Johnson, T.</span>; <span class="NLM_string-name">Kang, Z.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">McAfoos, T.</span>; <span class="NLM_string-name">Miller, M.</span>; <span class="NLM_string-name">Morlacchi, P.</span>; <span class="NLM_string-name">Palmer, W. S.</span>; <span class="NLM_string-name">Pang, J.</span>; <span class="NLM_string-name">Rogers, N.</span>; <span class="NLM_string-name">Shepard, H. E.</span>; <span class="NLM_string-name">Spencer, N. D.</span>; <span class="NLM_string-name">Theroff, J.</span>; <span class="NLM_string-name">Xu, Q.</span>; <span class="NLM_string-name">Yau, A.</span>; <span class="NLM_string-name">Draetta, G.</span>; <span class="NLM_string-name">Toniatti, C.</span>; <span class="NLM_string-name">Nazarenko, N.</span>; <span class="NLM_string-name">Heffernan, T. P.</span>; <span class="NLM_string-name">Jones, P.</span></span> In  <i>First-time Disclosure of IPN60090, a Potent and Selective GLS1 Inhibitor with Excellent Edit Reference</i>; Abstracts of Papers, 259th ACS National Meeting and Exposition, Philadelphia, PA, United States. <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">March 22–26, 2020</span>; MEDI  <span class="NLM_fpage">0288</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=March+22%E2%80%9326%2C+2020&pages=0288&author=M.+J.+Soth&author=K.+Le&author=G.+Liu&author=J.+J.+Kovacs&author=J.+P.+Burke&author=J.+P.+Bardenhagen&author=C.+A.+Bristow&author=B.+Czako&author=C.+L.+Carroll&author=M.+E.+Di+Francesco&author=M.+M.+Hamilton&author=M.+Geck+Do&author=A.+Harris&author=V.+Giuliani&author=S.+Huang&author=Y.+Jiang&author=T.+Johnson&author=Z.+Kang&author=Z.+Liu&author=T.+McAfoos&author=M.+Miller&author=P.+Morlacchi&author=W.+S.+Palmer&author=J.+Pang&author=N.+Rogers&author=H.+E.+Shepard&author=N.+D.+Spencer&author=J.+Theroff&author=Q.+Xu&author=A.+Yau&author=G.+Draetta&author=C.+Toniatti&author=N.+Nazarenko&author=T.+P.+Heffernan&author=P.+Jones&title=First-time+Disclosure+of+IPN60090%2C+a+Potent+and+Selective+GLS1+Inhibitor+with+Excellent+Edit+Reference"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSoth%26aufirst%3DM.%2BJ.%26btitle%3DFirst-time%2520Disclosure%2520of%2520IPN60090%252C%2520a%2520Potent%2520and%2520Selective%2520GLS1%2520Inhibitor%2520with%2520Excellent%2520Edit%2520Reference%26pub%3DAmerican%2520Chemical%2520Society%26date%3DMarch%252022%25E2%2580%259326%252C%25202020%26spage%3D0288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilbourn, M. R.</span></span> <span> </span><span class="NLM_article-title">Thiophenes as phenyl bio-isosteres: Application in radiopharmaceutical design-I. Dopamine uptake antagonists</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.1016/0883-2897(89)90138-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2F0883-2897%2889%2990138-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADyaK3cXntlSjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1989&pages=681-686&author=M.+R.+Kilbourn&title=Thiophenes+as+phenyl+bio-isosteres%3A+Application+in+radiopharmaceutical+design-I.+Dopamine+uptake+antagonists&doi=10.1016%2F0883-2897%2889%2990138-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Thiophenes as phenyl bio-isosteres:  application in radiopharmaceutical design.  I.  Dopamine uptake antagonists</span></div><div class="casAuthors">Kilbourn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">681-6</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    </div><div class="casAbstract">Possible applications of thiophenes in radiopharmaceutical chem. were explored.  Thiophene for benzene ring substitution was applied to the synthesis of thienyl-[18F]GBR 13119 (I), an analog of the potent and selective dopamine uptake inhibitor [18F]GBR 13119.  I was prepd. by the exchange reaction of Bu4N+18F- with (4-fluorophenyl) (2-thienyl)methanone followed by LiAlH4 redn., chloro substitution and reaction with N-(2-hydroxyethyl)-N-(3-phenylpropyl)piperazine.  In vivo regional brain distribution in mice shows essentially identical results for the thienyl and Ph compds. (striatum/cerebellum ratios of >4 at 60 min), suggesting successful substitution by the thiophene ring.  The extension of this concept to the synthesis of no-carrier-added, high specific activity [18F]fluorothiophenes was examd.: 5-[18F]fluoro-2-2-thiophenecarboxaldehyde was prepd. in 10-20% yields by an unprecedented [18F]fluoride-for-bromo substitution of 5-bromo-2-thiophenecarboxaldehyde.  The possible advantages of thiophenes (lower log P, altered metab.) in radiopharmaceutical chem. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYdMxG0Eqox7Vg90H21EOLACvtfcHk0ljXD0E22xfyGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXntlSjtA%253D%253D&md5=50fd9c852d8d98162bdcc4a0aeeffdf3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0883-2897%2889%2990138-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2897%252889%252990138-4%26sid%3Dliteratum%253Aachs%26aulast%3DKilbourn%26aufirst%3DM.%2BR.%26atitle%3DThiophenes%2520as%2520phenyl%2520bio-isosteres%253A%2520Application%2520in%2520radiopharmaceutical%2520design-I.%2520Dopamine%2520uptake%2520antagonists%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D1989%26volume%3D16%26spage%3D681%26epage%3D686%26doi%3D10.1016%2F0883-2897%2889%2990138-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thangavelu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uttamchandani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaraman, J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">7705</span>– <span class="NLM_lpage">7710</span>, <span class="refDoi"> DOI: 10.1073/pnas.1116573109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1073%2Fpnas.1116573109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=22538822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Knsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=7705-7710&author=K.+Thangaveluauthor=C.+Q.+Panauthor=T.+Karlbergauthor=G.+Balajiauthor=M.+Uttamchandaniauthor=V.+Sureshauthor=H.+Sch%C3%BClerauthor=B.+C.+Lowauthor=J.+Sivaraman&title=Structural+basis+for+the+allosteric+inhibitory+mechanism+of+human+kidney-type+glutaminase+%28KGA%29+and+its+regulation+by+Raf-Mek-Erk+signaling+in+cancer+cell+metabolism&doi=10.1073%2Fpnas.1116573109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism</span></div><div class="casAuthors">Thangavelu, K.; Pan, Catherine Qiurong; Karlberg, Tobias; Balaji, Ganapathy; Uttamchandani, Mahesh; Suresh, Valiyaveettil; Schuler, Herwig; Low, Boon Chuan; Sivaraman, J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7705-7710, S7705/1-S7705/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Besides thriving on altered glucose metab., cancer cells undergo glutaminolysis to meet their energy demands.  As the first enzyme in catalyzing glutaminolysis, human kidney-type glutaminase isoform (KGA) is becoming an attractive target for small mols. such as BPTES [bis-2-(5 phenylacetamido-1,2,4-thiadiazol-2-yl) Et sulfide], although the regulatory mechanism of KGA remains unknown.  On the basis of crystal structures, we reveal that BPTES binds to an allosteric pocket at the dimer interface of KGA, triggering a dramatic conformational change of the key loop (Glu312-Pro329) near the catalytic site. and rendering it inactive.  The binding mode of BPTES on the hydrophobic pocket explains its specificity to KGA.  Interestingly, KGA activity in cells is stimulated by EGF, and KGA assocs. with all three kinase components of the Raf-1/Mek2/Erk signaling module.  However, the enhanced activity is abrogated by kinase-dead, dominant neg. mutants of Raf-1 (Raf-1-K375M) and Mek2 (Mek2-K101A), protein phosphatase PP2A, and Mek-inhibitor U0126, indicative of phosphorylation-dependent regulation.  Furthermore, treating cells that coexpressed Mek2-K101A and KGA with suboptimal level of BPTES leads to synergistic inhibition on cell proliferation.  Consequently, mutating the crucial hydrophobic residues at this key loop abrogates KGA activity and cell proliferation, despite the binding of constitutive active Mek2-S222/226D.  These studies therefore offer insights into (i) allosteric inhibition of KGA by BPTES, revealing the dynamic nature of KGA's active and inhibitory sites, and (ii) cross-talk and regulation of KGA activities by EGF-mediated Raf-Mek-Erk signaling.  These findings will help in the design of better inhibitors and strategies for the treatment of cancers addicted with glutamine metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosvIi87QxUvrVg90H21EOLACvtfcHk0ljXD0E22xfyGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Knsbw%253D&md5=b628ca742b8d3b03c17db79a59d3e3b3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1116573109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1116573109%26sid%3Dliteratum%253Aachs%26aulast%3DThangavelu%26aufirst%3DK.%26aulast%3DPan%26aufirst%3DC.%2BQ.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DBalaji%26aufirst%3DG.%26aulast%3DUttamchandani%26aufirst%3DM.%26aulast%3DSuresh%26aufirst%3DV.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DLow%26aufirst%3DB.%2BC.%26aulast%3DSivaraman%26aufirst%3DJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520allosteric%2520inhibitory%2520mechanism%2520of%2520human%2520kidney-type%2520glutaminase%2520%2528KGA%2529%2520and%2520its%2520regulation%2520by%2520Raf-Mek-Erk%2520signaling%2520in%2520cancer%2520cell%2520metabolism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D7705%26epage%3D7710%26doi%3D10.1073%2Fpnas.1116573109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eZG3Jl5Ird0V7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lgXAqBNbGI_rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span> </span><span class="NLM_article-title">This fluorine
substitution was inspired by unpublished work in our group on an earlier,
structurally related chemical series containing the same four carbon
linker. Metabolite identification studies on an analog identified
an internal carbon as a site of metabolism, and microsomal stability
was improved by adding a fluorine to this carbon.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=This+fluorine%0Asubstitution+was+inspired+by+unpublished+work+in+our+group+on+an+earlier%2C%0Astructurally+related+chemical+series+containing+the+same+four+carbon%0Alinker.+Metabolite+identification+studies+on+an+analog+identified%0Aan+internal+carbon+as+a+site+of+metabolism%2C+and+microsomal+stability%0Awas+improved+by+adding+a+fluorine+to+this+carbon."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DThis%2520fluorine%250Asubstitution%2520was%2520inspired%2520by%2520unpublished%2520work%2520in%2520our%2520group%2520on%2520an%2520earlier%252C%250Astructurally%2520related%2520chemical%2520series%2520containing%2520the%2520same%2520four%2520carbon%250Alinker.%2520Metabolite%2520identification%2520studies%2520on%2520an%2520analog%2520identified%250Aan%2520internal%2520carbon%2520as%2520a%2520site%2520of%2520metabolism%252C%2520and%2520microsomal%2520stability%250Awas%2520improved%2520by%2520adding%2520a%2520fluorine%2520to%2520this%2520carbon." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span> </span><span class="NLM_article-title">The 100
mg/kg
BID dose of compound 27 was determined to be the maximally tolerated
dose in an earlier model study(unpublished), and we used it as our
default dose for subsequent studies, including the ones in this manuscript.
The 250 mg/kg BID dose of compound 4 (CB-839) was taken from in-house
studies showing consistent maximal in vivo target engagement at this
dose, and is slightly higher than the 200 mg/kg BID dose used by Calithera
in reference 9</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+100%0Amg%2Fkg%0ABID+dose+of+compound+27+was+determined+to+be+the+maximally+tolerated%0Adose+in+an+earlier+model+study%28unpublished%29%2C+and+we+used+it+as+our%0Adefault+dose+for+subsequent+studies%2C+including+the+ones+in+this+manuscript.%0AThe+250+mg%2Fkg+BID+dose+of+compound+4+%28CB-839%29+was+taken+from+in-house%0Astudies+showing+consistent+maximal+in+vivo+target+engagement+at+this%0Adose%2C+and+is+slightly+higher+than+the+200+mg%2Fkg+BID+dose+used+by+Calithera%0Ain+reference+9."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520100%250Amg%252Fkg%250ABID%2520dose%2520of%2520compound%252027%2520was%2520determined%2520to%2520be%2520the%2520maximally%2520tolerated%250Adose%2520in%2520an%2520earlier%2520model%2520study%2528unpublished%2529%252C%2520and%2520we%2520used%2520it%2520as%2520our%250Adefault%2520dose%2520for%2520subsequent%2520studies%252C%2520including%2520the%2520ones%2520in%2520this%2520manuscript.%250AThe%2520250%2520mg%252Fkg%2520BID%2520dose%2520of%2520compound%25204%2520%2528CB-839%2529%2520was%2520taken%2520from%2520in-house%250Astudies%2520showing%2520consistent%2520maximal%2520in%2520vivo%2520target%2520engagement%2520at%2520this%250Adose%252C%2520and%2520is%2520slightly%2520higher%2520than%2520the%2520200%2520mg%252Fkg%2520BID%2520dose%2520used%2520by%2520Calithera%250Ain%2520reference%25209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dientsmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span> <span> </span><span class="NLM_article-title">Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10.1158%2F1535-7163.MCT-13-0639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=24748656" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1021-1031&author=R.+Dientsmannauthor=J.+Rodonauthor=V.+Serraauthor=J.+Tabernero&title=Picking+the+point+of+inhibition%3A+A+comparative+review+of+PI3K%2FAKT%2FmTOR+pathway+inhibitors&doi=10.1158%2F1535-7163.MCT-13-0639"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0639%26sid%3Dliteratum%253Aachs%26aulast%3DDientsmann%26aufirst%3DR.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DPicking%2520the%2520point%2520of%2520inhibition%253A%2520A%2520comparative%2520review%2520of%2520PI3K%252FAKT%252FmTOR%2520pathway%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1021%26epage%3D1031%26doi%3D10.1158%2F1535-7163.MCT-13-0639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. J.</span>; <span class="NLM_string-name">Spencer, N. D.</span>; <span class="NLM_string-name">Bristow, C. A.</span>; <span class="NLM_string-name">Giuliani, V.</span>; <span class="NLM_string-name">Miller, M. A.</span>; <span class="NLM_string-name">Soth, M. J.</span>; <span class="NLM_string-name">Harris, A. L.</span>; <span class="NLM_string-name">Le, K.</span>; <span class="NLM_string-name">Burke, J. P.</span>; <span class="NLM_string-name">Carugo, A.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Xu, Q. A.</span>; <span class="NLM_string-name">Bardenhagen, J. P.</span>; <span class="NLM_string-name">Carrillo, C. C.</span>; <span class="NLM_string-name">Carroll, C. L.</span>; <span class="NLM_string-name">Chang, Q.</span>; <span class="NLM_string-name">Cross, J. B.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Feng, N.</span>; <span class="NLM_string-name">Gao, G.</span>; <span class="NLM_string-name">Garvey, J. R.</span>; <span class="NLM_string-name">Gay, J. P.</span>; <span class="NLM_string-name">Geck Do, M. K.</span>; <span class="NLM_string-name">Gera, S.</span>; <span class="NLM_string-name">Gogi, K.</span>; <span class="NLM_string-name">Greer, J.</span>; <span class="NLM_string-name">Hamilton, M.</span>; <span class="NLM_string-name">Han, M.</span>; <span class="NLM_string-name">Herrera, Z. J.</span>; <span class="NLM_string-name">Huang, S.</span>; <span class="NLM_string-name">Johnson, S. B.</span>; <span class="NLM_string-name">Johnson, T.</span>; <span class="NLM_string-name">Kang, Z.</span>; <span class="NLM_string-name">Kost-Alimova, M.</span>; <span class="NLM_string-name">Lewis, R. T.</span>; <span class="NLM_string-name">Linares, J.</span>; <span class="NLM_string-name">Liu, C.-Y.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Liu, J.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Yan Ma, X.</span>; <span class="NLM_string-name">McAfoos, T.</span>; <span class="NLM_string-name">Miao, L.</span>; <span class="NLM_string-name">Minelli, R.</span>; <span class="NLM_string-name">Molina, J.</span>; <span class="NLM_string-name">Morlacchi, P.</span>; <span class="NLM_string-name">Mseeh, F.</span>; <span class="NLM_string-name">Mullinax, R. A.</span>; <span class="NLM_string-name">Palmer, W.</span>; <span class="NLM_string-name">Pang, J.</span>; <span class="NLM_string-name">Parker, C. A.</span>; <span class="NLM_string-name">Peoples, M. D.</span>; <span class="NLM_string-name">Petrocchi, A.</span>; <span class="NLM_string-name">Quill, T. M.</span>; <span class="NLM_string-name">Ramamoorthy, V.</span>; <span class="NLM_string-name">Rogers, N.</span>; <span class="NLM_string-name">Shepard, H. E.</span>; <span class="NLM_string-name">Suarez, C.</span>; <span class="NLM_string-name">Sun, Y.</span>; <span class="NLM_string-name">Suzuki, E.</span>; <span class="NLM_string-name">Tan, L.</span>; <span class="NLM_string-name">Theroff, J. P.</span>; <span class="NLM_string-name">Wu, Q.</span>; <span class="NLM_string-name">Yau, A.</span>; <span class="NLM_string-name">Zhao, S.</span>; <span class="NLM_string-name">Zuniga, A. M.</span>; <span class="NLM_string-name">Weinstein, J. N.</span>; <span class="NLM_string-name">Lorenzi, P. L.</span>; <span class="NLM_string-name">de Stanchina, E.</span>; <span class="NLM_string-name">Rudin, C. M.</span>; <span class="NLM_string-name">Toniatti, C.</span>; <span class="NLM_string-name">Di Francesco, M. E.</span>; <span class="NLM_string-name">Marszalek, J. R.</span>; <span class="NLM_string-name">Draetta, G.</span>; <span class="NLM_string-name">Yap, T. A.</span>; <span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Heffernan, T. P.</span></span>, unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kovacs%2C+J.+J.%3B+Spencer%2C+N.+D.%3B+Bristow%2C+C.+A.%3B+Giuliani%2C+V.%3B+Miller%2C+M.+A.%3B+Soth%2C+M.+J.%3B+Harris%2C+A.+L.%3B+Le%2C+K.%3B+Burke%2C+J.+P.%3B+Carugo%2C+A.%3B+Jiang%2C+Y.%3B+Xu%2C+Q.+A.%3B+Bardenhagen%2C+J.+P.%3B+Carrillo%2C+C.+C.%3B+Carroll%2C+C.+L.%3B+Chang%2C+Q.%3B+Cross%2C+J.+B.%3B+Czako%2C+B.%3B+Feng%2C+N.%3B+Gao%2C+G.%3B+Garvey%2C+J.+R.%3B+Gay%2C+J.+P.%3B+Geck+Do%2C+M.+K.%3B+Gera%2C+S.%3B+Gogi%2C+K.%3B+Greer%2C+J.%3B+Hamilton%2C+M.%3B+Han%2C+M.%3B+Herrera%2C+Z.+J.%3B+Huang%2C+S.%3B+Johnson%2C+S.+B.%3B+Johnson%2C+T.%3B+Kang%2C+Z.%3B+Kost-Alimova%2C+M.%3B+Lewis%2C+R.+T.%3B+Linares%2C+J.%3B+Liu%2C+C.-Y.%3B+Liu%2C+G.%3B+Liu%2C+J.%3B+Liu%2C+Z.%3B+Yan+Ma%2C+X.%3B+McAfoos%2C+T.%3B+Miao%2C+L.%3B+Minelli%2C+R.%3B+Molina%2C+J.%3B+Morlacchi%2C+P.%3B+Mseeh%2C+F.%3B+Mullinax%2C+R.+A.%3B+Palmer%2C+W.%3B+Pang%2C+J.%3B+Parker%2C+C.+A.%3B+Peoples%2C+M.+D.%3B+Petrocchi%2C+A.%3B+Quill%2C+T.+M.%3B+Ramamoorthy%2C+V.%3B+Rogers%2C+N.%3B+Shepard%2C+H.+E.%3B+Suarez%2C+C.%3B+Sun%2C+Y.%3B+Suzuki%2C+E.%3B+Tan%2C+L.%3B+Theroff%2C+J.+P.%3B+Wu%2C+Q.%3B+Yau%2C+A.%3B+Zhao%2C+S.%3B+Zuniga%2C+A.+M.%3B+Weinstein%2C+J.+N.%3B+Lorenzi%2C+P.+L.%3B+de+Stanchina%2C+E.%3B+Rudin%2C+C.+M.%3B+Toniatti%2C+C.%3B+Di+Francesco%2C+M.+E.%3B+Marszalek%2C+J.+R.%3B+Draetta%2C+G.%3B+Yap%2C+T.+A.%3B+Jones%2C+P.%3B+Heffernan%2C+T.+P.%2C+unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DKovacs%26aufirst%3DJ.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-null"><span><span> </span><span class="NLM_article-title">The 5 day/2 off
schedule was standard for the research group running the study, chosen
for convenience of dosing. In other studies, including the H2122 study
contained in the supporting information, continuous every day schedules
were well-tolerated</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+5+day%2F2+off%0Aschedule+was+standard+for+the+research+group+running+the+study%2C+chosen%0Afor+convenience+of+dosing.+In+other+studies%2C+including+the+H2122+study%0Acontained+in+the+supporting+information%2C+continuous+every+day+schedules%0Awere+well-tolerated."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DThe%25205%2520day%252F2%2520off%250Aschedule%2520was%2520standard%2520for%2520the%2520research%2520group%2520running%2520the%2520study%252C%2520chosen%250Afor%2520convenience%2520of%2520dosing.%2520In%2520other%2520studies%252C%2520including%2520the%2520H2122%2520study%250Acontained%2520in%2520the%2520supporting%2520information%252C%2520continuous%2520every%2520day%2520schedules%250Awere%2520well-tolerated" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, S. R.</span></span> <span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination on in vitro half-life approach and nonspecific binding to microsomes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=S.+R.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+An+examination+on+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0ljsO87JbLL5VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DS.%2BR.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520An%2520examination%2520on%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i70"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01398">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_50368"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01398?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01398</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_001.csv">CSV</a>)</p></li><li><p class="inline">Experimental details for the preparation of compounds <b>5</b>–<b>26</b>; UPLC and high-resolution mass spectrometry data for componds <b>24</b>–<b>27</b>; log<i>D</i>, log<i>P</i>, and p<i>K</i><sub>a</sub> determinations for compound <b>27</b>; experimental procedures for oral dosing formulations and additional in vivo studies; standard deviations for GLS-1 and A549 assay results for compounds <b>2</b>, <b>4</b>, and <b>5</b>–<b>27</b>; representative IC<sub>50</sub> curve for compound <b>27</b> in the A549 assay; and Kinomescan and CEREP off-target screening data for <b>27;</b> Figures S1–S3 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_001.csv">jm0c01398_si_001.csv (2.0 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01398/suppl_file/jm0c01398_si_002.pdf">jm0c01398_si_002.pdf (1.59 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01398&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01398%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-21" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01398" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67999ccab8a624bf","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
